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Paul Tappenden,1* Christopher Carroll,1 Jean Hamilton,1
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Background: Medullary thyroid cancer (MTC) is a rare form of cancer that affects patients’ health-related
quality of life (HRQoL) and survival. Cabozantinib (Cometriq®; Ipsen, Paris, France) and vandetanib (Caprelsa®;
Sanofi Genzyme, Cambridge, MA, USA) are currently the treatment modality of choice for treating unresectable
progressive and symptomatic MTC.
Objectives: (1) To evaluate the clinical effectiveness and safety of cabozantinib and vandetanib. (2) To
estimate the incremental cost-effectiveness of cabozantinib and vandetanib versus each other and best
supportive care. (3) To identify key areas for primary research. (4) To estimate the overall cost of these
treatments in England.
Data sources: Peer-reviewed publications (searched from inception to November 2016), European Public
Assessment Reports and manufacturers’ submissions.
Review methods: A systematic review [including a network meta-analysis (NMA)] was conducted to
evaluate the clinical effectiveness and safety of cabozantinib and vandetanib. The economic analysis
included a review of existing analyses and the development of a de novo model.
Results: The systematic review identified two placebo-controlled trials. The Efficacy of XL184 (Cabozantinib)
in Advanced Medullary Thyroid Cancer (EXAM) trial evaluated the efficacy and safety of cabozantinib in
patients with unresectable locally advanced, metastatic and progressive MTC. The ZETA trial evaluated
the efficacy and safety of vandetanib in patients with unresectable locally advanced or metastatic MTC.
Both drugs significantly improved progression-free survival (PFS) more than the placebo (p < 0.001). The
NMA suggested that, within the symptomatic and progressive MTC population, the effects on PFS were
similar (vandetanib vs. cabozantinib: hazard ratio 1.14, 95% credible interval 0.41 to 3.09). Neither trial
demonstrated a significant overall survival benefit for cabozantinib or vandetanib versus placebo, although
data from ZETA were subject to potential confounding. Both cabozantinib and vandetanib demonstrated
significantly better objective response rates and calcitonin (CTN) and carcinoembryonic antigen (CEA)
response rates than placebo. Both cabozantinib and vandetanib produced frequent adverse events,
often leading to dose interruption or reduction. The assessment group model indicates that, within the
EU-label population (symptomatic and progressive MTC), the incremental cost-effectiveness ratios (ICERs)
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for cabozantinib and vandetanib are > £138,000 per quality-adjusted life-year (QALY) gained. Within
the restricted EU-label population (symptomatic and progressive MTC with CEA/CTN doubling times of
≤ 24 months), the ICER for vandetanib is expected to be > £66,000 per QALY gained. The maximum
annual budget impact within the symptomatic and progressive population is estimated to be ≈£2.35M for
cabozantinib and ≈£5.53M for vandetanib. The costs of vandetanib in the restricted EU-label population
are expected to be lower.
Limitations: The intention-to-treat populations of the EXAM and ZETA trials are notably different.
The analyses of ZETA subgroups may be subject to confounding as a result of differences in baseline
characteristics and open-label vandetanib use. Attempts to statistically adjust for treatment switching
were unsuccessful. No HRQoL evidence was identified for the MTC population.
Conclusions: The identified trials suggest that cabozantinib and vandetanib improve PFS more than the
placebo; however, significant OS benefits were not demonstrated. The economic analyses indicate that
within the EU-label population, the ICERs for cabozantinib and vandetanib are > £138,000 per QALY
gained. Within the restricted EU-label population, the ICER for vandetanib is expected to be > £66,000 per
QALY gained.
Future research priorities: (1) Primary research assessing the long-term effectiveness of cabozantinib
and vandetanib within relevant subgroups. (2) Reanalyses of the ZETA trial to investigate the impact of
adjusting for open-label vandetanib use using appropriate statistical methods. (3) Studies assessing the
impact of MTC on HRQoL.
Study registration: This study is registered as PROSPERO CRD42016050403.
Funding: The National Institute for Health Research Health Technology Assessment programme.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
vi
Contents
List of tables xi
List of figures xv
List of boxes xix
Glossary xxi
List of abbreviations xxiii
Plain English summary xxv
Scientific summary xxvii
Chapter 1 Background 1
Description of the health problem 1
Incidence and prevalence 1
Diagnosis and management 1
Prognosis 2
Impact of the health problem 2
Significance for patients 2
Significance for the NHS 3
Current service provision 3
Clinical guidelines 3
Current National Institute for Health and Care Excellence technology appraisal guidance 3
Current service cost 3
Variation in services and uncertainty about best practice 4
Current treatment pathway 4
Description of technology under assessment 4
Interventions considered in the scope of this report 4
Mode of action 6
Current usage in the NHS 6
Chapter 2 Definition of the decision problem 7
Decision problem 7
Population 7
Interventions 7
Relevant comparators 7
Outcomes 7
Subgroups 7
Overall aims and objectives of assessment 8
Chapter 3 Assessment of clinical effectiveness 9
Methods for reviewing effectiveness 9
Inclusion criteria 9
Searches 10
Study selection and data extraction 10
Quality assessment 11
Evidence synthesis 11
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
vii
Results 11
Quantity and quality of research available 11
Assessment of effectiveness 20
Progression-free survival 20
Safety outcomes 26
Network meta-analysis 30
Justification for conducting a network meta-analysis 30
Methods for the network meta-analysis 31
Results of the network meta-analysis 32
Discussion 32
Chapter 4 Assessment of cost-effectiveness 37
Systematic review of existing cost-effectiveness evidence 37
Review of existing economic evaluations: methods 37
Review of existing economic evaluations: results 37
Review of models submitted by the companies 38
Independent assessment group model 54
Model scope 54
Model structure 55
Evidence used to inform the model’s parameters 56
Model evaluation methods 68
Model validation 68
Assessment group model results 68
Budget impact analysis 83
Discussion 83
Assessment group analysis 1: EU-label population (symptomatic and progressive
medullary thyroid cancer), pairwise economic evaluation of cabozantinib versus best
supportive care 85
Assessment group analysis 2: EU-label population (symptomatic and progressive
medullary thyroid cancer), pairwise economic evaluation of vandetanib versus best
supportive care 85
Assessment group analysis 3: EU-label population (symptomatic and progressive
medullary thyroid cancer), fully incremental analysis, vandetanib progression-free
survival treatment effect applied to EXAM trial placebo baseline, vandetanib overall
survival assumed equivalent to cabozantinib overall survival 85
Assessment group analysis 4: EU-label population (symptomatic and progressive
medullary thyroid cancer), fully incremental analysis, progression-free and overall
survival outcomes assumed equivalent for vandetanib and cabozantinib 86
Assessment group analysis 5: restricted EU-label population (symptomatic and
progressive medullary thyroid cancer plus carcinoembryonic antigen/calcitonin
doubling times of ≤ 24 months), pairwise economic evaluation of vandetanib versus
best supportive care 86
Chapter 5 Assessment of factors relevant to the NHS and other parties 87
Additional monitoring requirements 87
Current availability of cabozantinib and vandetanib for medullary thyroid cancer 87
End-of-life considerations 87
Chapter 6 Discussion 89
Statement of principal findings 89
Strengths and limitations of the assessment 90
Uncertainties 90
Other relevant factors 91
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Chapter 7 Conclusions 93
Implications for service provision 93
Suggested research priorities 93
Acknowledgements 95
References 97
Appendix 1 Literature search strategies 107
Appendix 2 Excluded studies with reasons 119
Appendix 3 Additional tables and figures relating to the Sanofi model 123
Appendix 4 The Assessment group’s model: time-to-event analysis and other
model inputs 129
Appendix 5 The Assessment group’s model: disaggregated results 143
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
ix
List of tables
TABLE 1 Inclusion and exclusion criteria 9
TABLE 2 Characteristics of included RCTs 13
TABLE 3 Participants’ baseline characteristics from the EXAM and ZETA trials 14
TABLE 4 Participants’ baseline characteristics in the cabozantinib ‘progressive’
and the vandetanib EU-label and restricted EU-label populations 16
TABLE 5 Risk-of-bias assessment (Cochrane tool) of included RCTs 17
TABLE 6 The EXAM and ZETA trials’ median PFS durations (months) 21
TABLE 7 The RET-mutation status in the EXAM trial, in the post hoc analysis of
the EXAM trial (Ipsen CS, Sherman et al.) 22
TABLE 8 Progression-free survival by RET mutational status in the post hoc
analysis of the EXAM trial (Ipsen CS, Sherman et al.) 22
TABLE 9 Overall survival median duration (months) 24
TABLE 10 The EXAM trial CTN and CEA response rates 25
TABLE 11 Common AEs (any grade) reported for > 20% of participants in any
arm of the EXAM or ZETA trials 27
TABLE 12 Grade 3 or higher AES reported for ≥ 2% of participants in any arm of
the EXAM or ZETA trials 28
TABLE 13 Dose interruption or discontinuation rates in the EXAM and ZETA
trials (from Sanofi CS unless stated) 29
TABLE 14 Data for the NMA on PFS 31
TABLE 15 Sanofi model scope 39
TABLE 16 The company’s model parameters and evidence sources 42
TABLE 17 Sanofi’s base-case estimates of cost-effectiveness (excluding PAS) 46
TABLE 18 Adherence of the company’s economic analysis to the NICE Reference Case 48
TABLE 19 The AG model scope 54
TABLE 20 Evidence used to inform the AG model 56
TABLE 21 Summary of time-to-event data used in the AG model 58
TABLE 22 Clinical advisor’s preferred survivor functions 63
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
xi
TABLE 23 Survivor functions used in the AG’s base-case analysis 64
TABLE 24 Utility values reported by Fordham et al. 65
TABLE 25 Health utility values applied in other UK thyroid cancer submissions 66
TABLE 26 Analysis 1: EU-label population (symptomatic and progressive MTC),
cabozantinib vs. BSC (pairwise), central estimates of cost-effectiveness
(PFS= log-logistic, OS= log-logistic for both options) 68
TABLE 27 Analysis 1: EU-label population (symptomatic and progressive MTC),
cabozantinib vs. BSC (pairwise), DSA results 70
TABLE 28 Analysis 2: EU-label population (symptomatic and progressive MTC),
vandetanib vs. BSC (pairwise), central estimates of cost-effectiveness
(PFS= log-logistic, OS= log-logistic for both options) 71
TABLE 29 Analysis 2: EU-label population (symptomatic and progressive MTC),
vandetanib vs. BSC (pairwise), DSA results 72
TABLE 30 Analysis 3: EU-label population (symptomatic and progressive MTC),
fully incremental analysis of all options using vandetanib PFS treatment effect
from combined model, central estimates of cost-effectiveness (PFS= log-logistic,
OS= log-logistic for all options) 74
TABLE 31 Analysis 3: EU-label population (symptomatic and progressive MTC),
fully incremental analysis of all options using vandetanib PFS treatment effect
from combined model, DSA results 75
TABLE 32 Analysis 4: EU-label population (symptomatic and progressive MTC),
cabozantinib and vandetanib assumed equivalent, central estimates of
cost-effectiveness (PFS= log-logistic, OS= log-logistic for all options) 77
TABLE 33 Analysis 4: EU-label population (symptomatic and progressive MTC),
cabozantinib and vandetanib assumed equivalent, DSA results 78
TABLE 34 Analysis 5: restricted EU-label population (symptomatic and
progressive MTC with CEA/CTN doubling times of ≤ 24 months), vandetanib vs.
BSC (pairwise), central estimates of cost-effectiveness (PFS= log-normal,
OS=Gompertz for both options) 80
TABLE 35 Analysis 5: restricted EU-label population (symptomatic and
progressive MTC with CEA/CTN doubling times of ≤ 24 months), vandetanib vs.
BSC (pairwise), DSA results 81
TABLE 36 Budget impact analysis (£): cabozantinib and vandetanib, EU-label
(symptomatic and progressive) MTC population 84
TABLE 37 Summary of the AG’s cost-effectiveness results 85
TABLE 38 Key differences between the Sanofi model and the AG model 86
TABLE 39 Undiscounted survival estimates used in the AG model 88
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xii
TABLE 40 The AIC and BIC statistics from Sanofi’s covariate-adjusted analysis of
the ZETA trial observed OS 123
TABLE 41 The AIC and BIC statistics from Sanofi’s covariate-adjusted analysis of
ZETA trial observed PFS 124
TABLE 42 The HRQoL parameters used in the Sanofi model 124
TABLE 43 Use of vandetanib during progression-free period 124
TABLE 44 Vandetanib acquisition costs according to pack size 124
TABLE 45 Vandetanib monitoring costs assumed in the Sanofi model 125
TABLE 46 Incidence and costs associated with grade 3/4 AEs 125
TABLE 47 Comparison of DICE model results and double-programmed AG
partitioned survival model 126
TABLE 48 Health state populations by year, PFS (log-normal) and OS (Weibul) 127
TABLE 49 Model fit statistics: the EXAM trial’s ITT population, individual models
for each treatment arm, PFS and OS 130
TABLE 50 Model fit statistics: the ZETA trial’s EU-label population, individual
models for each treatment, PFS and OS 134
TABLE 51 Model fit statistics: the ZETA trial’s restricted EU-label population,
individual models for each treatment, PFS and OS 136
TABLE 52 ZETA trial EU-label model fit statistics and treatment-effect estimates
(HR or AFT factor) for single parametric models, PFS 137
TABLE 53 Health utilities used in the AG model 137
TABLE 54 Grade 3/4 AE rates assumed in the AG model 138
TABLE 55 Proportion of patients who switched to vandetanib or continued
vandetanib post progression 138
TABLE 56 Drug acquisition costs: vandetanib and cabozantinib 138
TABLE 57 Cabozantinib: proportion of PFS time spent at dose level 139
TABLE 58 Vandetanib: proportion of PFS time spent at dose level 139
TABLE 59 Annual BSC resource use included in the AG model 139
TABLE 60 Total annual health state resource use for cabozantinib and
vandetanib included in the AG model 140
TABLE 61 Unit costs applied in the AG model 140
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
xiii
TABLE 62 Distributions used in PSA 141
TABLE 63 Analysis 1: EU-label population (symptomatic and progressive MTC),
cabozantinib vs. BSC (pairwise), disaggregated LYGs, QALYs and costs 143
TABLE 64 Analysis 2: EU-label population (symptomatic and progressive MTC),
vandetanib vs. BSC (pairwise), disaggregated LYGs, QALYs and costs 143
TABLE 65 Analysis 3: EU-label population (symptomatic and progressive MTC),
fully incremental analysis of all options using vandetanib PFS treatment effect
from combined model, disaggregated LYGs, QALYs and costs 144
TABLE 66 Analysis 4: EU-label population (symptomatic and progressive MTC),
cabozantinib and vandetanib assumed equivalent, disaggregated LYGs, QALYs
and costs 144
TABLE 67 Analysis 5: restricted EU-label population (symptomatic and
progressive MTC with CEA/CTN doubling times of ≤ 24 months), vandetanib vs.
BSC (pairwise), disaggregated LYGs, QALYs and costs 144
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xiv
List of figures
FIGURE 1 Current treatment pathway for adults with symptomatic and
progressive MTC 5
FIGURE 2 PRISMA flow chart 11
FIGURE 3 Progression-free survival according to subgroups in the ZETA trial
(reproduced from the Sanofi CS, figure 4, p. 51 and AstraZeneca’s unpublished
CSR dated July 2011) 23
FIGURE 4 Network diagram for the NMA 31
FIGURE 5 Results of the NMA for investigator-read PFS 32
FIGURE 6 Results of the NMA for central-read PFS 33
FIGURE 7 Study selection results 38
FIGURE 8 Schematic of the Sanofi DICE model (reproduced from the Sanofi CS) 40
FIGURE 9 Cost-effectiveness acceptability curves generated using the Sanofi
model: vandetanib vs. BSC (redrawn by the AG) 46
FIGURE 10 The DSA results generated using the Sanofi model (reproduced from
the Sanofi model) 47
FIGURE 11 The AG model structure 55
FIGURE 12 Analysis 1: EU-label population (symptomatic and progressive MTC),
cabozantinib vs. BSC (pairwise), CEACs (PFS = log-logistic, OS = log-logistic for
both options) 69
FIGURE 13 Analysis 2: EU-label population (symptomatic and progressive MTC),
vandetanib vs. BSC (pairwise), CEACs (PFS = log-logistic, OS = log-logistic for both
options) 71
FIGURE 14 Analysis 3: EU-label population (symptomatic and progressive MTC),
fully incremental analysis of all options using vandetanib PFS treatment effect
from combined model, CEACs (PFS= log-logistic, OS= log-logistic for all options) 75
FIGURE 15 Analysis 4: EU-label population (symptomatic and progressive MTC),
cabozantinib and vandetanib assumed equivalent, CEACs (PFS= log-logistic,
OS= log-logistic for all options) 77
FIGURE 16 Analysis 5: restricted EU-label population (symptomatic and
progressive MTC with CEA/CTN doubling times of ≤ 24 months), vandetanib vs.
BSC (pairwise), CEACs (PFS = log-normal, OS =Gompertz for both options) 81
FIGURE 17 (Confidential information has been removed) 123
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
xv
FIGURE 18 (Confidential information has been removed) 123
FIGURE 19 (Confidential information has been removed) 126
FIGURE 20 EXAM trial ITT population PFS 129
FIGURE 21 ITT EXAM trial standard diagnostic plots for PFS 129
FIGURE 22 EXAM trial ITT population, PFS, cabozantinib group (extrapolation up
to 10 years) 131
FIGURE 23 EXAM trial ITT population, PFS, placebo group (extrapolation up to
10 years) 131
FIGURE 24 EXAM trial ITT population OS 132
FIGURE 25 EXAM trial ITT population, standard diagnostic plots for OS 132
FIGURE 26 EXAM trial ITT population, OS, cabozantinib group (extrapolation up
to 20 years) 133
FIGURE 27 EXAM trial ITT population, OS, placebo group (extrapolation up to
20 years) 133
FIGURE 28 (Confidential information has been removed) 134
FIGURE 29 (Confidential information has been removed) 134
FIGURE 30 (Confidential information has been removed) 134
FIGURE 31 (Confidential information has been removed) 134
FIGURE 32 (Confidential information has been removed) 134
FIGURE 33 (Confidential information has been removed) 135
FIGURE 34 (Confidential information has been removed) 135
FIGURE 35 (Confidential information has been removed) 135
FIGURE 36 (Confidential information has been removed) 135
FIGURE 37 (Confidential information has been removed) 135
FIGURE 38 (Confidential information has been removed) 135
FIGURE 39 (Confidential information has been removed) 135
FIGURE 40 (Confidential information has been removed) 135
FIGURE 41 (Confidential information has been removed) 136
FIGURE 42 (Confidential information has been removed) 136
LIST OF FIGURES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xvi
FIGURE 43 (Confidential information has been removed) 136
FIGURE 44 (Confidential information has been removed) 136
FIGURE 45 (Confidential information has been removed) 136
FIGURE 46 (Confidential information has been removed) 136
FIGURE 47 (Confidential information has been removed) 137
FIGURE 48 (Confidential information has been removed) 137
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
xvii
List of boxes
BOX 1 The CDF indication for cabozantinib and vandetanib for the treatment of
locally advanced or metastatic MTC 5
BOX 2 Inclusion criteria for review of published economic evaluations and health
utility data 38
BOX 3 Main issues identified by the AG 50
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
xix
Glossary
Calcitonin A hormone produced by the parafollicular cells (C cells) of the thyroid gland.
Carcinoembryonic antigen A protein that might appear in the blood of people who have certain types
of cancer.
Extended dominance A situation in which the incremental cost-effectiveness ratio for a given treatment
alternative is higher than that of the next most effective (non-dominated) comparator.
Medullary thyroid cancer A rare type of thyroid cancer that originates from the parafollicular cells
(also called C cells) of the thyroid.
Meta-analysis A statistical method by which the results of a number of studies are pooled to give a
combined summary statistic.
Network meta-analysis A meta-analysis in which multiple treatments are compared using both direct
comparisons of interventions within randomised controlled trials and indirect comparisons across trials,
based on a common comparator.
Partitioned survival model A model in which individuals reside in one of a series of mutually exclusive
and jointly exhaustive health states. State membership is determined fully by a series of independently
modelled non-mutually exclusive survival curves. A survival curve must be specified for each alive health
state that describes time from model start (i.e. patient entry in to the model) to transiting to any health
state that is further along the sequence.
Simple dominance A situation in which an intervention is less effective and more expensive than
its comparator.
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Plain English summary
Medullary thyroid carcinoma (MTC) is a rare form of cancer that presents as a mass of tumours inthe thyroid gland of the neck. MTC affects both patients’ health-related quality of life and survival.
Targeted therapies (cabozantinib and vandetanib) are currently used to treat unresectable progressive and
symptomatic MTC.
The evidence for the use of cabozantinib and vandetanib in patients with unresectable locally advanced
or metastatic MTC was reviewed, and two clinical trials were identified. The trials suggest that both drugs
improve progression-free survival. Neither trial demonstrated significant survival benefits for cabozantinib or
vandetanib. Both drugs produced frequent adverse events, often leading to dose interruption or reduction.
Whether or not these therapies represent good value for money for the NHS was also assessed. Analyses
indicate that the incremental cost-effectiveness ratios (ICERs) (a measure of cost-effectiveness) for cabozantinib
and vandetanib versus best supportive care (BSC) in patients with symptomatic and progressive MTC are
> £138,000 per quality-adjusted life-year (QALY) gained. Within a subgroup of patients with symptomatic and
progressive MTC and carcinoembryonic antigen and/or calcitonin doubling times of ≤ 24 months, the ICER for
vandetanib versus BSC remains > £66,000 per QALY gained.
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Scientific summary
Background
Thyroid cancer is the most common malignant endocrine tumour, but represents only ≈1% of all
malignancies. According to Cancer Research UK, 3404 new diagnoses of thyroid cancer were reported in
England in 2014: 966 cases (28%) were in men and 2438 cases (72%) were in women [Cancer Research
UK. Thyroid Cancer Statistics. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-
by-cancer-type/thyroid-cancer (accessed 27 March 2017)]. There are four main types of thyroid cancer:
(1) papillary, (2) follicular, (3) medullary and (4) anaplastic. Medullary thyroid cancer (MTC) is a rare type of
cancer that presents as a mass of tumours in the thyroid gland of the neck. MTC occurs in the parafollicular
cells (also known as C cells). There are four types of MTC: (1) sporadic, (2) multiple endocrine neoplasia
(MEN) 2, (3) MEN 3 and (4) familial MTC. Approximately 75% of cases of MTC are sporadic in nature.
MTC is very rare and accounts for ≈5% of all thyroid cancers. The estimated annual incidence of MTC in
England is ≈170 cases. For patients with regional disease spread, 10-year survival rates are reported to be
≈75%, whereas survival estimates of 21–40% have been reported for patients presenting with metastases
at diagnosis (stage IV disease). Patients with MTC typically present with a lump in the neck (which may
represent a thyroid or lymph node mass) or distant metastases. The lumps are not usually associated with
other symptoms but may occasionally cause dysphagia (difficulty or discomfort in swallowing) or dysphonia
(difficulty in speaking). Symptoms might also relate to the effect of metastases, especially diarrhoea, flushing,
dyspnoea and bone pain.
For many patients, surgery can be curative. Treatment options for patients with unresectable locally
advanced or metastatic MTC include tyrosine kinase inhibitor (TKI) therapy and best supportive care (BSC),
which typically comprises symptom control and palliative treatments, such as radiotherapy and palliative
surgery. Currently, vandetanib (Caprelsa®; Cambridge, MA, USA) and cabozantinib (Cometriq®; Ipsen,
Paris, France) are the modality of choice for unresectable progressive and symptomatic MTC. Both
cabozantinib and vandetanib are currently available through the Cancer Drugs Fund (CDF) for the first-line
treatment of symptomatic and progressive MTC.
The evidence presented within this assessment relates to two populations of patients with MTC: (1) patients
with symptomatic and progressive disease [referred to as the ‘European Union (EU)-label population’] and
(2) patients with symptomatic and progressive disease with carcinoembryonic antigen (CEA) and calcitonin
(CTN) doubling times of ≤ 24 months (referred to as the ‘restricted EU-label population’).
Aims
The aims of the assessment were to:
l evaluate the clinical effectiveness and safety of cabozantinib and vandetanib within their marketing
authorisations for treating unresectable locally advanced or metastatic MTC
l estimate the incremental cost-effectiveness of cabozantinib and vandetanib compared with each other
and with BSC
l identify key areas for primary research
l estimate the overall cost of these treatments in England.
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Methods
Clinical effectiveness
A systematic review was conducted following standard methods. Systematic searches were undertaken
in 10 electronic databases up to November 2016 to identify randomised controlled trials (RCTs) of
cabozantinib and vandetanib for treating unresectable locally advanced or metastatic MTC. The quality
of included studies was assessed using the Cochrane Risk of Bias Tool. Results were reported using
narrative synthesis and were presented in a tabular format. In the absence of direct evidence comparing
cabozantinib and vandetanib with each other, a network meta-analysis (NMA) was performed using data
relating to the ZETA trial EU-label and EXAM [Efficacy of XL184 (Cabozantinib) in Advanced Medullary
Thyroid Cancer] trial intention-to-treat (ITT) populations.
Cost-effectiveness
A comprehensive search was undertaken to systematically identify economic evaluations of treatments for
locally advanced or metastatic MTC and studies reporting on the health-related quality of life (HRQoL) of
patients with locally advanced or metastatic thyroid cancer (including MTC, as well as other more common
forms of thyroid cancer). The submissions received by the National Institute for Health and Care Excellence
(NICE) included one unpublished economic analysis of vandetanib versus BSC in the restricted EU-label
population (symptomatic and progressive MTC with CEA/CTN doubling times of ≤ 24 months) based
on a partitioned survival structure implemented using the discretely integrated condition event (DICE)
approach. The executable model used to undertake the analysis was also submitted to NICE. The model
was scrutinised by the assessment group (AG) and the economic analysis was critically appraised using the
key items contained within published checklists. Two errors were identified; hence all submitted analyses
were repeated by the AG using a corrected version of the company’s model. The manufacturer of
cabozantinib did not submit any economic evidence relating to this product.
In the light of the absence of published evidence relating to the cost-effectiveness of vandetanib or
cabozantinib, the absence of a submitted economic analysis of cabozantinib and concerns regarding
the submitted economic analysis of vandetanib, the AG developed a de novo health economic model.
The AG model used a partitioned survival approach based on three health states: (1) progression free,
(2) post progression and (3) dead. Costs and health utilities were assumed to differ according to the
presence/absence of disease progression. The model parameters were informed by analyses of individual
patient data (IPD) from the EXAM trial, replicated IPD from the ZETA trial, the submissions from Sanofi
Genzyme (Cambridge, MA, USA) and Ipsen (Paris, France) and data contained within subsequent clarification
responses, as well as published literature, standard reference cost sources and expert judgement. The model
was evaluated across five sets of analyses from the perspective of the NHS and Personal Social Services (PSS)
over a lifetime horizon. Four sets of analyses related to the evaluation of cabozantinib and/or vandetanib
versus BSC in the EU-label population (symptomatic and progressive MTC); the remaining analysis set
evaluated vandetanib versus BSC in the restricted EU-label population (symptomatic and progressive MTC
with CEA/CTN doubling times of ≤ 24 months). Costs and health outcomes were discounted at a rate of
3.5% per annum. Costs were valued at 2016/17 prices. Confidential Patient Access Schemes have been
proposed for both products. All economic analyses within this report relate to the list prices of vandetanib
and cabozantinib; separate analyses including price discounts are presented in separate confidential
appendices to this report.
Results
Clinical effectiveness
The systematic review identified and included two placebo-controlled trials. The EXAM trial evaluated
the efficacy and safety of cabozantinib in patients with unresectable locally advanced, metastatic and
progressive MTC (n = 330). The ZETA trial evaluated the efficacy and safety of vandetanib in patients with
unresectable locally advanced or metastatic MTC (n = 331). The two trials assessed different populations
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because the ZETA trial inclusion criteria did not specify ‘progressive’ disease; therefore, the ITT population
in this trial generally had less severe disease (there were more patients with potentially indolent disease).
However, the ZETA trial did include a subgroup of patients with ‘progressive and symptomatic disease’
(n = 186), which formed the EU-label population. Clinical advice received by the AG confirmed that this
group was comparable to the EXAM trial ITT population.
In terms of efficacy, both cabozantinib and vandetanib significantly improved progression-free survival (PFS)
compared with placebo. For the principal comparison between the EXAM trial ITT population and the ZETA
trial EU-label population, PFS was similar for cabozantinib versus placebo [investigator-read hazard ratio
(HR) 0.29, 95% confidence interval (CI) 0.21 to 0.42; p < 0.001; central review HR 0.28, 95% CI 0.19 to
0.40; p < 0.001] and vandetanib versus placebo (investigator-read HR 0.33, 95% 0.20 to 0.53; p = 0.0226;
central review, excluding patients switching treatments, HR 0.47, 95% CI 0.29 to 0.77; p = 0.0024 and
including open-label populations, HR 0.32 95% CI 0.19 to 0.54; p < 0.0001).
The NMA undertaken by the AG suggested that the treatment effects on PFS were broadly similar [vandetanib
vs. cabozantinib HR 1.14, 95% credible interval (CrI) 0.41 to 3.09]. The magnitude of the treatment effect
was more favourable towards cabozantinib when the comparison was based on central-read PFS rather than
investigator-read PFS (HR 1.68, 95% CrI 0.61 to 4.62); however, the difference between the two interventions
was not statistically significant. The NMA was, however, limited by the sparsity of the network and the use of
HRs, which ignore any treatment-by-time interaction.
Based on the trial evidence, there was no significant benefit in terms of overall survival (OS) for either
cabozantinib or vandetanib compared with placebo, although the data from the ZETA trial were subject to
potential confounding as a result of open-label vandetanib use in the placebo group. Both cabozantinib
(p < 0.001) and vandetanib (ITT group, p < 0.001, and EU-label group, p < 0.0001) demonstrated
significantly better objective response rates (ORRs) than placebo, as determined by modified or standard
Response Evaluation Criteria in Solid Tumours (RECIST). Both cabozantinib (p < 0.001) and vandetanib
(p < 0.001) also demonstrated significantly better CTN and CEA response rates than placebo. Both
cabozantinib and vandetanib produced frequent adverse events (AEs). The overall incidence rate of any
serious adverse event (SAE) in the EXAM trial was 42% in the cabozantinib arm compared with 23% in
the placebo arm, whereas in the ZETA trial, the incidence rate of SAEs was 31% in the vandetanib arm
compared with 13% in the placebo arm.
Cost-effectiveness
The corrected version of the company’s (Sanofi Genzyme) model suggests that the probabilistic incremental
cost-effectiveness ratio (ICER) for vandetanib versus BSC in the restricted EU-label population (symptomatic
and progressive MTC with CEA/CTN doubling times of ≤ 24 months) is approximately £31,546 per quality-
adjusted life-year (QALY) gained. However, the AG noted several concerns with this analysis, in particular
(1) the questionable relevance of the restricted EU-label population to current clinical practice, (2) the failure to
adjust for open-label vandetanib use in both treatment groups of the ZETA trial, (3) the likely overestimation of
the costs of vandetanib use in the post-progression state, (4) questionable assumptions regarding the amount
of vandetanib received and (5) concerns regarding the robustness of the company’s covariate-adjusted survival
modelling in the restricted EU-label population. The AG considers it likely that the ICER for vandetanib is
considerably higher than the estimates presented within the Sanofi submission to NICE.
Based on the AG’s probabilistic analysis of cabozantinib versus placebo in the EU-label (symptomatic and
progressive) MTC population, the ICER for cabozantinib versus BSC is expected to be £150,874 per QALY
gained. Within the EU-label (symptomatic and progressive MTC) population of the ZETA trial, the AG’s
probabilistic analysis suggests that the ICER for vandetanib versus BSC is expected to be £352,508 per
QALY gained. The fully incremental analysis of cabozantinib, vandetanib and BSC, based on the EXAM
trial ITT population and the vandetanib PFS treatment effect from the ZETA trial, suggests that the ICER
for vandetanib versus BSC is expected to be £138,405 per QALY gained, whilst the ICER for cabozantinib
versus vandetanib is expected to be £195,593 per QALY gained. Within the fully incremental analysis,
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in which the PFS and OS outcomes for vandetanib were assumed to be equivalent to the cabozantinib group
outcomes in the EXAM trial, cabozantinib is expected to be dominated, whilst the ICER for vandetanib versus
BSC is expected to be £144,841 per QALY gained. Within the restricted EU-label population (symptomatic and
progressive MTC plus CEA/CTN doubling times of ≤ 24 months), the ICER for vandetanib versus BSC is
expected to be £66,779 per QALY gained.
Discussion
Two RCTs comparing active treatment with placebo were identified: one of cabozantinib (the EXAM trial)
and one of vandetanib (the ZETA trial). The EXAM trial was rated as being at low risk of bias. The ZETA trial
was rated as being at moderate or high risk of bias, principally as a consequence of treatment switching that
led to the potential confounding of outcome data. There was no direct evidence comparing outcomes for
cabozantinib and vandetanib with each other. Both cabozantinib and vandetanib demonstrated significant
benefits compared with placebo in terms of PFS and appeared to be broadly similar in terms of efficacy,
although neither has demonstrated significant OS benefits compared with placebo. Both cabozantinib and
vandetanib produced frequent AEs, with substantial proportions of patients experiencing AEs that led to
dose interruption or reduction.
The economic analyses undertaken by Sanofi and the AG are each limited by the evidence used to inform
them. In particular, the use of open-label vandetanib in the placebo group of the ZETA trial is likely to have
confounded OS outcomes. The Sanofi submission states that, although attempts were made to adjust for
this potential confounding in OS using the rank-preserving structural failure time approach, these were
not successful. The AG did not have access to the underlying IPD (including data on relevant covariates),
hence further attempts to adjust for treatment switching were not possible. Consequently, the pairwise
analyses of vandetanib versus BSC may not be meaningful for decision-making. For this reason, the AG
undertook fully incremental analyses based principally on the observed outcomes within the EXAM
trial. Although these incremental analyses necessarily reflect potentially strong assumptions concerning
transferable/equivalent treatment effects between vandetanib and cabozantinib, they are not subject
to confounding as a result of post-progression vandetanib use. These analyses suggest that within the
EU-label population (symptomatic and progressive MTC), the ICERs for vandetanib and cabozantinib versus
BSC are expected to be > £138,000 per QALY gained. The analyses undertaken in the restricted EU-label
population (symptomatic and progressive MTC plus CEA/CTN doubling times of ≤ 24 months) suggest
that the ICER for vandetanib versus BSC is expected to be more favourable but still remains > £66,000
per QALY gained; these latter analyses are also subject to potential confounding as a result of open-label
vandetanib use.
The AG’s economic analysis suggests that NICE’s criteria for life-extending therapies given at the end
of life are not met for cabozantinib in the symptomatic and progressive MTC population, or for vandetanib
in either the EU-label population or the restricted EU-label population. There is, however, uncertainty
surrounding the mean survival duration of patients who do not receive either cabozantinib or vandetanib.
Conclusions
In terms of efficacy, both cabozantinib and vandetanib significantly improved PFS compared with placebo.
In the absence of direct evidence comparing the two interventions, a NMA was performed. This analysis
suggests that the treatment effect of both drugs on PFS is broadly similar, although these findings depend
on the assumption of comparability between the EXAM trial ITT population and the ZETA trial EU-label
population and should be treated with caution because of the sparsity of the network. Neither cabozantinib
nor vandetanib demonstrated significant OS benefits compared with placebo and both drugs produced
frequent AEs.
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Based on the economic analyses undertaken by the AG, the ICERs for cabozantinib and vandetanib versus
BSC in the EU-label population (symptomatic and progressive MTC) are > £138,000 per QALY gained.
The analyses undertaken within the restricted EU-label population (symptomatic and progressive MTC
with CEA/CTN doubling times of ≤ 24 months) suggest that the ICER for vandetanib versus BSC is more
favourable but remains > £66,000 per QALY gained. The impact of adjusting for open-label vandetanib
use on the cost-effectiveness of vandetanib versus BSC is unknown.
Future research priorities include (1) primary research assessing the long-term effectiveness of cabozantinib
and vandetanib within relevant subgroups, (2) reanalyses of the ZETA trial to investigate the impact of
adjusting for open-label vandetanib use using appropriate statistical methods and (3) studies assessing the
impact of MTC on HRQoL.
Study registration
This study is registered as CRD42016050403.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Incidence and prevalence
Thyroid cancer is the most common malignant endocrine tumour, but represents only ≈1% of all
malignancies.1,2 The disease is more common in women than in men. According to Cancer Research UK,
3404 new diagnoses of thyroid cancer were reported in England in 2014: 966 cases (28%) were in men
and 2438 cases (72%) were in women.1 The age-standardised incidence rate of thyroid cancer is reported
to be 7 per 100,000 women and 3 per 100,000 men.1 The UK incidence rate is the 11th lowest in Europe
for men and the 15th lowest in Europe for women. The median age at diagnosis is approximately 50 years.3,4
There are four main types of thyroid cancer: (1) papillary, (2) follicular, (3) medullary and (4) anaplastic.
Papillary and follicular thyroid cancer are the most common types of thyroid cancer and account for > 90%
of all cases.3 Medullary thyroid cancer (MTC), the disease type considered in this report, develops from
the parafollicular cells (also known as C cells) and commonly presents as a mass in the neck.2 MTC is very
rare and accounts for ≈5% of all thyroid cancers,2 although a lower frequency has been quoted by the
American Thyroid Association guidelines.5 Anaplastic cancers, thyroid lymphomas and metastases to
thyroid from other primary tumours are rarer than MTC; anaplastic thyroid cancer accounts for ≈2% of all
thyroid cancers.3 MTC is reported to account for 3% of all thyroid cancers in adults and 10% of all thyroid
cancers in children.2 Based on 2014 estimates of disease incidence,1 the number of new cases of MTC in
England in any year would be ≈170 individuals (5% of 3404).
There are four types of MTC: (1) sporadic, (2) multiple endocrine neoplasia (MEN) 2 (formerly MEN 2A),
(3) MEN 3 (formerly MEN 2B) and (4) familial MTC. Incidence rates for each type differ by age and sex.1
Approximately 75% of MTC cases are sporadic in nature, whereas the remaining 25% are genetically
determined (MEN 2, MEN 3 and familial MTC).2,3 The RE-arranged during Transfection (RET) oncogene
is central to the development of sporadic and hereditary MTC.5 Germline testing of the RET oncogene
mutation is recommended for all confirmed cases of MTC to establish the possible hereditary basis for
the disease within an individual and to facilitate the identification of family members who might be at
risk.2 Almost all patients with MEN 2, MEN 3 and familial MTC have germline RET mutation, whereas
approximately 40–50% of patients with sporadic MTC have somatic RET mutations.2,5 Only germline RET
mutation testing is routinely undertaken in the NHS.
Diagnosis and management
In > 75% of cases, patients with MTC will typically present with a lump in the neck (which may represent
a thyroid or lymph node mass) or distant metastases.2 The lumps are not usually associated with other
symptoms but may occasionally cause dysphagia (difficulty or discomfort in swallowing) or dysphonia
(difficulty in speaking).2,6 Symptoms might also relate to the effect of metastases, especially diarrhoea,
flushing, dyspnoea and bone pain.
Diagnosis is usually made by either fine-needle aspiration cytology of a thyroid nodule or lymph node
or core needle biopsy with ultrasound guidance, alongside biochemical investigations of serum-based
biomarkers, especially calcitonin (CTN).2,3,5,7 CTN is the major product secreted by C cells:5 CTN levels of
> 100 pg/ml are considered to have a 100% positive predictive value for the presence of MTC.2,3
The disease is staged and, if appropriate, surgery is performed (usually total thyroidectomy and central
compartment node dissection, with or without lateral neck dissection).2,8,9 Patients with MTC may be
classified into three groups: (1) patients with localised disease without evidence of metastases, in whom
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surgical cure is possible; (2) patients with metastatic disease limited to the neck, in whom surgical cure
might be possible but is not always achieved; and (3) patients with distant metastasis, that is the disease
has spread outside the neck and in whom surgery is not curative.3 The only curative treatment for MTC is
complete surgical resection, but lymph node or systemic metastases are present at initial diagnosis in
around half of MTC cases5 and resection is sometimes incomplete because of extensive lateral spread.3,4
Patients with unresectable locally advanced or metastatic MTC were the focus of this review. For these
patients, the treatment options are limited because MTC is relatively unresponsive to conventional doses of
radiation therapy and to all tested chemotherapeutic regimens (see Impact of health problem and Current
service provision).2,3,5 Therefore, patients with symptomatic and progressive disease, according to the
Response Evaluation Criteria in Solid Tumours (RECIST) criteria,10 are the principal candidates for
systemic treatment.6
Prognosis
Compared with other advanced solid tumours, MTC can be relatively indolent, but it can sometimes be
aggressive; data indicate that survival is influenced by age and stage at diagnosis.4,5,11 It has been reported
that patients who are < 40 years of age at the time of diagnosis have a significantly higher adjusted
survival rate than older patients,4,12 and 10-year survival rates are reported to be up to 100% for stage I
disease, that is, if tumours are confined to the thyroid gland.4,5,9,13 In the absence of progressive and
symptomatic disease, health-related quality of life (HRQoL) can be maintained for months or years.2,6
However, reported 10-year survival rates decrease to ≈75% with regional disease spread3,14 and range
from 21 to 40% for subjects with metastatic disease at diagnosis.2,3,5 Distant metastases, which can affect
multiple organs, most commonly the liver, lungs and bones, are reported to be present in between 7%
and 23% of MTC cases at diagnosis.3,6 Just under half of all patients with sporadic MTC will present with
stage III or IV (advanced) disease.5
Calcitonin and, to a lesser extent, carcinoembryonic antigen (CEA) are used as biological markers of
post-operative MTC burden, progression and survival.15 CEA levels are not specific to MTC and are less
sensitive and less reliable than CTN for diagnosis; however, when measured alongside CTN, they are
considered to be potentially useful in assessing disease progression.5,15 Certain levels of CEA might indicate
regional spread to draining lymph nodes or more distant spread to non-regional lymph nodes, but are
particularly important as an indicator of disease progression.3,5 Studies16–20 have indicated that patients
with CTN and CEA doubling times of ≤ 24 months have more progressive disease and a reduced survival
time compared with patients with CTN and CEA doubling times of > 24 months. A 2005 study16 reported
5- and 10-year survival rates of 25% and 8%, respectively, in MTC patients with post-operative CTN
doubling times of < 6 months, compared with 92% and 37%, respectively, in patients with doubling times
of between 6 and 24 months. In the same study,16 the 10-year survival rate for patients with CTN doubling
times of > 24 months was 100%.
Impact of the health problem
Significance for patients
There is little published research concerning the impact of MTC on patients’ HRQoL. As noted in the Ipsen
(Paris, France) submission to the National Institute for Health and Care Excellence (NICE),21 most of the
available HRQoL evidence is derived from studies of patients with other more common types of thyroid
cancer. MTC is associated with a number of symptoms that may impair patients’ HRQoL, including the
presence of a thyroid mass (usually a non-tender thyroid nodule or diffuse thyroid enlargement), cervical
lymphadenopathy, airway compromise, pain, dysphagia and dysphonia. Diarrhoea is commonly seen in
patients with advanced MTC as a result of hormonal excess caused by increased CTN secretion from the
parafollicular cells; this may be debilitating and can lead to problems with nutrition. Distant metastases
may result in additional symptoms including spinal cord compression, bone fracture, bronchial obstruction
and pain.5 Debilitating symptoms associated with MTC (e.g. severe diarrhoea) may lead to workplace
absence and lost productivity.
BACKGROUND
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Significance for the NHS
Medullary thyroid cancer is a very rare disease and, for many patients, surgery can be curative; hence,
the population of patients with advanced or metastatic MTC eligible for treatment with vandetanib and
cabozantinib is very small. However, given the list prices of the drugs and the lack of effective alternative
treatments, the cost per patient treated may be considerable. Both vandetanib (Caprelsa®; Cambridge,
MA, USA) and cabozantinib (Cometriq®; Ipsen, Paris, France) are also associated with additional monitoring
costs. The Summary of Product Characteristics (SmPC) for vandetanib22 states the following:
An ECG [electrocardiography], and levels of serum potassium, calcium and magnesium and thyroid
stimulating hormone (TSH) should be obtained at baseline, at 1, 3, 6 and 12 weeks after starting
treatment and every 3 months for at least a year thereafter. This schedule should apply to the period
after dose reduction due to QTc [corrected QT interval] prolongation and after dose interruption for
more than two weeks. ECGs and blood tests should also be obtained as clinically indicated during this
period and afterwards. Frequent ECG monitoring of the QTc interval should be continued.
Serum potassium, serum magnesium and serum calcium should be kept within normal range to
reduce the risk of ECG QTc prolongation. Additional monitoring of QTc, electrolytes and renal function
are required especially in case of diarrhoea, increase in diarrhoea/dehydration, electrolyte imbalance
and/or impaired renal function. If QTc increases markedly but stays below 500 msec, cardiologist
advice should be sought.
European Medicines Agency, vandetanib SmPC. © EMA [1995–2018].
Reproduced with permission from the European Medicines Agency22
The SmPC for cabozantinib23 also recommends close monitoring during the first 8 weeks of treatment:
As most events can occur early in the course of treatment, the physician should evaluate the patient
closely during the first eight weeks of treatment to determine if dose modifications are warranted.
Events that generally have early onset include hypocalcaemia, hypokalaemia, thrombocytopenia,
hypertension, palmarplantar erythrodysaesthesia syndrome (PPES), and gastrointestinal (GI) events
(abdominal or mouth pain, mucosal inflammation, constipation, diarrhoea, vomiting).
European Medicines Agency, cabozantinib SmPC. © EMA [1995–2018].
Reproduced with permission from the European Medicines Agency23
One of the clinical advisors to the assessment group (AG) noted that although cardiac toxicity is less for
cabozantinib than vandetanib, electrocardiographic monitoring may also be required.
Current service provision
Clinical guidelines
There are no clinical guidelines for the management of MTC in the UK. A NICE quality standard for head
and neck cancer has recently been published;24 however, this does not include the management of MTC.
Current National Institute for Health and Care Excellence technology appraisal guidance
There is currently no NICE technology appraisal guidance for interventions for the treatment of unresectable
locally advanced or metastatic MTC.
Current service cost
The current cost of managing MTC is uncertain. However, MTC is a very rare disease, with an estimated
annual incidence for England of around 170 new patients.1 Prescribing data from the Cancer Drugs Fund
(CDF) indicate that in 2016 (confidential information has been removed) new patients received vandetanib
and (confidential information has been removed) new patients received cabozantinib (Professor Peter Clark,
Chairperson of CDF, 2017, personal communication). The data from 2015 indicate very similar prescribing
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levels, with (confidential information has been removed) new patients starting vandetanib and (confidential
information has been removed) patients starting cabozantinib (Professor Peter Clark, personal communication).
Based on current prescribing levels, the cost of treating new MTC patients with cabozantinib and vandetanib
for 1 year (assuming full dose and excluding any discontinuation) is approximately £1.96M.
Variation in services and uncertainty about best practice
Clinical advisors to the AG noted that although the indications set out in the marketing authorisations for
cabozantinib and vandetanib22,23 relate to patients with progressive disease, this may be determined on the
basis of radiographic evidence or the presence of symptomatic disease. They also noted that, elsewhere in
Europe, clinicians often initiate treatment earlier on the basis of imaging, whereas clinicians in the UK tend to
consider symptomatic progression as the more important time point at which to initiate palliative treatment.
The SmPCs for both vandetanib and cabozantinib state that ‘For patients in whom Rearranged during
Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken
into account before individual treatment decision’ (p. 2) (© EMA [1995–2018]. Reproduced with
permission from the European Medicines Agency).22,23 Clinical advisors to the AG noted that all patients
should have an assessment of their germline RET status to check if their disease is sporadic or genetic. This
is, however, different from checking if the tumour expresses RET (somatic RET mutation testing). In the UK,
it is not routine practice to check the tumour (either primary or metastases) for RET mutations. Although
clinicians do not currently have routine access to mutation analysis, this may change in the future. The
clinical advisors warned that the RET status of the primary thyroid cancer may not reflect the mutation
landscape in the metastases and that it would be inadvisable to base recommendations about the use of
vandetanib and cabozantinib in the NHS on RET mutation status without a full and accurate picture of the
significance of somatic RET status. Furthermore, the clinicians commented that the thyroid primary may
have been removed many years before metastases develop; hence, at the time of relapse, the mutation
analysis may no longer be accurate. In addition, as cabozantinib and vandetanib have multiple targets,
although a patient may be RET mutation negative in the metastases, they may still obtain a treatment
response by virtue of other mutations that are targeted by the individual drug received.
Current treatment pathway
A summary of the treatment pathway, as developed by the AG, is presented in Figure 1. For patients who
are ineligible to receive cabozantinib or vandetanib, treatment is likely to comprise palliative treatments.
Both cabozantinib and vandetanib are currently available on the CDF as first-line treatments for unresectable,
locally advanced or metastatic MTC.25 The CDF indication for each therapy is the same, as shown in Box 1.
Description of technology under assessment
Interventions considered in the scope of this report
This assessment includes two interventions: cabozantinib and vandetanib.
Cabozantinib
Cabozantinib has an European Union (EU) marketing authorisation for the treatment of adult patients with
progressive, unresectable locally advanced or metastatic MTC. The SmPC for cabozantinib23 states that for
patients in whom RET mutation status is not known or is negative, a possible lower benefit should be taken
into account before an individual treatment decision. Cabozantinib is administered orally at a recommended
dose of 140 mg once daily, taken as one 80-mg capsule and three 20-mg capsules. Treatment should
continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.23
Cabozantinib is available in packs of (1) 80 × 20-mg capsules, (2) 28 × 20-mg capsules and 28 × 80-mg
capsules or (3) 84 × 20-mg capsules and 28 × 80-mg capsules. The list price for cabozantinib is £4800 per
pack. A confidential Patient Access Scheme (PAS) has been proposed for cabozantinib.
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Vandetanib
Vandetanib has an EU marketing authorisation for the treatment of aggressive and symptomatic MTC in
patients with unresectable locally advanced or metastatic disease (including children and adolescents aged
≥ 5 years).22 The SmPC for vandetanib22 states that, for patients in whom RET mutation is not known or is
negative, a possible lower benefit should be taken into account before an individual treatment decision.
Vandetanib is administered orally at a recommended dose of 300 mg once a day. Vandetanib may be
administered until disease progression or until the benefits of treatment continuation no longer outweigh
its risk, taking into account the severity of adverse events (AEs) in relation to the degree of clinical
stabilisation of the tumour status.22 Vandetanib is available in packs of (1) 30 × 100-mg tablets (cost per
pack of £2500) and (2) 30 × 300-mg tablets (cost per pack of £5000). A confidential PAS has also been
proposed for vandetanib.
BOX 1 The CDF indication for cabozantinib and vandetanib for the treatment of locally advanced or
metastatic MTC25
Cabozantanib and vandetanib are the first-line treatments of MTC when all of the following criteria are met:
l Aconsultantspecialistspecificallytrainedandaccredited intheuseofsystemicanticancertherapy
prescribesapplicationandfirstcycleofsystemicanticancertherapy.
l Unresectable, locallyadvancedormetastaticMTC,confirmedhistologically.
l First-line indication.
l Progressive,symptomaticdisease.
l Forcabozantinib:nohistoryoftyrosinekinasetherapyunless intolerantofvandetanibwithin3monthsof
starting itand,onvandetanib,toxicitythatcannotbemanagedbydosedelayordosemodificationand
absenceofdiseaseprogression.
l Forvandetanib:nohistoryoftyrosinekinasetherapyunless intolerantofcabozantinibwithin3monthsof
starting itand,oncabozantanib,toxicitythatcannotbemanagedbydosedelayordosemodificationDQG
absenceofdiseaseprogression.
Patients with symptomatic and
progressive disease
Known risk of GI
perforation,
haemorrhage or fistulae
Vandetanib
+ BSC
Known prolonged
corrected QT interval in
which risk factors cannot
be corrected for
Cabozantinib
+ BSC
No known GI or cardiac
risks
Vandetanib or
cabozantiniba
+ BSC
Other known
contraindications
to TKI therapy
BSC symptom relief
Palliative careb,c
FIGURE 1 Current treatment pathway for adults with symptomatic and progressive MTC. a, Patient may switch
to other TKI if intolerant or severe AEs are experienced within 3 months. Note that the vandetanib licence is in
aggressive and symptomatic disease, whereas the licence for cabozantinib is for progressive, unresectable locally
advanced or metastatic MTC. b, May include palliative surgery, palliative radiotherapy and/or treatments for bone
pain. c, Nuclear medicine therapies, such as MIBG/dotatate, may be considered in some patients. AE, adverse event;
BSC, best supportive care; GI, gastrointestinal; MIBG, iodine-123 metaiodobenzylguanidine; TKI, tyrosine kinase
inhibitor.
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Mode of action
Cabozantinib
Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in
tumour growth and angiogenesis, pathological bone remodelling and metastatic progression of cancer.
Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an
inhibitor of MET (hepatocyte growth factor receptor protein) and vascular endothelial growth factor (VEGF)
receptors. In addition, cabozantinib inhibits other tyrosine kinases including RET, the GAS6 receptor (AXL),
the stem cell factor receptor (KIT) and FMS-like tyrosine kinase-3.23
Vandetanib
Vandetanib is a potent inhibitor of VEGF receptor-2 (VEGFR-2) (also known as kinase insert domain-
containing receptor), epidermal growth factor receptor (EGFR) and RET tyrosine kinases. Vandetanib is
also a submicromolar inhibitor of vascular endothelial receptor-3 tyrosine kinase. Vandetanib inhibits
VEGF-stimulated endothelial cell migration, proliferation, survival and new blood vessel formation in in vitro
models of angiogenesis. In addition, vandetanib inhibits epidermal growth factor (EGF)-stimulated EGF RTK
in tumour cells and endothelial cells. Vandetanib inhibits EGFR-dependent cell proliferation and cell survival
in vitro. Vandetanib also inhibits both wild type and the majority of mutated, activated forms of RET, and
significantly inhibits the proliferation of MTC cell lines in vitro. In vivo vandetanib administration reduced
tumour cell-induced angiogenesis, tumour vessel permeability, tumour microvessel density, and inhibited
tumour growth of a range of human xenograft tumour models in athymic mice. Vandetanib also inhibited
the growth of MTC xenograft tumours in vivo. The precise mechanism of action of vandetanib in locally
advanced or metastatic MTC is unknown.22
Current usage in the NHS
As noted in Current service cost, both cabozantinib and vandetanib are currently available for use through
the CDF. Given the rarity of MTC, total prescribing rates of these products are low. In 2016, (confidential
information has been removed) new patients were prescribed cabozantinib or vandetanib through the CDF.
BACKGROUND
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Chapter 2 Definition of the decision problem
This assessment evaluates the clinical effectiveness and cost-effectiveness of cabozantinib and vandetanibwithin their marketing authorisations for treating unresectable or metastatic MTC. Vandetanib holds
an EU marketing authorisation for the treatment of aggressive and symptomatic MTC in patients with
unresectable locally advanced or metastatic MTC. Vandetanib is indicated in adults, adolescents and children
aged ≥ 5 years.22 Cabozantinib holds an EU marketing authorisation for the treatment of adult patients with
progressive, unresectable locally advanced or metastatic MTC.23 The SmPCs for each product state that, for
patients in whom RET mutation status is not known or is negative, a possible lower benefit should be taken
into account before an individual treatment decision.22,23
Decision problem
In line with the final NICE scope,26 the decision problem is specified as follows.
Population
l Adults with unresectable locally advanced or metastatic MTC.
In December 2016, the marketing authorisation for vandetanib was extended to include adolescents
and children aged ≥ 5 years;22 this population is beyond the scope of this appraisal.26 Clinical advisors
to the AG note that the incidence of unresectable locally advanced or metastatic MTC in children and
adolescents aged ≥ 5 years is expected to be extremely low.
Interventions
l Cabozantinib (oral).
l Vandetanib (oral).
Relevant comparators
Cabozantinib and vandetanib were compared with:
l each other
l best supportive care (BSC).
Outcomes
The following outcomes are included in this assessment:
l overall survival (OS)
l progression-free survival (PFS)
l response rates
l adverse effects of treatment
l HRQoL.
Although response rates were not included in the final NICE scope,26 this outcome has been included in
this assessment as it is a clinically relevant end point in the key trials considered in this report.27,28
Subgroups
The final NICE scope26 states that ‘If the evidence allows subgroups according to RET mutation status will
be considered.’ Based on the guidance of the clinical advisors to the AG (see Chapter 1, Variation in
services and uncertainty about best practice), RET mutation status has not been considered within the
health economic analysis presented in this report.
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Overall aims and objectives of assessment
The aims of the assessment are to:
1. evaluate the clinical effectiveness and safety of cabozantinib and vandetanib within their marketing
authorisations for treating unresectable locally advanced or metastatic MTC
2. estimate the incremental cost-effectiveness of cabozantinib and vandetanib compared with each other
and BSC
3. identify key areas for primary research
4. estimate the overall cost of these treatments in England.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Assessment of clinical effectiveness
This section presents a summary and critique of relevant studies on the efficacy and safety ofcabozantinib and vandetanib for the treatment of unresectable locally advanced or metastatic MTC.
The systematic review was conducted and reported following the general principles outlined in the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and checklist29
and the Centre for Reviews and Dissemination (CRD) guidance.30 The protocol for this review has been
registered with, and is available from, the PROSPERO database (registration number CRD42016050403).31
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
Methods for reviewing effectiveness
Inclusion criteria
The inclusion criteria for the reviews are described in Table 1. These criteria are in accordance with the
decision problem set out in the final NICE scope.26
TABLE 1 Inclusion and exclusion criteria
Element
Criteria
Inclusion Exclusion
Population Participants with unresectable locally advanced or metastatic
MTC, aged ≥ 18 years. Studies with populations broader
than unresectable locally advanced or metastatic MTC will be
considered only if data for the relevant study population are
available and are reported separately
Studies conducted in paediatric
populations
Interventions l Cabozantinib (oral)
l Vandetanib (oral)
Comparators Interventions will be compared with each other and against
BSC (including locally ablative treatments, such as
radiotherapy)
Outcomes The following outcomes will be included in the assessment:
l OS
l PFS
l Response rates
l Adverse effects of treatment
l HRQoL
Study design RCTs are to be included in the clinical effectiveness
systematic review. If no relevant RCTs are identified for an
intervention, non-randomised comparative studies will be
considered for inclusion. Non-randomised comparative
studies are also to be included, when necessary, as a source
of additional evidence (e.g. regarding AEs related to the
interventions)
Pre-clinical or biological studies, as well as
studies of animal models, will be excluded.
The following publication types will not be
considered for inclusion in the review and
synthesis, although the reference lists of
reviews and guidelines will be checked for
additional relevant trials: narrative reviews,
systematic reviews, clinical guidelines,
editorials, letters, opinion pieces and
abstracts with insufficient details to assess
study quality or results
Language Searches were not limited by language N/A
N/A, not applicable; RCT, randomised controlled trial.
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Searches
A comprehensive literature search was undertaken to systematically identify randomised controlled trials
(RCTs) and systematic reviews (for the identification of additional trials) of the clinical effectiveness of
cabozantinib and vandetanib for the treatment of unresectable locally advanced or metastatic MTC.
The following electronic databases were searched from inception to November 2016:
l MEDLINE – via Ovid, 1946 to present.
l MEDLINE In-Process & Other Non-Indexed Citations – via Ovid, 1946 to present.
l MEDLINE Epub Ahead of Print – via Ovid, 1946 to present.
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) – via EBSCOhost, 1982 to present.
l EMBASE – via Ovid, 1980 to present.
l Cochrane Database of Systematic Reviews – via Wiley Online Library, 1996 to present.
l Cochrane Central Register of Controlled Trials (CENTRAL) – via Wiley Online Library, 1995 to present.
l Database of Abstracts of Reviews of Effects – via Wiley Online Library, 1995 to 2015.
l Health Technology Assessment Database (HTA) – via Wiley Online Library, 1995 to present.
l Web of Science [Science Citation Index (SCI)] – via Clarivate Analytics (formerly Thomson Reuters),
1900 to present.
l Conference Proceedings Citation Index (CPCI) – via Clarivate Analytics (formerly Thomson Reuters),
1990 to present.
To identify ongoing or recently completed studies, trial registers were searched using the International
Clinical Trials Registry Portal of the World Health Organization (WHO),32 which regularly compiles and
updates data from > 15 clinical trial registers.
Searches were not limited by language or publication date and were not restricted to published research
only. Search terms included medical subject heading (MeSH) terms and free-text synonyms for MTC
combined with a RCT or systematic review study design filter. The search strategy was designed to be
deliberately broad to capture all intervention studies within the MTC population, that is, studies of
cabozantinib and vandetanib, as well as additional evidence for possible comparators, including BSC and
radiotherapy, as such studies may be used to inform indirect comparisons. The MEDLINE search strategy is
presented in Appendix 1.
To identify additional studies, reference lists of relevant studies, systematic reviews, clinical guidelines and
submissions to regulatory authorities and advisory bodies [All Wales Medicines Strategy Group (AWMSG),
Scottish Medicines Consortium (SMC), European Medicines Agency (EMA) and the US Food and Drug
Administration] were examined. In addition, company submissions (CSs) to NICE related to the interventions
within the scope of this review were examined. Citation searches of key included studies using the Web of
Science database were also conducted. Clinical advisors to the AG provided advice on whether or not any
relevant studies were missing from the search results.
A comprehensive database of relevant published and unpublished articles was constructed using EndNote
version 8 [Clarivate Analytics (formerly Thomson Reuters), Philadelphia, PA, USA] software.
Study selection and data extraction
Following standard systematic review processes, two reviewers (CC and EK) independently screened
all titles and abstracts using the eligibility criteria outlined in Table 1; full papers were retrieved for any
publication that was deemed by a reviewer to be potentially includable. The two reviewers independently
screened all full texts to identify studies that satisfied the inclusion criteria. Any discrepancies between
reviewers were resolved through discussion. Results were reported in text, tables and a PRISMA flow chart.
Data extraction was performed by one reviewer (CC) and was independently checked for errors against the
original and published trial reports by the second reviewer (EK). Any discrepancies were resolved through
discussion. Results were reported in text and tables.
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Quality assessment
For the RCT evidence, critical appraisal of included trials was conducted by one reviewer (CC) using the
Cochrane Risk of Bias tool;33 this was checked by a second reviewer (EK) and any discrepancies were
resolved through discussion.
Evidence synthesis
Details of the included RCTs, including population characteristics, interventions, comparators and outcomes,
were tabulated and discussed in a narrative review. On account of the small number of included studies,
with just one study contributing evidence for each of the interventions, pairwise meta-analysis was not
appropriate. In the absence of direct evidence comparing cabozantinib with vandetanib, a network
meta-analysis (NMA) was performed using the ZETA trial EU-label and Efficacy of XL184 (Cabozantinib) in
Advanced Medullary Thyroid Cancer (EXAM) trial intention-to-treat (ITT) populations (see Network
meta-analysis).
Results
Quantity and quality of research available
The details of the study selection process are outlined in the PRISMA flow chart (Figure 2). The search
identified 1581 references after deduplication, of which 1516 were excluded because they did not satisfy
the eligibility criteria. The full texts of 65 studies were retrieved to assess eligibility; 38 of these studies were
excluded for the following reasons: absence of a control arm (n = 17), review (n = 6), letter/commentary
(n = 6), wrong population (n = 5), wrong intervention (n = 2), animal study (n = 1) and a duplicate (n = 1).
A list of excluded full papers, with reasons, is provided in Appendix 2. The excluded studies included
 Reasons for exclusion:
 • Non-controlled, n = 17
 • Review, n = 6
 • Letter/commentary, n = 6
 • Population, n = 5
 • Intervention, n = 2
 • Animal study, n = 1
 • Duplicate, n = 1
• Cabozantinib papers, n = 15
• Studies, n = 2
• EXAM trial papers, n = 13
• Ongoing EXAMINER trial, n = 2
• Vandetanib papers, n = 12
• Studies, n = 3
• ZETA trial papers, n = 10
• Two ongoing trials, n = 2
Total number of hits
(n = 2189)
Number after deduplication
(n = 1581)
Full papers
(n = 65)
Total number of papers
(n = 27)
Total number of studies
(n = 5)
Exclusions
(n = 38)
Titles/abstracts excluded 
(n = 1516)
FIGURE 2 PRISMA flow chart.
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two single-arm studies of vandetanib in children and adolescents with unresectable locally advanced or
metastatic MTC as a result of MEN 2 (one published study34 and one ongoing study35). These studies may
be relevant to the extension to the marketing authorisation for vandetanib;22 however, this population is
beyond the scope of this appraisal.
There were five potentially relevant controlled trials of comparator interventions, principally other tyrosine
kinase inhibitors (TKIs), one of which ended prematurely because of recruitment issues;36 the remaining
four studies37–40 are ongoing. There is also one published retrospective study41 comparing MTC patients
who received radioactive iodine therapy with those whose did not. As a result, there was no appropriate
additional controlled trial evidence of other potential comparators to cabozantinib or vandetanib
(e.g. radiotherapy) that could may have been used to inform a NMA.
The final result was 27 publications and protocols relating to five RCTs. For cabozantinib, this included
13 publications28,42–53 relating to the Phase III EXAM trial,28,42 which compared 140 mg per day of
cabozantinib with placebo, and two publications54,55 relating to the ongoing EXAMINER trial,54 which
compares 140mg per day with 60mg per day of cabozantinib, and seeks to recruit 188 participants (expected
completion date: March 2019).55 For vandetanib, this included 10 publications18,27,56–63 relating to the Phase III
ZETA trial,27,56 which compares 300 mg per day of vandetanib with placebo, and two publications64,65 relating
to two ongoing vandetanib trials: one trial64 comparing 300mg per day with 150 mg per day of vandetanib,
and one65 comparing vandetanib with vandetanib plus bortezomib (Velcade®, Takeda, Osaka, Japan).
No additional relevant papers or studies were identified from the reference lists of included studies or
reviews, or from citation searching of the key publications for the EXAM or ZETA trials. The clinical advisors
to the AG were satisfied that no other relevant studies were missing.
The two pivotal Phase III trials, EXAM and ZETA, were international, multicentre, placebo-controlled trials.
The characteristics of the EXAM and ZETA trials are presented in Table 2.
The clinical evidence submitted to NICE by the manufacturers of cabozantinib21 and vandetanib66 included
data from six studies. All of these studies were identified by the search for this review, but only four studies
satisfied the review eligibility criteria: for cabozantinib, the EXAM trial and ongoing EXAMINER trial,54 and for
vandetanib, the ZETA trial and the ongoing NCT01496313 trial.64 The submissions also included data from a
Phase I, non-controlled, single-arm cabozantinib, dose-escalation trial, which included a subset of relevant
MTC patients;67,68 a controlled study to assess the addition of an outreach programme to vandetanib
treatment;69 and two ‘real-world’, non-controlled, single-arm vandetanib studies.70–72 All of these studies
were identified by the search but were excluded from this review because they did not satisfy the eligibility
criteria; either they were single-arm cohort studies without a control group or the intervention evaluated in
the trial did not relate to either cabozantinib or vandetanib (see Appendix 2).
The inclusion and exclusion criteria of the two trials were virtually identical, with the exception that the
cabozantinib EXAM trial participants were required to have radiographic evidence of progressive disease
(PD) at baseline. This was not an eligibility criterion for the vandetanib ZETA trial as the percentage of
participants with ‘aggressive and symptomatic disease’ at baseline is reported to be 56% (186/331).57 The
cabozantinib trial had a median follow-up of 13.9 months, compared with 24 months for the vandetanib
trial. The two trials had common primary (PFS) and secondary [OS, objective response rate (ORR), RET
mutation status, CTN and CEA levels] end points. The cabozantinib trial assessed quality of life using the MD
Anderson Symptom Inventory for thyroid cancer (MDASI-Thy), whereas the vandetanib trial also assessed
disease control rate, and measured quality of life using the Functional Assessment of Cancer Therapy –
General (FACT-G) tool and time to worsening of pain (TWP). It is noteworthy that the MDASI-Thy and TWP
were both listed in the protocols but were not reported in the publications of the EXAM trial [only in the
clinical study reports (CSRs)], whereas the FACT-G was not listed in any publication of the ZETA trial, but its
results were reported in the Sanofi CS.66
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The definitions of PFS used in the trials were similar (i.e. the time from random assignment to the date
of disease progression or death) and both trials employed a central committee to confirm investigator
assessments. However, the EXAM trial used the modified RECIST (mRECIST) criteria10 and employed a blinded
independent review committee, whereas the ZETA trial used the standard RECIST criteria, and it is unclear
whether or not the central review was blinded.
The EXAM and ZETA trials had 330 and 331 participants, respectively (Table 3). Both trials randomised
patients 2 : 1 to receive the active drug or placebo, respectively. In terms of baseline characteristics, the two
arms of the cabozantinib EXAM trial are generally well balanced with the possible exceptions of Eastern
Cooperative Oncology Group (ECOG) performance status of 0 (56.2% in the cabozantinib arm vs. 50.5% in
the placebo arm), the proportion who had received prior systemic therapy for MTC (37% in the cabozantinib
arm vs. 42% in the placebo arm) and positive RET mutation status (46.1% in the cabozantinib arm vs.
52.3% in the placebo arm), indicating that the control group might have had more severe disease.
TABLE 2 Characteristics of included RCTs
Study
Trial
EXAM28 (carbozantinib) ZETA27 (vandetanib)
Design International (including Europe), multicentre, Phase III,
parallel-group, double-blind RCT
International (including Europe), multicentre,
Phase III, parallel-group, double-blind RCT
Follow-up 13.9 months (median); range 3.6–32.5 months 24 months (median)
Populationa l Eligible participants were adults with
histologically confirmed, unresectable, locally
advanced or metastatic MTC
l Participants were required to have radiographic
disease progression per mRECIST guidelines at
screening compared with an image obtained
within the previous 14 months. Documentation
of PD to establish eligibility was by independent
review in 89.4% of patients, and by investigator
assessment in the remaining patients
Exclusion criteria:
l Included – prior systemic anticancer therapy
within 4 weeks or significant cardiac,
haematopoietic, hepatic, or renal dysfunction.
There was no limit on prior therapy beyond the
exclusion criteria
l Eligible participants were adults who
had measurable, unresectable locally
advanced or metastatic, hereditary or
sporadic MTC. Submission of a tumour
sample was required except from
patients with hereditary MTC who had
a documented germline RET mutation
l Other key inclusion criteria were WHO
performance status of 0–2 and a serum
CTN level of ≥ 500 pg/ml
Exclusion criteria:
l Included – administration of chemotherapy
and/or radiation therapy within 4 weeks
before random assignment, or significant
cardiac, haematopoietic, hepatic or renal
dysfunction
Intervention 140mg of cabozantinib (free-base equivalent),
taken orally once per day until either intolerable
toxicity or disease progression as per mRECIST.
Dose holds and up to two dose level reductions
(to a minimum dose of 60 mg per day) were allowed
300mg of vandetanib taken orally once per
day until disease progression
Comparator Placebo Placebo
Outcomes l Primary end point: PFS (assessed every 12 weeks
until progression)
l Secondary end points: OS, ORR, RET mutation
status, CTN and CEA levels
l AEs measured using CTCAE
l Primary end point: PFS (assessed every
12 weeks until progression)
l Secondary end points: OS, ORR and
duration of response, disease control rate
at 24 weeks; RET mutation status, CTN,
time to worsening of pain, CEA
l AEs measured using CTCAE
CTCAE, Common Terminology Criteria for Adverse Events; mRECIST, modified Response Evaluation Criteria in Solid Tumours;
ORR, objective response rate; PD, progressive disease.
a Some additional criteria are detailed in the protocols for cabozantinib42 and vandetanib.56
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RET mutation status was unknown in 39% of participants as a result of missing sequence data or the presence
of a mutation of unknown significance.28 The two arms of the vandetanib ZETA trial were also generally
well balanced, albeit with higher proportions of participants in the control arm than the treatment arm also
potentially having more severe disease on account of a WHO performance status of 1–2 (42% for the placebo
arm vs. 33% for the vandetanib arm) and having involvement of two or more organs (92% for the placebo
arm vs. 87% for the vandetanib arm).
TABLE 3 Participants’ baseline characteristics from the EXAM and ZETA trials
Participant characteristics
Trial
EXAM28 (N= 330) ZETA27 (N= 331)
Cabozantinib,
140mg (n= 219)
Placebo
(n= 111)
Vandetanib,
300mg (n= 231)
Placebo
(n= 100)
Male, n (%) 151 (69) 70 (63) 134 (58) 56 (56)
Age (years), median (range) 55 (20–86) 55 (21–79) 51a (NR) 53a (NR)
Disease type, n (%)
Hereditary 12 (6) 8 (7) 28 (12) 5 (5)
Sporadic or unknown 207b (95) 103 (93) 203 (88) 95 (95)
Locally advanced NR 14 (6) 3 (3)
Metastatic NR 217 (94) 97 (97)
RET mutation status, n (%)
Positive 101 (46) 58 (52) 137 (59) 50 (50)
Negative 31 (14) 10 (9) 2 (1) 6 (6)
Unknown 87 (40) 43 (39) 92 (40) 44 (44)
Performance status, n (%) (ECOG/WHO)
0 123 (56) 56 (51) 154 (67) 58 (58)
1 or 2 95 (43) 55 (50) 77 (33) 42 (42)
Number of organs involvedc
0 or 1 28 (13) 15 (14) 29 (13) 8 (8)
≥ 2 191 (87) 96 (87) 202 (87) 92 (92)
Prior systemic therapy for MTC 81 (37) 47 (42) 90 (39) 42 (42)
Prior thyroidectomy 201 (92) 104 (94) NR NR
Prior anticancer therapy 85 (39) 48 (43) NR NR
Prior TKI, n (%)
Yes 44 (20) 24 (22) NR NR
No 171 (78) 86 (78) NR NR
Unknown 4 (2) 1 (1) NR NR
ECOG, Eastern Cooperative Oncology Group; NR, not reported.
a Mean.
b Discrete data for sporadic disease are reported for the EXAM trial (191/291= 88%), which is higher than the proportion
of patients usually presenting with sporadic disease (75%).27,28
c Excluding thyroid.
Note
All decimals are rounded up to the nearest whole number.
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Comparing the two trials, the vandetanib ZETA trial included substantially greater proportions of participants
with hereditary disease (12% in the vandetanib arm vs. 6% in the cabozantinib intervention arm) and
participants with a performance status of 0 (67% in the vandetanib arm vs. 56% in the cabozantinib arm).
However, the principal difference between the EXAM and ZETA trial populations concerns the presence
of PD: participants in the EXAM trial were required to have evidence of PD, whereas participants in the
ZETA trial were not. The two ITT populations are therefore sufficiently different to invalidate a standard
indirect comparison.
In both trials, participants discontinued study treatment if there was evidence of disease progression or toxicity.
The ZETA trial, however, also permitted treatment continuation or treatment switching post progression.27
During the randomised phase, if there was disease progression based on investigator assessment, participants
discontinued study treatment, but were offered the opportunity to receive vandetanib post progression as
unblinded open-label treatment until normal discontinuation criteria applied (e.g. toxicity or progression).27 In
the vandetanib arm during the randomised stage of the trial, 120 out of 231 (52%) participants discontinued
treatment because of progression or toxicity (compared with 55% in the cabozantinib trial28), but 44 of these
120 (37%) participants continued to receive vandetanib in the open-label phase. In the placebo arm of the
ZETA trial, 71 out of 99 (72%) discontinued ‘treatment’ because of progression or toxicity (compared with
86% in the cabozantinib trial), and 58 of these 71 (82%) participants then switched to receive vandetanib in
the open-label phase. All efficacy and safety data reported subsequently are subject to bias because of
treatment switching, unless otherwise stated. This raises issues of confounding for some of the outcome data
from the ZETA trial.
The marketing authorisation for vandetanib states that it is indicated ‘for the treatment of aggressive and
symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic
disease’.22 The terms ‘aggressive’ and ‘symptomatic’ are not defined in the licence, but were defined
post hoc. The Sanofi CS for vandetanib66 presents PFS and OS outcome data from post hoc analyses on
two preplanned subpopulations within the ZETA trial (and, as such, are more restrictive than the overall
population recruited to this trial):
l Patients with unresectable, locally advanced or metastatic MTC and whose disease is ‘progressive
and symptomatic’ (defined as having ‘documented progression 12 months prior to enrolment and at
least one of the following symptoms at baseline: pain score > 4, ≥ 10 mg/day opioid use, diarrhoea,
flushing, fatigue, pain, nausea, dysphagia, dysphonia, respiratory symptoms, and weight loss.’57 This
corresponds to the ‘EU-label’ or ‘progressive and symptomatic’ population (n = 186) referred to in the
Sanofi CS.66 In the post hoc analyses conducted by the company, the data reported by Kreissl et al.57
could not be replicated exactly, and the number reported is n = 190 for PFS and n = 189 for OS
data in the Sanofi CS (see the Sanofi CS,66 appendix 6, tables 5 and 7, respectively). Numbers from
the published Kreissl et al.57 analyses are used throughout the clinical-effectiveness section, whereas
the cost-effectiveness section is based on the slightly larger subgroup defined for the purposes of the
NICE submission.
l Patients with unresectable, locally advanced or metastatic MTC whose disease is ‘progressive and
symptomatic’ (as above) and is ‘aggressive’, that is, with CTN and CEA doubling times of < 24 months
from screening. This is the so-called ‘restricted EU-label population’ [n = (confidential information has
been removed)] presented in the Sanofi CS. The Sanofi CS claims that ‘This population closely reflects
UK clinical practice for TKI treatment’ (Sanofi CS,66 pp. 11 and 54). However, clinical advice received by
the AG suggests that CTN and CEA monitoring would not usually inform decisions about whether or
not to commence TKI therapy, as this is principally determined by radiographic evidence of progression
and symptoms.
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The data presented for these groups are partly unpublished (only the PFS and ORR data for the EU-label
population are published)57 and are reported here because they are used to inform the health economic
model developed by the AG. The baseline characteristics of these subgroups are presented in Table 4,
together with the comparable baseline data for the EXAM trial ITT population. Despite the EXAM trial ITT
population being ‘progressive’ and the EU-label ZETA trial population being ‘progressive and symptomatic’,
clinical advice received by the AG confirmed that these two populations were comparable.
It should also be noted that, among the EU-label population, (confidential information has been removed) of
patients in the intervention group continued to receive vandetanib in the open-label phase, whereas (confidential
information has been removed) of patients in the placebo arm ‘crossed over’ to receive open-label vandetanib
(see Sanofi clarification response,73 question 3). In the restricted EU-label population, (confidential information
has been removed) of patients in the intervention group continued to receive vandetanib in the open-label
phase, whereas (confidential information has been removed) of patients in the placebo arm ‘crossed over’
to receive open-label vandetanib (Sanofi CS,66 pp. 17 and 63). All efficacy and safety data reported
TABLE 4 Participants’ baseline characteristics in the cabozantinib ‘progressive’ and the vandetanib EU-label and
restricted EU-label populations
Participant
characteristics
Trial
EXAM28 ‘progressive’
(N= 330)
ZETA
EU label, ‘progressive
and symptomatic’
(N= 186)
Restricted EU label, ‘progressive, symptomatic
and with CTN/CEA criteria’ (confidential
information has been removed)
Intervention
Cabozantinib,
140 mg
(n= 219)
Placebo
(n= 111)
Vandetanib,
300 mg
(n= 126)
Placebo
(n= 60)
(Confidential
information has been
removed)
(Confidential
information has been
removed)
Male (%) 69 69 63 65 (Confidential information
has been removed)
(Confidential information
has been removed)
Age (years),
median
55 55 53.1 53.9 (Confidential information
has been removed)
(Confidential information
has been removed)
Disease type (%)
Hereditary 6 7 8.7 3.3 (Confidential information
has been removed)
(Confidential information
has been removed)
Sporadic 95 93 50.8 46.7 (Confidential information
has been removed)
(Confidential information
has been removed)
Locally
advanced
NR NR 5.6 1.7 (Confidential information
has been removed)
(Confidential information
has been removed)
Metastatic NR NR 94.4 98.3 (Confidential information
has been removed)
(Confidential information
has been removed)
RET mutation status (%)
Positive 46.1 52.3 59.5 50.0 (Confidential information
has been removed)
(Confidential information
has been removed)
Negative 13.2 9.0 0.8 10.0 (Confidential information
has been removed)
(Confidential information
has been removed)
Unknown 39.7 38.7 39.7 40.0 (Confidential information
has been removed)
(Confidential information
has been removed)
Prior systemic
therapy for
MTC
37 42 35.7 48.3 (Confidential information
has been removed)
(Confidential information
has been removed)
NR, not reported.
Data from Sanofi CS,66 tables 17 and 19, and Wells et al.27
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subsequently for this group are subject to bias because of treatment switching, unless otherwise stated.
This raises issues of confounding for some of the trial data, including for the restricted EU-label population.
The risk of bias in the EXAM and ZETA trials was assessed using the Cochrane Risk of Bias Tool (Table 5).
These assessments made use of the protocols (published and unpublished), the trial publications and
unpublished CSRs for each trial.
TABLE 5 Risk-of-bias assessment (Cochrane tool) of included RCTs
Risk of bias Criteria
Trial
EXAM (cabozantinib)28 ZETA (vandetanib)27
Selection bias Random-sequence
generation and
allocation
concealment
Unclear
l ‘Patients were randomly assigned
in a 2 : 1 ratio to receive
cabozantinib or placebo in a
double-blinded fashion and were
stratified by age (< 65 years,
> 65 years) and prior TKI
treatment (yes, no)’
l Protocols (manuscript supplement
and published NCT record) and
unpublished CSR55 (section 9.4.3)
provide no further details on how
randomisation was conducted
Unclear
l Participants recruited to this
multicentre, Phase III study were
randomly assigned in a 2 : 1 ratio to
receive oral vandetanib at a starting
dose of 300 mg per day or placebo
until disease progression
l The published protocol (NCT),
published CSR, which accompanied
the full publication,27 and an earlier
unpublished CSR,74 provide no
further details on how randomisation
was conducted. An unpublished CSR
(October 2014) clarified that the
randomisation was computer-
generated. Independent
randomisation does not appear to
have been conducted
Performance
bias
Blinding of
participants and
personnel
Low
l ‘Double-blind’ was reported but
not described in publications,
but the unpublished CSR details
who was blinded and the manner
in which the placebo was
‘indistinguishable’ from the active
treatment (section 9.4.7 of the
unpublished CSR).57 There was no
evaluation of blinding
Moderate to high
l ‘Double-blind’ was reported but
not described. Published CSR and
unpublished CSRs state: ‘placebo
to match vandetanib.’ The CSR
from October 201475 states that:
. . . methods for ensuring blinding
and the procedures for unblinding
the study are described in Section
5.4 of the CSP
These details could not be verified
(as they were not reported in any
available protocol). Therefore, there
was no evaluation of blinding and
insufficient detail was provided
regarding how blinding was
guaranteed
l A number of outcomes were also
potentially confounded by the
inclusion of individuals who had
switched to open-label (unblinded)
treatment (e.g. OS and safety
outcomes, as well as post-progression
PFS and ORR)
continued
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TABLE 5 Risk-of-bias assessment (Cochrane tool) of included RCTs (continued )
Risk of bias Criteria
Trial
EXAM (cabozantinib)28 ZETA (vandetanib)27
Detection bias Blinding of
outcome
assessment
Low
Tumor assessments were
performed by a blinded IRC to
determine response and/or
progression for the primary
efficacy analyses . . .
l The primary outcome, PFS,
was assessed by a blinded
independent radiology
review committee (IRC)
Moderate
Tumor assessments were categorized
by the investigator by using Response
Evaluation Criteria in Solid Tumors v1.0
(RECIST). Responses were confirmed by
central review of separate assessments
performed at least 4 weeks apart.
RECIST assessments derived from an
independent central review of patient
scans were the basis for the primary
analysis
Wells et al.27
l The majority of trial documents
do not state whether or not the
confirmatory ‘independent central
review’ was blinded. This is stated
only in an unpublished CSR from
July 2011,74 in which the PFS efficacy
results are described as being ‘based
on an independent, blinded central
review’ (p. 180) (repeated in the
Sanofi CS,66 p. 41). This information
does not appear elsewhere in available
protocols, other CSRs or publications
l The CSR accompanying the main
publication27 and the unpublished
CSR of July 201174 are the only
documents to indicate that the
RECIST criteria applied in the ZETA
trial were ‘modified’; this is detailed
in the unpublished CSR as being
based on ‘particular radiographic
characteristics, hypodense lesions,
and calcified lesions.’ (p. 48)
l A number of outcomes are also
potentially confounded by the
inclusion of individuals who had
switched to open-label treatment
(e.g. OS, ORR, AEs)
Attrition bias Incomplete
outcome data
Low
l There were high levels of attrition
(discontinuation of treatment), but
the assumption was that disease
had progressed from the point
at which data were censored28
The primary analysis of PFS was
event driven . . . and included all
randomly assigned patients (i.e.,
the intention-to-treat population)
. . . all patients except the first 138
to experience an event were
censored in the PFS analysis,
contributing time-to-event data
until the date of censoring
Low
l There were high levels of attrition
(discontinuation of treatment), but
the assumption is that disease had
progressed from the point at which
data are censored.27 PFS and OS
analyses were conducted using the
log-rank test (unadjusted model with
treatment factor only) in the ITT
population. Patients who were
progression free or who had died at
the time of analysis were censored
at the time of their last evaluable
RECIST assessment. If a patient was
progression-free according to the
central read when the patient started
to receive open-label treatment, the
open-label assessments were included
in the derivation of these endpoints
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The AG considers the EXAM trial to be of generally good quality, being assessed as having a low risk of
performance, detection and attrition bias on account of measures to ensure blinding and the management
of dropouts. The EXAM trial is at unclear risk of selection bias because full details of the randomisation
and allocation concealment processes were absent from the documents identified from the searches, or
from those made available during this appraisal. It was at moderate risk of reporting bias on account of
the failure to report the results of some outcomes in published documents, and at moderate risk of other
bias owing to potential conflicts of interest and the failure to control for the possible treatment effect
modifier of CTN and CEA doubling times.
Overall, the AG considers that the ZETA trial was at moderate to high risk of bias across most domains.
As with the EXAM trial, the likelihood of attrition bias was considered to be low and the risk of selection
bias was unclear. However, there was a moderate risk of reporting and other bias because of the presence
of selective reporting and some potential conflicts of interest, although post hoc analyses were conducted
on the potential treatment effect modifier of CTN and CEA doubling times. In contrast to the EXAM trial,
performance bias and detection bias were assessed as being of moderate to high risk because there was a
lack of detail on blinding procedures and certain outcomes, and their results were potentially confounded
by the inclusion of patients switching to open-label treatment within the analysis.
TABLE 5 Risk-of-bias assessment (Cochrane tool) of included RCTs (continued )
Risk of bias Criteria
Trial
EXAM (cabozantinib)28 ZETA (vandetanib)27
Reporting bias Selective reporting Moderate
l The primary and principal
secondary outcomes (OS, ORR)
are reported, but some outcomes
listed in the protocol that
accompanied the publication28
were not reported in the
publication or its related data
supplement, only in the
unpublished CSR (e.g. sections
11.4.4.2 and 12.1.6).76 These are
the patient-reported outcome
MDASI-Thy module, plus two
‘safety endpoints’: ECOG
performance status and
concomitant medications
Moderate
l All of the outcomes reported in
the protocol were reported in the
publication or the published CSR,27
except the FACT-G quality-of-life
measure, which was not listed in
the published protocols and was
only reported in an unpublished CSR
from October 201475 (data were not
reported, only a summary finding).
TWP was listed in the protocol, but
results only appear in the published
and unpublished CSRs
Other bias Any important
concerns about
bias not addressed
above
Moderate
l Many declared conflicts of
interests among the authors
l There were reported differences
between the two trial arms in the
prognostic factors CTN and CEA,
although in the publication ‘these
baseline values were judged to be
not meaningfully different’.28
However, CTN and CEA doubling
times are a potential confounder
and is neither controlled for (e.g.
by stratification) nor assessed15
Moderate
l Many declared conflicts of interests
among the authors
The principal investigator, in
collaboration with the study sponsor,
AstraZeneca, designed the clinical
trial. The sponsor provided funding
and organisational support, collected
and managed the data, and
performed the statistical analysis
l CTN and CEA doubling times were
assessed as confounders19 (and the
Sanofi CS,66 figure 4, p. 51)
CSP, clinical study protocol; NCT, National Clinical Trial.
Note
All quotations are taken from the full trial publication, except where otherwise specified.
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Assessment of effectiveness
In the EXAM trial, at the data cut-off point (15 June 2011), the median duration of follow-up was 13.9
months. At this time point, 98 out of 219 (45%) participants in the cabozantinib arm were still receiving
blinded study treatment, whereas only 15 out of 111 (14%) participants in the placebo arm were still
receiving blinded study treatment.28 In the ZETA trial, at the data cut-off point (July 2009), the median
duration of follow-up was 24 months. At this time point, 111 out of 231 (48%) participants in the
vandetanib arm were still receiving blinded study treatment, whereas only 28 out of 100 (28%) participants
in the placebo arm were still receiving blinded study treatment.27
Progression-free survival
Both pivotal trials reported PFS as their primary outcome using similar definitions and based on tumour
measurements performed at screening and every 12 weeks. Both treatments resulted in a significantly
reduced risk of progression. For cabozantinib, the hazard ratio (HR) for PFS was reported to be 0.28
[95% confidence interval (CI) 0.19 to 0.40; p < 0.001] by central review and 0.29 (95% CI 0.21 to 0.42;
p < 0.001) by investigator read28,43 (Table 6). For vandetanib, the HR for PFS was reported to be 0.46
(95% CI 0.31 to 0.69; p < 0.001) by central review of all patients (ITT population), 0.28 (95% CI 0.18 to 0.42;
p < 0.001) by central review excluding open-label patients, and (confidential information has been removed).
In the post hoc analysis, PFS was also calculated for the EU-label (n = 186) and restricted EU-label
(confidential information has been removed) populations. For the vandetanib EU-label population, the HR
for PFS was reported to be 0.47 (95% CI 0.29 to 0.77; p = 0.0024) by central review66 and 0.33 (95% CI
0.20 to 0.53; p = 0.0226) by investigator read.57 The HR by central review but excluding open-label patients57
was reported to be 0.32 (95% CI 0.19 to 0.54; p < 0.001). According to the Sanofi CS (p. 55),66 the median
PFS for the restricted EU-label group was (confidential information has been removed) in the placebo arm
compared with (confidential information has been removed) in the vandetanib arm (confidential information
has been removed).
The investigator-read risk of progression, compared with placebo, for the comparable EXAM trial (n = 331)
and ZETA trial EU-label (n = 186) populations was HR 0.29 (95% CI 0.21 to 0.42; p < 0.001) for cabozantinib
and HR 0.33 (95% CI 0.2 to 0.53; p = 0.0226) for vandetanib, respectively.
The proportion of randomised patients progressing was similar in the treatment and placebo groups across
the two trials. The EXAM trial publication (i.e. Elisei et al.)28 states that 57 out of 219 (26%) participants
randomised to cabozantinib had progressed at follow-up compared with 67 out of 111 (60%) participants
in the placebo group. The ZETA trial publication27 reported data on 124 participants who progressed:
73 out of 231 (32%) participants randomised to vandetanib had progressed (previously reported as 37%
at 24 months58) and 51 out of 100 (51%) participants randomised to placebo had progressed.
In the EXAM trial, the Kaplan–Meier estimates for the proportion of participants alive and progression free
at 1 year were reported to be 47.3% for cabozantinib compared with 7.2% for placebo.28 In the ZETA
trial, the proportion of participants in the ITT population alive and progression free at 6 months was
reported to be 91% for vandetanib compared with 74% for placebo.59
Subgroup analyses according to prespecified subgroups were conducted for PFS for both cabozantinib
and vandetanib. For both interventions, all subgroups demonstrated a beneficial effect with treatment
(HR < 1.0), although 95% CIs indicated non-statistically significant treatment effects for some small
subgroups, as may be expected. Subgroups considered included sex, performance status, and number of
previous anticancer regimens or other TKIs received and response to those therapies.27,28,43,44,77 The Ipsen
CS21 for cabozantinib reported that PFS was also prolonged in a subgroup of cabozantinib patients (n = 34)
who had received prior vandetanib (median PFS was 12.8 months for cabozantinib and 2.8 months for
placebo, and ORR was 28%, when prior vandetanib use reported). PFS for cabozantinib was also consistent
across subgroups according to age and the presence of bone metastases28 and PFS for vandetanib was not
sensitive to ethnicity.27
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Subgroup analyses based on RET mutation status (as specified in the final NICE scope26) were also conducted
for the EXAM trial. Details of the number of participants in each of these groups within the EXAM trial are
presented in Tables 7 and 8. The data demonstrate that cabozantinib was associated with a beneficial effect
compared with placebo for all subgroups tested (see Tables 7 and 8) although the treatment effect was not
statistically significant at the 95% level (p = 0.21) for the RET-negative subgroup, and PFS improvement was
least pronounced in the small subset of RET mutation-negative participants who were also RAt Sarcoma
(RAS) mutation negative.45,46
With respect to vandetanib, the Sanofi CS states that, ‘subgroups relating to two different definitions for
“aggressive disease” were included in a pre-specified subgroup analysis: calcitonin (CTN) doubling time
(DT) ≤ 24 months and CEA DT ≤ 24 months’ (Sanofi CS,66 section 4.3, p. 45). Subgroup analyses by these
criteria were reported in this CS66 and the unpublished CSR.74 These found that all subgroups demonstrated
TABLE 6 The EXAM and ZETA trials’ median PFS durations (months)
Assessed by
Trial arm
HR (95% CI; p-value)Cabozantinib (n= 219) Placebo (n= 111)
EXAM trial, (n = 330)28
Central review 11.2 4.0 0.28 (0.19 to 0.40;
< 0.001)
Investigator 13.8 3.1 0.29 (0.21 to 0.42;
< 0.001)
Vandetanib (n= 231) Placebo (n= 100)
ZETA trial ITT population (n = 331)27
Central review (ITT population)a 30.5 19.3b 0.46 (0.31 to 0.69;
< 0.001)
Central review (excluding
open-label)a
32.4 16.4b b0.28 (0.18 to 0.42;
< 0.001c)
Investigator (all patients, ITT
population)
22.3 8.3b 0.40 (0.27 to 0.58;
< 0.001)
Vandetanib (n= 126) Placebo (n= 60)
ZETA trial EU-label population (n = 186)57,66
Central review (all patients)a,b 28.0 16.4 0.47 (0.29 to 0.77;
0.0024)
Central review (excluding
open-label)a,d
30.1 11.1 0.32 (0.19 to 0.54;
< 0.0001)
Investigatord 22.1 8.3 0.33 (0.2 to 0.53;e
0.0226)
Vandetanib (confidential
information has been
removed)
Placebo (confidential
information has been
removed)
ZETA trial restricted EU-label population (confidential information has been removed)
(Confidential information has been
removed)
(Confidential information
has been removed)
(Confidential information
has been removed)
(Confidential information
has been removed)
NR, not reported.
a Weibull model-predicted median because median not reached.
b CS only.
c 0.27, 95% CI 0.18 to 0.41; p< 0.001.27
d Kreissl et al.57
e Confidence intervals only provided in the Sanofi CS,66 tables 18 and 22, which also states a p-value of < 0.0001 for this HR.
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a beneficial effect on PFS (HR < 1.0), with a statistically significant treatment effect observed between patients
with a CTN doubling time of ≤ 24 months and patients with a CEA doubling time of ≤ 24 months (Figure 3).
Overall survival
The authors of the EXAM trial paper28 reported that there was no statistically significant difference between
cabozantinib and placebo based on an interim analysis. According to a 2015 abstract,47 the EXAM trial was
designed with 80% power to detect a HR of 0.667 for the secondary end point of OS. A final analysis was
conducted after 218 deaths (the trial required 217 deaths for the analysis28) at a median follow-up of
52.4 months.47 The estimated median OS was 26.6 months for cabozantinib compared with 21.1 months
for placebo (stratified HR 0.85, 95% CI 0.64 to 1.12), which was not statistically significantly different
(p = 0.241; Table 9).47
For the 215 (65%) participants with known positive or negative RET mutations in the EXAM trial,45 median
OS was 31.6 months in the cabozantinib arm compared with 24.8 months in the placebo arm (HR 0.79,
95% CI 0.54 to 1.17; p = 0.240).79 For the 126 participants with known RET M918T-positive mutations,
median OS was 44.3 months for cabozantinib compared with 18.9 months for placebo (HR 0.60, 95% CI
TABLE 7 The RET-mutation status in the EXAM trial28,45 in the post hoc analysis of the EXAM trial (Ipsen CS,21
Sherman et al.45)
Mutation status
Patients, n (%)
Total (N= 330) Cabozantinib arm (N= 219) Placebo arm (N= 111)
RET mutation subgroup
Positive NR (51.2) 46.1 (48.9) 52.3 (55.9)
Negative NR (13.9) 14.2 (16.0) 9.0 (9.9)
Unknown NR (34.8) 39.7 (35.2) 38.7 (34.2)
RET M918T status
Positive NR (38.2) 34.2 (37.0) 38.7 (40.5)
Negative NR (32.4) 30.6 (34.2) 27.0 (28.8)
Unknown NR (29.4) 35.2 (28.8) 34.2 (30.6)
NR, not reported.
TABLE 8 Progression-free survival by RET mutational status in the post hoc analysis of the EXAM trial (Ipsen CS,21
Sherman et al.45)
Mutation status
Trial arm
HR (95% CI) p-value
Cabozantinib Placebo
n
Median PFS
(weeks) n
Median PFS
(weeks)
RET positive 107 60 62 20 0.23 (0.14 to 0.38) < 0.0001
RET negative 35 25 11 23 0.53 (0.19 to 1.50) 0.2142
RET unknown 77 48 38 13 0.30 (0.16 to 0.57) 0.0001
RET M918T positive 81 61 45 17 0.15 (0.08 to 0.28) < 0.0001
RAS positive 13 47 3 8 0.15 (0.02 to 1.10) 0.0317
RET negative and RAS negative 22 24 8 23 0.88 (0.24 to 3.22) 0.8330
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RET mutation status negative
Unknown RET mutation status
CTN doubling time of ≤ 24 months
CTN doubling time of > 24 months
Unknown CTN doubling time
CEA doubling time of ≤ 24 months
CEA doubling time of > 24 months
Unknown CEA doubling time
High baseline p-VEGF
Low baseline p-VEGF
Unknown baseline p-VEGF
High baseline p-VEGFR2
Low baseline p-VEGFR2
Unknown baseline p-VEGFR2
High baseline p-bFGF
Low baseline p-bFGF
Unknown baseline p-bFGF
V = 73/231 (31.6%)
V = 47/137 (34.3%)
V = 1/2 (50.0%)
V = 25/92 (27.2%)
V = 39/124 (31.5%)
V = 23/83 (27.7%)
V = 11/24 (45.8%)
V = 25/69 (36.2%)
V = 28/119 (23.5%)
V = 20/43 (46.5%)
V = 41/115 (35.7%)
V = 25/101 (24.8%)
V = 7/15 (46.7%)
V = 40/155 (25.8%)
V = 26/61 (42.6%)
V = 7/15 (46.7%)
V = 39/107 (36.4%)
V = 27/108 (25.0%)
V = 7/16 (43.8%)
P = 51/100 (51.0%)
P = 27/50 (54.0%)
P = 5/6 (83.3%)
P = 19/44 (43.2%)
P = 27/46 (58.7%)
P = 19/43 (44.2%)
P = 5/11 (45.5%)
P = 26/33 (78.8%)
P = 14/48 (29.2%)
P = 11/19 (57.9%)
P = 25/51 (49.0%)
P = 20/42 (47.6%)
P = 6/7 (85.7%)
P = 26/69 (37.7%)
P = 19/24 (79.2%)
P = 6/7 (85.7%)
P = 26/49 (53.1%)
P = 19/43 (44.2%)
P = 6/8 (75.0%)
FIGURE 3 Progression-free survival according to subgroups in the ZETA trial (reproduced from Sanofi CS66, figure 4, p. 51 and AstraZeneca’s unpublished CSR dated July 201174).
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0.38 to 0.94; p= 0.026).47,79 Subgroups of participants lacking RET mutations or lacking RET M918T showed
no increase in OS.47,79 The secondary end point of improved OS was not met because the difference between
arms was not statistically significant in the ITT population.47
The data on OS from the ZETA trial were immature: a non-significant interim result was reported (HR 0.89,
95% CI 0.48 to 1.65; p-value not reported),27 as well as the intention to conduct a final analysis when 50%
of participants had died. The number of participants who had died at the data cut-off point (31 July 2009)
was reported in the published CSR:27 32 out of 231 (14%) participants in the vandetanib arm compared
with 16 out of 100 (16%) participants in the placebo arm (p = 0.711527; and Sanofi CS,66 p. 49). In the
final analysis set (data cut-off point of 7 September 2015), there remained no survival benefit: 50% of
participants randomised to vandetanib had died compared with 52% of participants randomised to placebo
(HR 0.99, 95% CI 0.72 to 1.38; p = 0.975), although the placebo group included participants who had
crossed over to vandetanib in the unblinded stage of the trial, thereby potentially confounding these results
(Sanofi CS,66 p. 49).
For the ZETA trial’s EU-label population, the estimated median OS was (confidential information has been
removed) for vandetanib compared with (confidential information has been removed) for placebo
(confidential information has been removed).
According to the Sanofi CS66 (p. 55 and table 20), the median OS for the restricted EU-label group was
(confidential information has been removed) in the placebo arm compared with (confidential information
has been removed) in the vandetanib arm (confidential information has been removed).
Response rate
The end point of ORR was reported in both trials, including complete and partial response, and was determined
using the stated RECIST criteria27,28 In the EXAM trial (n = 312 for this outcome), no participant had a complete
response. Twenty-eight per cent of participants had a partial response in the cabozantinib arm compared with
0% in the placebo arm (p < 0.001), with a median estimated duration of response of 14.6 months (95% CI
11.1 to 17.5 months)28 and similar rates for RET mutation-positive and -negative subgroups.43,44
TABLE 9 Overall survival median duration (months)
Treatment Placebo HR (95% CI; p-value)
EXAM trial arm (N = 330)47
Cabozantinib (n = 219) Placebo (n = 111)
26.6 21.1 0.85 (0.64 to 1.12; 0.2409)
ZETA ITT population (N = 331)27
Vandetanib (n = 231) Placebo (n = 100)
NR NR 0.99 (0.72 to 1.38; 0.9750)
aEU-label population (N = 189)78
Vandetanib (n = 126) Placebo (n = 60)
(Confidential information has
been removed)
(Confidential information has
been removed)
(Confidential information has
been removed)
Restricted EU-label population (confidential information has been removed)a
Vandetanib (confidential information has
been removed) Placebo (confidential information has been removed)
(Confidential information has
been removed)
(Confidential information has
been removed)
(Confidential information has
been removed)
NR, not reported.
a Survival time was originally reported in years but has been converted to months.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
In the full publication of the ZETA trial27 (n = 331 for this outcome), the ORR was 45% in the vandetanib
group compared with 13% in the placebo group (p < 0.001), with a predicted median duration of response
of 22 months. Within an earlier abstract,60 the odds ratio (OR) was reported to be 5.4 compared with
placebo (95% CI 2.99 to 10.79; p < 0.0001). It should be noted that 12 out of 13 participants in the placebo
group had a response only when they switched to vandetanib in the open-label phase of the trial.27,58
The OR was reported to be 45.7% (p < 0.0001) compared with placebo for the EU-label patients (n = 186)
in the ZETA trial before any switching occurred.57 The Sanofi CS66 (table 24, p. 67) states that 43.7% of these
participants had a response in this vandetanib group (n = 126), compared with (confidential information
has been removed) in the restricted EU-label vandetanib group (confidential information has been removed).
Small numbers of RET-negative participants were deemed to render findings from the subgroup analysis
of the EU-label group inconclusive, although other analyses did suggest that M918T mutation-positive
participants had a better response to vandetanib than M918T mutation-negative patients.27 The Sanofi CS66
(p. 51) also stated that higher proportions of participants with a CTN or CEA doubling time of < 24 months
(47% and 54%, respectively) achieved ORR than participants with a CTN or CEA doubling time of ≥ 24 months
(40% and 37%, respectively).
Calcitonin and carcinoembryonic antigen response
Serum levels of CTN and CEA are recognised indicators of tumour burden and prognosis.15–17 In both the
EXAM and ZETA trials, CTN and CEA were evaluated from serum samples at baseline and, at the most,
every 12 weeks after initiation of treatment, to coincide with radiological tumour assessments; response
was calculated as a percentage change compared with baseline.27,28 In the EXAM trial, the cabozantinib
and placebo groups did not have statistically significantly different baseline levels of CTN or CEA, but at
12 weeks’ follow-up, evaluated participants in the cabozantinib group had statistically significantly better
responses than those in the placebo group: levels of both biomarkers decreased in the treatment group and
increased in the placebo group (Table 10).28,48,49
In the ZETA trial, higher, statistically significant percentages of participants receiving vandetanib achieved a
CTN and CEA response (69% and 52%, respectively) than participants receiving placebo (3% for CTN and
2% for CEA).27,66
Lesion size
Lesion size was only measured and reported within the EXAM trial. To be included, participants needed
measurable disease at baseline and at least one subsequent assessment.28 A total of 180 out of 219
cabozantinib participants and 89 out of 111 placebo participants satisfied these criteria. Ninety-four per
cent of these cabozantinib participants and 27% of these placebo participants had a detectable decrease
in target lesion size.28 Elisei et al.28 also noted that there was a ‘generally linear relationship’ in the
reductions in lesion size and both CTN and CEA levels.
TABLE 10 The EXAM trial CTN and CEA response rates
Time point Biomarkers
Trial arm, mean (SD)
p-valueCabozantinib Placebo
Baseline CTN (n= 330), pmol/l 6370 (11,332) 8846 (15,722) 0.27a
CEA (n= 330), µg/l 736 (3555) 1108 (5168) 0.58a
Percentage change, mean (SD)
Week 12 CTN (n= 201) –45.2 (60.71) 57.3 (115.4) < 0.001
CEA (n= 241) –23.7 (58.21) 88.7 (182) < 0.001
SD, standard deviation.
a Welsh’s t-test.
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MD Anderson Symptom Inventory – Thyroid
The MDASI-Thy module was the only patient-reported outcome measure used in the EXAM trial and data
on this outcome were reported only in the unpublished CSR.76 Data were also provided by the company at
the request of the AG. The analysis was exploratory and was evaluated at screening and every 12 weeks
(±5 days) to disease progression, coinciding with tumour assessments. The tool measured clinical symptoms,
such as pain, fatigue, nausea, diarrhoea and mood, with higher scores indicating more symptoms. The CSR
reported (section 11.4.4.2) that, although no formal statistical testing had been performed, in terms of
change from baseline to the data cut-off point, there was no apparent difference between the treatment
arms. However, it was stated that there were data for only 75% of participants at week 12, with declining
numbers for subsequent assessments.76
Functional Assessment of Cancer Therapy – General, and time to worsening of pain
The FACT-G and TWP outcomes were only measured and reported for the ZETA trial; the details and results
appear in the published and unpublished CSR,27,74 although data were also provided by Sanofi at the request
of the AG. The CSR74 states that quality of life was measured using the FACT-G instrument and that, overall,
scores between the two arms were similar. TWP was a composite end point, derived from opioid analgesic
use and the worst pain item of the Brief Pain Inventory. The ZETA trial reported a significantly longer median
TWP for vandetanib (7.85 months) than placebo (3.25 months: HR 0.61, 95% CI 0.43 to 0.87; p = 0.0062)
in the published CSR.27 In the EU-label population, TWP was 11.1 months in the vandetanib arm compared
with 3.4 months in the placebo arm (HR 0.62; 95% CI 0.39 to 0.99; p = 0.45).66
Safety outcomes
In order to be considered for safety outcomes, participants had to receive at least one dose of the
study drug.27,28
Any adverse event
The EXAM trial safety data were taken from the trial publications or the EXAM Final Analysis Set of August
2014, which was provided in the Ipsen CS21 for cabozantinib (median follow-up of 10.8 months). The ZETA
trial safety data were taken from the final Safety Analysis Set, provided in the Sanofi CS for vandetanib66
and the unpublished CSR of 201174 (median total exposure was 90.1 weeks for vandetanib compared with
39.9 weeks for placebo). Seven participants were missing from the EXAM safety population data; therefore,
there were 214 participants for cabozantinib, rather than 219, in the ITT population, and 109 participants for
placebo rather than 111.
Adverse events were very common in both trials. Overall, 100% of participants were affected by at least
one AE in the cabozantinib arm of the EXAM trial, and 99.6% of participants were affected by at least
one AE in the vandetanib arm of the ZETA trial, 96% of which were attributed to vandetanib by the
investigator.27 Both trials reported many AEs affecting ≥ 10% and < 20% of participants. Some of these
AEs were dry skin, insomnia, abdominal pain, dermatitis acneiform, cough, nasopharyngitis, prolonged
ECG QT [as defined by the National Cancer Institute’s Common Terminology Criteria for Adverse Events
(CTCAE80)], alopecia, pain in extremity, dyspnoea, arthralgia, dizziness, oral pain, dry mouth, dysphagia,
cough, muscle spasms, dyspepsia, erythema and glossodynia.27,28
Given their high frequency, only the most common AEs, that is, those affecting ≥ 20% of participants in
any trial arm, are presented in Table 11. The most common AEs for cabozantinib were diarrhoea (63%),
hand–foot syndrome (HFS) (50%), decreased weight (48%), decreased appetite (46%), nausea (43%) and
fatigue (41%).28
Similarly, the most common AEs for vandetanib were diarrhoea (56%), decreased appetite (21%), nausea
(33%) and fatigue (24%). In addition, there was a high incidence of rash (45%), hypertension (32%) and
headache (26%), but low or no incidence of HFS.27,58 Hypertension is a known AE for TKIs.81,82 The incidence
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of diarrhoea in patients receiving vandetanib treatment for MTC appears to be similar to that reported for
patients receiving vandetanib treatment for other cancers,83 but the rates of any grade or high-grade severity
rash and hypertension appear to be higher for vandetanib in MTC patients than in most other cancer
patients,84,85 which might be attributable to longer treatment duration.85
It should be noted that patients with MTC have a substantial disease burden. This is demonstrated by the
AEs and comorbidities in the placebo arm and baseline data for EXAM and ZETA trial participants (see
Table 11), and especially those in the EXAM trial, with radiographic evidence of PD (n = 330); for example,
percentages of participants with reported symptoms at baseline were pain in 46.1%, diarrhoea in 39.7%,
fatigue in 25.8% and dysphonia in 23%.50 Most symptoms were of grade 1 or 2 severity.
TABLE 11 Common AEs (any grade) reported for > 20% of participants in any arm of the EXAM or ZETA trials
AE
Trial (% with event)
EXAM ZETA
10.8 months’ follow-up (median)a 90.1 weeks’ follow-upb 39.9 weeks’ follow-upb
Cabozantinib
(n= 214)
Placebo
(n= 109) Vandetanib (n= 231) Placebo (n= 99)
Overall 100a 95a 9727 9127
Diarrhoea 63 33 56 26
HFS 50 2 – –
Decreased weight 48 10 10 9
Decreased appetite 46 16 21 12
Nausea 43 21 33 16
Fatigue 41 28 24 23
Dysgeusia 34 6 – –
Hair colour changes 34 1 – –
Hypertension 33 5 32 5
Stomatitis 29 3 – –
Constipation 27 6 – –
Haemorrhage 25 16 – –
Vomiting 24 2 14 7
Mucosal inflammation 23 4 – –
Asthenia 21 15 14 11
Dysphonia 20 9 – –
Rash 19 10 45 11
Headache 18 8 26 9
Acne – – 20 5
Back pain 15 11 9 20
HFS, hand–foot syndrome.
a Ipsen CS21 from the final analysis of August 2014.
b Median duration of exposure: Sanofi CS,66 table 33 and CSR 2011,74 table 40.
Notes
Figures are rounded up to the nearest whole number.
– indicates not reported or < 10%.
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Grade 3 or higher adverse events, and serious adverse events
The adverse events, grade 3 or higher, reported for ≥ 2% of participants are presented in Table 12. The
most common grade 3 or higher AEs for cabozantinib were diarrhoea (16%), HFS (13%), fatigue (9%),
hypertension (8%), asthenia (6%), and decreased weight (5%) and appetite (5%).28,43 These appear to be
consistent with other anti-VEGF TKIs and the open-label cabozantinib studies.86–89 However, it should be
noted that the incidence and severity of HFS reported in the EXAM trial are lower than those reported in
other cabozantinib trials for the treatment of other solid malignancies.90
TABLE 12 Grade 3 or higher AES reported for ≥ 2% of participants in any arm of the EXAM or ZETA trials
Adverse event
Trial (% with event)
EXAM ZETA
10.8 months’ follow-up (median)a 90.1 weeks’ follow-upb 39.9 weeks’ follow-upb
Cabozantinib
(n= 214)
Placebo
(n= 109) Vandetanib (n= 231) Placebo (n= 99)
Overall 69 (78a) 33 55 (CSR, Langmuir and Yver19);
61 (Kreissl et al.57)
24 (CSR and Kreissl et al.57)
Diarrhoea 16 2 11 2
HFS 13 0 – –
Fatigue 9 3 6 1
Hypertension 8 1 9 0
Asthenia 6 2 3 1
Decreased weight 5 0 – –
Decreased
appetite
5 1 4 0
Dysphagia 4 1 – –
Abdominal pain 3 1 – –
Haemorrhage 3 1 – –
Dyspnoea 2 10 1 3
Back pain 2 1 0 3
Mucosal
inflammation
3 0 – –
Vomiting 2 1 – –
Rash 1 0 4 1
Headache 1 0 – –
Syncope – – 0 2
Prolonged ECG
QT
– – 8 1
a Ipsen CS,21 2017 from final analysis of August 2014.
b Median duration of exposure: Sanofi CS,66 table 33 and AstraZeneca,74 table 46.
Notes
Figures are rounded up to the nearest whole number.
– indicates not reported or < 2%.
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The most common grade 3 or higher AEs for vandetanib were diarrhoea (11%), hypertension (9%),
fatigue (6%) and decreased appetite (4%) as well as rash (4%) and prolonged ECG QT (8%). An
exploratory study of a subset of the ZETA trial participants has indicated potential benefits of vandetanib
in terms of weight and muscle loss.61–63 This study also identified significant toxicities in the presence of
higher mean vandetanib plasma concentration, the most frequent toxicities being asthenia grade 3 (36%),
prolongation of the corrected QT interval (QTc) (25%), and cutaneous symptoms (11%).62 Vandetanib is
one of only two TKIs (the other being sunitinib) identified as being associated with prolonged QTc.91
Serious adverse events (SAEs), as defined by the National Cancer Institute’s CTCAE,80 affected more
participants receiving cabozantinib (42.1%28 or 53%,21 depending on the source) than placebo (22.9%28 or
24%,21 depending on the source) in the EXAM trial.21,28 The overall incidence of any SAE in the ZETA trial
was 31% in the vandetanib arm and 13% in the placebo arm.27 SAEs that occurred in ≥ 2% of participants
in any arm of the EXAM or ZETA trials were mucosal inflammation, hypocalcaemia, pulmonary embolism,
hypertension and diarrhoea.
Grade 5 AEs occurring within 30 days of the last dose were reported in more cabozantinib participants than
placebo participants (7.9% and 7.3%, respectively).28 A number of these grade 5 AEs were specified as
being related to cabozantinib: fistula, respiratory failure, haemorrhage, sepsis/multiorgan failure, sudden
death, cardiopulmonary failure and ‘death, not other specified.’ At 52.4 months’ follow-up, the most
common SAEs (≥ 2%) were pneumonia (4.2% of those receiving cabozantinib experienced this event),
pulmonary embolism (3.3%), mucosal inflammation (2.8%), hypocalcaemia (2.8%), and hypertension,
dysphagia, dehydration and lung abscess (2.3% each).92
Adverse events leading to discontinuation or dose interruption/reduction
Adverse events leading to dose reductions/interruptions and/or discontinuation of treatment were reported
for both trials (Table 13). There were similar proportions of participants across the two trials who discontinued
because of AEs (16% or 23% for cabozantinib and 12% for vandetanib); however, there was a higher
percentage of participants experiencing AEs, leading to dose interruption or reduction on cabozantinib (65%)
than on vandetanib (35%).27,28 A later abstract detailing this outcome for the EXAM trial reported that
TABLE 13 Dose interruption or discontinuation rates in the EXAM and ZETA trials (from the Sanofi CS66 unless stated)
Trial Trial arm (%)
EXAM Cabozantinib (n = 214) Placebo (n = 109)
Dose interruption because of AE28 65 17
Discontinuation because of AE28 16 (23a) 8 (9a)
Dose interruption or reduction 87 22
Dose reductiona 79s 9
ZETA Vandetanib (n = 231) Placebo (n = 99)
Dose interruptionb 47 15
Discontinuation because of AEs27 12 3
Dose interruption or reduction 49 15
Dose reduction27 35 3
EU-label population only (Sanofi CS, table 33)b Vandetanib (n = 126) Placebo (n = 60)
Discontinuation because of AEs 12 2
Dose reduction 33 3
a Data from Sanofi CS,66 p. 73 only.
b From Sanofi CS,66 table 33.
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dose reduction to manage AEs was performed for 82% of participants treated with cabozantinib,55 which
increased again to 87% in the final analysis.21 The percentages of participants experiencing AEs leading to
dose interruption (17%) or discontinuation (8%) were also higher in the placebo arm of the cabozantinib
trial28 than in the placebo arm of the vandetanib trial (3% for dose interruption and 3% for discontinuation).
High rates of dose reduction and discontinuation have also been reported for a retrospective study of
15 patients with progressive MTC on cabozantinib.77
Deaths
In the EXAM trial, at the data cut-off point, 30% of participants (65/214) had died in the cabozantinib
arm compared with 28% (30/109) in the placebo arm. Twenty-three per cent (15/65) of deaths in the
cabozantinib arm were attributable to AEs, compared with 20% (6/30) in the placebo arm;28 other deaths
were attributable to disease progression. Full details of the AEs leading to death were not reported.28
By the final analysis (August 2014), the figures had increased to 65% (138/214) in the cabozantinib arm
and 70% (76/109) in the placebo arm, with deaths deemed to be treatment related remaining at 4–5%
for cabozantinib and 1% for placebo at both the interim analysis and the final analysis.21
During the randomised phase of the ZETA trial, five participants who received vandetanib experienced
AEs that led to death. Reasons given were aspiration pneumonia, respiratory arrest, respiratory failure,
staphylococcal sepsis, and, in one participant, arrhythmia and acute cardiac failure. Instances of gastroenteritis
and gastrointestinal haemorrhage led to death in two participants in the placebo group.27 The number of
deaths reported at the safety follow-up was 10 (4.3%) in the vandetanib group and 6 (6.1%) in the placebo
group, although two of the deaths in the vandetanib group did not have MTC as either the primary or
secondary cause; no such deaths were recorded in the placebo group.74
Supplementary safety evidence
The Sanofi CS66 also presented safety data from two additional published studies69,71 and one ongoing
study;64 the data from this third, ongoing study are unpublished. The findings on the most frequent AEs
and SAEs, and the incidence and type of AEs, were all similar to the ZETA trial for the 300-mg vandetanib
dose. Dose interruption and reduction rates were also similar, except for higher rates in a trial arm that
included additional monitoring through an outreach programme.69 Only the ‘real world’ study of 68 MTC
patients treated with vandetanib in France71 had a markedly higher incidence of death (42% compared
with ≤ 12% in the other studies for the 300-mg vandetanib dose) and AE-related discontinuations
(27% compared with ≤ 15%) than the other study69 or the ZETA trial. These trials had a similar or shorter
duration of follow-up than the ZETA trial, but were not subject to potential confounding because of
treatment switching.
Network meta-analysis
Justification for conducting a network meta-analysis
In the absence of head-to-head evidence comparing cabozantinib with vandetanib, an indirect comparison
using a NMA was considered. An indirect comparison has previously been published as an abstract93 and is
presented in the Ipsen CS;21 however, owing to the differences between the ITT population of the EXAM
and ZETA trials, this analysis was not deemed appropriate for formal consideration within this assessment.
The validity of the NMA depends on the assumption that there is no difference in the distribution of
trial-level treatment effect modifiers between the populations in the two trials. This is unlikely to be the case
for the ITT populations of the ZETA and EXAM trials in particular, because participants in the EXAM trial had
confirmed disease progression, whereas the ZETA trial recruited a broader population of participants with no
requirement for established disease progression. HRs for the effectiveness of vandetanib compared with
placebo for investigator-assessed PFS in the ZETA trial were reported for the symptomatic and progressive
subgroup (n = 186, HR 0.33, 95% CI 0.20 to 0.53) and the full analysis set excluding symptomatic and
progressive participants (n = 139, HR 0.49, 95% CI 0.27 to 0.58) within the Sanofi CS.66 This suggests that
progression may be a treatment-effect modifier, with a greater treatment effect observed for the subgroup
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with confirmed progression (though a statistically significant difference between the two groups cannot
be inferred).
Despite differences in the ITT populations, the AG considered a NMA based on the EU-label subgroup of
the ZETA population to be appropriate. There was a marked difference in the median PFS in the control
groups of the two studies [EXAM trial: 4.0 months, ZETA trial EU-label population: 16.4 months (by central
review)]; however, differences in baseline characteristics of the included studies as a result of differences in
study protocols are to be expected and do not invalidate an indirect comparison. For a NMA to be valid,
it is important that there is not an imbalance in treatment-effect modifiers. Clinical advisors to the AG
identified severity of disease as an important potential treatment-effect modifier. Information on ECOG/
WHO performance status at baseline was not available for the ZETA trial EU-label population, so balance
across the two studies could not be assessed, and there is no clear evidence to demonstrate the balance
of this potential treatment-effect modifier. However, subgroup analyses indicated consistent treatment
effects according to performance status at baseline for both interventions,27,28 and clinical advice received
by the AG suggested that the ZETA trial EU-label and EXAM trial ITT populations could be considered to
be broadly comparable. Therefore, on the basis of clinical advice, and since there was no evidence to
invalidate indirect comparison, a NMA was considered to be justified.
Methods for the network meta-analysis
The NMA was conducted by the AG to provide an indirect comparison between cabozantinib and
vandetanib for central-read PFS and investigator-read PFS. For OS, the HRs for both treatment groups are
confounded by treatment switching; therefore, a NMA was not conducted for this outcome, as it would not
provide a meaningful comparison.
The network diagram is presented in Figure 4 and data contributing to the NMA are presented in Table 14.
Analyses were conducted using a Bayesian random-effects model, as described by Dias et al.94 Given that
there is potential heterogeneity between the trials, a random effects model was considered to be the most
appropriate so that this uncertainty is appropriately reflected in the estimated treatment effects. There
was insufficient information to estimate the between-study variance from the data alone, hence a weakly
informative prior was used for this parameter (log-normal –2.56, 1.742 based on the recommendation in
Turner et al.95), which has a median of 0.08 and 95% range of 0.003 to 2.34 on the untransformed scale.
Placebo
Vandetanib
Cabozantinib
EXAM trial
ZETA trial EU-label 
population
FIGURE 4 Network diagram for the NMA.
TABLE 14 Data for the NMA on PFS
Trial Treatment Comparator
PFS HR (95% CI)
Investigator read Central read
EXAM (n= 330), Elisei et al.28 Cabozantinib Placebo 0.29 (0.21 to 0.42) 0.28 (0.19 to 0.40)
ZETA EU label (n = 186), Kreissl et al.57 Vandetanib Placebo 0.33 (0.20 to 0.53) 0.47 (0.29 to 0.77)
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This prior was also truncated such that the ratio of the upper and lower 95% CI of the prior does not
exceed 10, based on evidence from Speigelhalter et al.96 and Smith et al.97 that the between-study
treatment effects are unlikely to vary by more than an order of magnitude.
Analyses were conducted in the freely available software packages WinBUGS98 (MRC Biostatistics Unit,
Cambridge, UK) and R (The R Foundation for Statistical Computing, Vienna, Austria) using the R2WinBUGS
interface package. Convergence to the target posterior distributions was assessed using the Gelman–Rubin
statistic, as modified by Brooks and Gelman,99 for two chains with different initial values. A burn-in of 50,000
iterations of the Markov chain was used with a further 20,000 iterations retained to estimate parameters.
There was no evidence of high autocorrelation between successive iterations of the Markov chain.
It should be noted that the results from the NMA are not used to inform the health economic model
developed by the AG (see Chapter 4, Independent assessment group model). The NMA utilises HRs,
which are averaged estimates of treatment effect, and their use in the health economic model would be
appropriate only if the hazards are proportional over the entire extrapolation period. However, the AG’s
health economic model considers a broader range of parametric functions, not all of which conform to the
proportional hazards assumption; hence the use of HRs from the NMA would not be appropriate. Instead,
estimation of the treatment effects and baseline model is conducted using the same parametric model
type (see Time to event analysis using individual patient data), conforming to the recommendation in
Guyot et al.100
Results of the network meta-analysis
The results of the NMA are shown in Figure 5 for investigator-read PFS and Figure 6 for central-read PFS.
Based on investigator-read PFS, the results of the two treatments are broadly similar [vandetanib vs.
cabozantinib, HR 1.14, 95% credible interval (CrI) 0.41 to 3.09]. The magnitude of the treatment effect
is more favourable towards cabozantinib when the comparison is based on central-read PFS (HR 1.68,
95% CrI 0.61 to 4.62); however, the difference between the two interventions is not statistically significant.
Discussion
The systematic review of the clinical effectiveness evidence identified two placebo-controlled RCTs.
The EXAM trial evaluated the efficacy and safety of cabozantinib in patients with unresectable locally
advanced or metastatic and progressive MTC (n = 330). The ZETA trial evaluated the efficacy and safety
of vandetanib in patients with unresectable locally advanced or metastatic MTC (n = 331). The EXAM
trial was deemed to be at low risk of bias across most domains (although the risk of selection bias was
unclear because the method of randomisation was not explicitly reported). In contrast, the ZETA trial was
rated as being at moderate to high risk of bias across a number of domains; in particular, the method of
Comparison
Placebo
Cabozantinib
Vandetanib
Vandetanib
Cabozantinib
HR 95% Crl 95% Prl
0.29 0.15 to 0.58 0.12 to 0.73
0.33 0.16 to 0.70 0.13 to 0.86
1.14
0 1 2 3
0.41 to 3.09 0.31 to 4.35
FIGURE 5 Results of the NMA for investigator-read PFS. PrI, prediction interval.
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randomisation was not described and several outcomes were confounded by the inclusion of individuals
who had switched to open-label treatment.
The two trials assessed different populations. The EXAM trial (n = 330) included only patients with
unresectable locally advanced or metastatic and progressive MTC, whereas the ZETA trial inclusion criteria
(n = 331) did not specify the requirement for patients to have ‘progressive’ disease; therefore, the ITT
population in the ZETA trial generally had less severe disease (there were more participants with potentially
indolent disease). The more progressive and severe disease of EXAM trial participants is evidenced by the
between-trial baseline differences in performance status (see Table 3) and the relatively shorter duration
of PFS for the participants in the placebo arm of the EXAM trial. However, a published abstract57 and the
Sanofi CS66 provided data on a subgroup of the ZETA ITT population, that is, those with ‘progressive and
symptomatic disease’ (n = 186) – the EU-label population. Despite slight differences in definition (e.g. the
explicit requirement for defined symptoms in the ZETA trial EU-label population subgroup), clinical advice
received by the AG confirmed that the EXAM trial and ZETA trial ‘progressive and symptomatic’ (EU-label)
populations are comparable. Clinical advice also confirmed that these populations reflect patients who are
likely to present in clinical practice in England. The Sanofi CS66 also presented data on a restricted EU-label
subgroup from the ZETA trial (confidential information has been removed), which was composed of
‘progressive and symptomatic’ patients who also had ‘aggressive’ disease, defined by CTN and CEA
doubling times of < 24 months. CTN and CEA doubling times are acknowledged prognostic factors for
MTC15–17 and were not controlled for in the EXAM trial. However, clinical advice received by the AG
suggests that these biomarkers are unlikely to be relevant in the presence of other criteria indicating PD
(e.g. RECIST criteria and symptoms), and, although they might be used to determine whether or not
treatment is still working, they would not be used to inform decisions about whether or not to initiate
TKI treatment.
In terms of efficacy, both cabozantinib and vandetanib significantly improved PFS compared with
placebo. For the principal comparison between the EXAM trial ITT population and the ZETA trial EU-label
population, PFS was similar for cabozantinib (investigator-read HR 0.29, 95% CI 0.21 to 0.42; p < 0.001,
central-read HR 0.28, 95% CI 0.19 to 0.40; p < 0.001) and vandetanib [investigator-read HR 0.33 (95% CI
0.2 to 0.53; p = 0.0226), central-read, excluding participants switching treatments, HR 0.47 (95% CI
0.29 to 0.77; p = 0.0024), including open-label populations HR 0.32 (95% CI 0.19 to 0.54; p < 0.001),
see Progression-free survival)]. The difference in PFS between vandetanib and placebo was (confidential
information has been removed) for the restricted EU-label population (confidential information has been
removed).66 Subgroup analyses demonstrated a favourable treatment effect for all subgroup categories.
The publications and CSs also presented data for PFS based on RET mutation status, but clinical advice
received by the AG indicated that germline RET mutation status testing is conducted in the NHS in England
only for the purpose of identifying patients with hereditary MTC. Somatic and other RET mutation testing
is not routinely undertaken to inform treatment choices. Subgroup analyses reported in the Sanofi CS66
and the unpublished ZETA trial CSR showed that participants with a CTN or CEA doubling time of
Comparison
Placebo
Cabozantinib
Vandetanib
Vandetanib
Cabozantinib
HR 95% Crl 95% Prl
0.28 0.14 to 0.56 0.11 to 0.71
0.47 0.22 to 0.99 0.18 to 1.23
1.68
0 1 2 3
0.61 to 4.62 0.45 to 6.48
FIGURE 6 Results of the NMA for central-read PFS. PrI, prediction interval.
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< 24 months had a PFS response to vandetanib that was more pronounced than that of participants with a
doubling time of > 24 months and those in whom the doubling time is unknown.66,74
The NMA suggests that the PFS effects for the two treatments are broadly similar (vandetanib vs.
cabozantinib PFS HR 1.14, 95% CrI 0.41 to 3.09). The magnitude of the treatment effect is more
favourable towards cabozantinib when the comparison is based on central-read PFS rather than
investigator-read PFS (HR 1.68, 95% CrI 0.61 to 4.62), but the difference between the two interventions
was not statistically significant. In the absence of direct evidence comparing the two interventions, the
results of the NMA provide a useful comparison but should be interpreted with caution for the following
reasons. Owing to the sparsity of the network, it was necessary to use a weakly informative prior for the
between-study variance. This was considered to be more realistic than assuming that the between-study
heterogeneity would be zero (i.e. taking a fixed-effects approach); however, the results are subject to
the suitability of the prior and the resulting CrIs and prediction intervals are relatively wide, representing
genuine uncertainty in the network. Furthermore, the NMA utilises HRs, which are averaged estimates
of treatment effect, and ignore any potential treatment-by-time interaction. Alternative methods that
allow the relative treatment effects to vary over time have been proposed, including the use of fractional
polynomials.101 The AG did not deem this approach to be necessary as the results of the NMA are used to
judge the comparative effectiveness of the interventions over the observed trial period and have not been
used to inform the health economic model (see Chapter 4, Independent assessment group model).
Based on the available trial evidence, there was no significant survival benefit in terms of OS for either
cabozantinib or vandetanib compared with placebo, although the data from the vandetanib ZETA trial
were confounded by treatment switching. In the EXAM trial, the estimated median OS was 26.6 months
for cabozantinib compared with 21.1 months for placebo (stratified HR 0.85, 95% CI 0.64 to 1.12;
p = 0.241).47 Within this study, the only significant difference in OS was found for 126 participants with
known RET M918T-positive mutations: the median OS was 44.3 months for cabozantinib compared with
18.9 months for placebo (HR 0.60, 95% CI 0.38 to 0.94; p = 0.026). In the ZETA trial, the reported OS for
the ITT population was 50% for vandetanib compared with 52% for placebo (HR 0.99, 95% CI 0.72 to
1.38; p = 0.975), although the placebo group included participants who had switched to vandetanib in
the open-label stage of the trial, thus potentially confounding these results.66 According to the Sanofi
CS,66 the median OS for the restricted EU-label group was (confidential information has been removed)
in the placebo arm compared with (confidential information has been removed) in the vandetanib arm
(confidential information has been removed).
Both cabozantinib (p < 0.001) and vandetanib (ITT group, p < 0.001; EU-label group, p < 0.0001)
demonstrated significant benefits compared with placebo in terms of ORR, as determined by the RECIST
criteria. Both cabozantinib (p < 0.001) and vandetanib (p < 0.001) also demonstrated significantly better
CTN and CEA response rates than placebo.
The two trials conducted exploratory assessments of participants’ quality of life using instruments that
evaluated various criteria, including symptoms: the MDASI-Thy in the EXAM trial and the FACT-G in the
ZETA trial. However, when assessed, no difference was found between the treatment or placebo arms
in either trial; this covers both baseline and follow-ups. Clinical advice received by the AG suggested
that these tools did not necessarily capture symptomatic benefit produced by improved PFS or response
on treatment.
Both cabozantinib and vandetanib produced frequent AEs. Based on the EXAM trial, the most common
AEs for cabozantinib were diarrhoea (63%), HFS (50%), decreased weight (48%) and appetite (46%),
nausea (43%) and fatigue (41%). The most common AEs for vandetanib were diarrhoea (56%), decreased
appetite (21%), nausea (33%) and fatigue (24%); in addition, there was a high incidence of rash (45%),
hypertension (32%) and headache (26%), and low or no incidence of HFS. Hypertension is a known AE of
TKIs.81,82 The incidence rates of rash and hypertension appear to be higher for vandetanib in MTC patients
than in most other cancer patients,84,85 which might be attributable to a longer treatment duration.85
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The most common grade 3 or higher AEs for cabozantinib, as reported from the EXAM trial, were diarrhoea
(16%), HFS (13%), fatigue (9%), hypertension (8%), asthenia (6%), and decreased weight (5%) and
appetite (5%). These appear to be consistent with other anti-VEGF TKIs and the open-label cabozantinib
studies. The most common grade 3 or higher AEs for vandetanib, as reported for the ITT population from
the ZETA trial, were diarrhoea (11%), hypertension (9%), fatigue (6%) and decreased appetite (4%);
however, rash (4%) and prolonged ECG QT (8%) were also common. An exploratory study also identified
significant toxicities in the presence of higher mean vandetanib plasma concentration, the most frequent
toxicities being asthenia grade 3 (36%), prolongation of the QTc interval (25%) and cutaneous symptoms
(11%).62 Vandetanib is one of only two TKIs (the other being sunitinb) identified as being particularly
associated with prolonged QTc interval.91
Similar proportions of participants across the two trials discontinued treatment because of AEs (16% for
cabozantinib and 12% for vandetanib), but a higher percentage of participants on cabozantinib experienced
AEs leading to dose interruption or reduction (65%) than on vandetanib (35%). A later abstract55 detailing
this outcome for the EXAM trial reported that dose reduction to manage AEs was performed for 82% of
participants treated with cabozantinib, which increased again to 87% in the final analysis. The percentages
of participants experiencing AEs leading to dose interruption or discontinuation were also higher in the
placebo arm of the cabozantinib EXAM trial (17% for dose interruption and 8% for discontinuation) than
in the vandetanib ZETA trial (3% for dose interruption and 3% for discontinuation). High rates of dose
reduction and discontinuation have also been reported for a retrospective study of 15 patients with
progressive MTC on cabozantinib.77 The authors of the EXAM trial28 acknowledged the high rate of dose
interruption with 140 mg of cabozantinib: the EXAMINER trial54 has therefore been developed to assess
the efficacy and safety of a lower dose of cabozantinib (60 mg) compared with the current standard
dose (140 mg).
Finally, in the EXAM trial, up to 5% of deaths were reported as being treatment related for cabozantinib
and 1% for placebo.21 During the randomised phase of the ZETA trial, 2% of participants who received
vandetanib (5/231) experienced AEs leading to death. The reasons given were aspiration pneumonia,
respiratory arrest, respiratory failure, staphylococcal sepsis, and, in one participant, arrhythmia and acute
cardiac failure.27 Instances of gastroenteritis and gastrointestinal haemorrhage led to deaths in two
participants in the placebo group.27
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Chapter 4 Assessment of cost-effectiveness
This chapter presents a systematic review of existing economic evaluations of treatments for locallyadvanced or metastatic MTC, and a summary and critique of economic analyses submitted by the
manufacturers of vandetanib and cabozantinib, together with details of the methods and results of a de
novo health economic analysis undertaken by the AG.
Systematic review of existing cost-effectiveness evidence
Review of existing economic evaluations: methods
A comprehensive search was undertaken to systematically identify economic evaluations of treatments for
locally advanced or metastatic MTC and studies reporting on the HRQoL of patients with locally advanced
or metastatic thyroid cancer (including MTC as well as other commoner forms of thyroid cancer).
In anticipation of the likely lack of relevant evidence, the AG’s search strategy was designed to be
intentionally broad.
The following electronic databases were searched from inception to 3 November 2016:
l MEDLINE – via Ovid, 1946 to present
l MEDLINE In-Process & Other Non-Indexed Citations – via Ovid, 1946 to present
l MEDLINE Epub Ahead of Print – via Ovid, 1946 to present
l CINAHL – via EBSCOhost, 1982 to present
l EMBASE – via Ovid, 1980 to present
l HTA database, 1995 to present
l NHS Economic Evaluation Database (NHS EED), 1995 to 2015
l Web of Science (SCI) – via Clarivate Analytics (formerly Thomson Reuters) 1899 to present
l CPCI – via Clarivate Analytics (formerly Thomson Reuters) 1990 to present.
The search strategy comprised MeSH or Emtree Thesaurus terms and free-text synonyms for ‘thyroid
cancer’. Searches were translated across databases and were not limited by either language or publication
date. The search strategies are presented in Appendix 1. Search filters designed to identify economic
evaluations and HRQoL studies were applied in MEDLINE and other databases, when appropriate.
Reference and citation searching of included papers was also undertaken.
Potentially includable studies were sifted by title and abstract by one reviewer (PT). In keeping with the
breadth of the search strategy, the inclusion criteria were also defined broadly and the sifting process
followed an inclusive approach in order to maximise sensitivity. Given that the cost-effectiveness search
also identified studies relating to health utilities (e.g. those used within models), and the HRQoL search
also identified health economic evaluation studies, the results of both searches were sifted together
using a common set of inclusion criteria (Box 2). Although the inclusion criteria for the review of existing
economic evaluation studies were specific to MTC, HRQoL studies were considered to be potentially
includable if they were undertaken in patients with MTC or other types of thyroid cancer (papillary,
follicular, Hürthle cell carcinoma).
Review of existing economic evaluations: results
Figure 7 presents the study selection results. Before deduplication, the searches yielded 3161 citations
(HRQoL search, n = 1282 studies; economic evaluation search, n = 1879 citations). Following the initial sift,
3057 of these studies were excluded. Full texts of the remaining 104 potentially includable studies were
retrieved for further examination. However, none of these studies contained an economic evaluation of
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treatments for MTC; hence all studies were excluded from the review. In addition, none of these studies
reported health utilities for patients with locally advanced or metastatic MTC. One study102 reported health
utilities for patients with radioactive iodine-refractory differentiated thyroid cancer; this study is discussed in
further detail in Independent assessment group model and Health-related quality of life.
Review of models submitted by the companies
The Sanofi submission66 includes a health economic evaluation of vandetanib for the treatment of locally
advanced or metastatic MTC, together with a fully executable health economic model. The Ipsen
submission21 does not include any economic evidence for this appraisal.
BOX 2 Inclusion criteria for review of published economic evaluations and health utility data
Inclusion criteria
l Comparative economic evaluations of interventions for the treatment of locally advanced or
metastatic MTC.
l Studies reporting preference-based health utilities relating to any type of thyroid cancer.
Exclusion criteria
l Studies evaluating diagnostic/staging interventions, for example FNAB (unless the study specifically
mentions utilities for advanced/metastatic disease or reports QALYs).
l Partial economic analyses, for example costing studies.
l Editorials.
l Reviews.
l Clinical studies that do not report costs.
l Letters and commentaries.
l Non-English language.
FNAB, fine-needle aspiration biopsy; QALY, quality-adjusted life-year.
Company submissions
received by NICE
(n = 2)
Studies identified by
HRQoL search
(n = 1282)
Studies identified by economic
evaluations search
(n = 1879)
Full texts of studies obtained
following deduplication
(n = 104)
Studies included in review of
economic evaluations
(n = 0)
Submissions including
economic evaluations
(n = 1)
FIGURE 7 Study selection results.
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Scope of the Sanofi economic evaluation
The Sanofi CS66 presents the methods and results of a model-based economic evaluation of vandetanib for
the treatment of MTC, based largely on analyses of a subgroup of the ZETA trial. The scope of the company’s
model is summarised in Table 15. The model assesses the incremental cost-effectiveness of vandetanib versus
BSC over a lifetime (20-year) time horizon from the perspective of the NHS. Cost-effectiveness is expressed in
terms of the incremental cost per quality-adjusted life-year (QALY) gained. The population considered
within the company’s model relates to the restricted EU-label population, that is, patients with aggressive
and symptomatic unresectable locally advanced or metastatic MTC, defined as progressive (documented
progression within 12 months prior to enrolment) and symptomatic (at least one symptom at baseline,
including pain score of > 4, ≥ 10 days of opioid use, diarrhoea, flushing, fatigue, pain, nausea, dysphagia,
dysphonia, respiratory symptoms, weight loss) plus CTN and CEA doubling times within 24 months of
screening.66 The AG noted that this population is narrower than the indication permitted by the EMA
marketing authorisation for vandetanib;22 a health economic analysis of the broader licensed population
is not presented within the CS.66 Costs and health outcomes are discounted at a rate of 3.5% per annum.
The company’s economic analysis includes a PAS that takes the form of a simple price discount for
vandetanib. The results presented within this report use the list price for vandetanib; the results of the
Sanofi model including the PAS are presented within a separate confidential appendix to this report.
Costs were valued at 2015/16 prices.
It is important to note from the outset that a substantial proportion of participants (confidential information
has been removed) in the restricted EU-label population who were allocated to the placebo arm of the ZETA
trial switched to open-label vandetanib (either post progression or in any participant following a protocol
amendment in January 2010, see the Sanofi clarification response,73 question A2). In addition, a proportion
of participants (confidential information has been removed) in the restricted EU-label population who were
allocated to the intervention group continued to receive open-label vandetanib following disease progression.
Although the company attempted to adjust for treatment switching using the rank-preserving structural
failure time (RPSFT) method, this was not successful (see the Sanofi CS,66 pp. 98–9); hence, the estimates of
TABLE 15 Sanofi model scope
Model component Description
Population The restricted EU-label population for vandetanib: patients with aggressive and symptomatic
unresectable locally advanced or metastatic MTC defined as progressive (documented progression
within 12 months prior to enrolment) and symptomatic (at least one symptom at baseline,
including pain score of > 4, ≥ 10 days of opioid use, diarrhoea, flushing, fatigue, pain, nausea,
dysphagia, dysphonia, respiratory symptoms, weight loss) plus CTN and CEA doubling times
within 24 months of screening
Intervention 300mg per daya of vandetanib [with post-progression continuation of vandetanib in (confidential
information has been removed) of participants]
Comparator BSC [with switch to 300 mg per day of vandetanib post progression in (confidential information
has been removed) of patients]
Analysis type Cost–utility analysis
Economic outcome Incremental cost per QALY gained
Perspective NHS
Time horizon 20 years (lifetime)
Discount rate 3.5% per annum for health outcomes and costs
a Dose adjustments, treatment interruption and treatment discontinuation are included for participants receiving vandetanib.
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OS for both modelled treatment groups are unadjusted and remain potentially confounded by the use of
open-label vandetanib. As the potential impact of open-label vandetanib use could not be addressed,
the company’s model includes the estimated costs of post-progression vandetanib use within both the
intervention and comparator treatment groups. The economic comparison made by the company’s model
is, therefore, vandetanib, including continued use in some participants post progression, versus BSC with
vandetanib use in most participants post progression. The AG notes that this may not be useful for decision-
making; the same issue also applies to the two pairwise comparisons of vandetanib versus BSC undertaken
using the AG model (see Independent assessment group model).
The AG also notes that two errors were identified within the company’s original submitted model, which
related to (1) the duration over which QALY losses owing to AEs are applied and (2) inputs relating to the
proportion of participants who discontinued vandetanib prior to disease progression (see Critical appraisal
of the economic analysis presented by Sanofi). All results presented within this report include corrections to
these errors.
Sanofi model structure
The economic analysis presented by Sanofi takes the form of a cohort-level partitioned survival model
implemented using the discretely integrated condition event (DICE) simulation methodology103 (Figure 8).
The model includes three health states: (1) progression free, (2) post progression and (3) dead. The model
operates as follows. At any time t, the probability that a participant allocated to treatment group k is alive
is given by S(t)OS_k, whereas the probability that a participant allocated to treatment group k is alive and
progression free is given by S(t)PFS_k. The probability that a participant is alive following disease progression is
calculated as the difference between the two survivor functions: S(t)OS_k – S(t)PFS_k for any time t. Given the
presence of censoring, parametric survivor functions were fitted to Kaplan–Meier curves for OS and PFS
from the ITT/safety populations of the ZETA trial, including adjustment for two covariates: (1) ‘SympProg’
(presence of symptomatic and progressive disease) and (2) ‘BiomarkerChg’ (CEA and CTN doubling times
of ≤ 24 months). Weibull functions were selected to model both OS and PFS, assuming independent
(non-proportional) hazards between treatment groups. The DICE routine is evaluated using a monthly
cycle length over a 20-year lifetime horizon and includes a half-cycle correction to account for the timing
of events.
The model assumes that health utility is determined by the presence/absence of disease progression, with
higher utilities applied to the progression-free state. In addition, a once-only QALY loss is applied to each
group to account for the incidence of grade 3/4 AEs.
The model includes the following resource costs: (1) vandetanib drug acquisition costs, (2) monitoring for
participants receiving vandetanib, (3) BSC costs, (4) palliative care costs and (5) costs associated with
managing AEs.
Assign: tmt
Set: tmt-specific
parameters
Set time to:
partition
Update: states
Apply: tmt
discontinuation
Derive: deaths
Update: costs,
utilities
Accrue: QALYs
life-years, costs
Record: Markov
trace
Report all
results
Start
Partition
Valuation
End
FIGURE 8 Schematic of the Sanofi DICE model (reproduced from the Sanofi CS66).
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The model employs the following structural assumptions:
l Health-related quality of life is determined according to the presence/absence of disease progression
and the incidence of grade 3/4 AEs.
l Progression-free survival and OS are modelled using Weibull functions assuming independent
(non-proportional) hazards.
l Survival models were fitted to the overall ITT population for PFS and the safety population for OS,
including covariate adjustments to reflect the characteristics of the restricted EU-label population.
l No adjustment is made to account for logical inconsistencies [i.e. when S(t)PFS > S(t)OS].
l The modelling of costs and health outcomes includes the level of open-label vandetanib use (either
post progression or in any patient following the January 2010 protocol amendment73) observed in the
ZETA trial.
l Adverse events are assumed to affect both costs and HRQoL. According to the Sanofi CS,66 AE impacts on
HRQoL apply only during the first month of the time horizon. This aspect of the model is subject to a
programming error (see Critical appraisal of the economic analysis presented by Sanofi) and was
corrected by the company in its clarification response73 (question A18).
l Palliative care costs are assumed to be incurred only during the final month of life.
Evidence used to inform the company’s model
Table 16 summarises the evidence used to parameterise the company’s model. The derivation of these
parameters and their evidence sources are discussed in further detail in the following sections.
Overall survival
Overall survival was defined as the time from randomisation to death or the last date at which the subject was
known to be alive.66 The analyses of OS used individual patient data (IPD) for all participants who received
randomised treatment (the safety population) including follow-up to the data cut-off point of 7 September
2015. As noted in Scope of the Sanofi economic evaluation, the Sanofi CS66 states that although attempts
were made to adjust for treatment switching using the RPSFT method, these were unsuccessful (Sanofi CS,66
pp. 98–9). Therefore, the OS data used in the model remain subject to potential confounding as they include
data relating to the use of open-label vandetanib in both treatment groups. With respect to this issue, the
company states: ‘the OS data are more likely to show the impact of treatment with immediate vs delayed
vandetanib, rather than be a true comparison of vandetanib vs placebo’. (Sanofi CS,66 p. 63). Parametric
survival models (Weibull, log-normal, log-logistic, exponential and gamma functions) were fitted to the
available data including two covariates – (1) ‘SympProg’ (presence of symptomatic and progressive disease)
and (2) ‘BiomarkerChg’ (CEA and CTN doubling times of ≤ 24 months) – using the LIFEREG procedure in SAS®
(SAS Institute Inc., Cary, NC, USA. SAS and all other SAS Institute Inc. product or service names are registered
trademarks or trademarks of SAS Institute Inc. in the USA and other countries. ® indicates USA registration.).
In order to reflect the restricted EU-label population within the model, the coefficients for both covariates
were set equal to 100%. Statistical goodness-of-fit was assessed using the Akaike information criterion (AIC)
and the Bayesian information criterion (BIC). The CS states that the plausibility of the long-term projections
for each model was also assessed, although the CS does not provide details about who undertook this
assessment or whether or not any external data were used to inform these judgements. The company’s
subsequent clarification response states that assessments of clinical plausibility involved an expert clinician,
the statistical consultants and the modelling team (Sanofi clarification response,73 question A15).
The observed and predicted OS curves are presented in Figure 17 in Appendix 3, based on the comparison
presented in both the Sanofi CS66 and the model. As the CS includes only a comparison of the Weibull
function against the empirical Kaplan–Meier data, the AG digitised the Kaplan–Meier data and plotted the
predictions of the covariate-adjusted Weibull, log-normal and log-logistic OS functions for the purposes of
comparison. The AG considers this comparison of observed and predicted OS to be inappropriate as the
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TABLE 16 The company’s model parameters and evidence sources
Parameter group Evidence source
PFS Parametric survival models fitted to ZETA trial ITT population PFS data, and
subsequently adjusted by setting the coefficients for covariates ‘SympProg’ and
‘BiomarkerChg’ to 100%66
OS Parametric survival models fitted to ZETA trial safety population OS data, and
subsequently adjusted by setting the coefficients for covariates ‘SympProg’ and
‘BiomarkerChg’ to 100%
Health utilities Progression-free state: the FACT-G scores for the progression-free state observed in the
ZETA trial were mapped to the EQ-5D-3L instrument using the algorithm reported by
Dobrez et al.104
Post-progression state: calculated using utility multiplier (0.766) for post progression vs.
pre progression from SG study of societal preferences for advanced melanoma health
states reported by Beusterien et al.105
Disutility due to AEs: disutility for any grade 3/4 AE taken from Beusterien et al.’s105
advanced melanoma SG study
Time spent receiving vandetanib Vandetanib group BSC group
(a) Pre progression
l Percentage of PFS time spent receiving
300 mg/200mg/100 mg/interrupted
dose based on the restricted EU-label
population of the ZETA trial66,78
l An additional constant discontinuation
probability (confidential information has
been removed) is also assumed66
(b) Pre progression
l N/A
(c) Post progression
l Same as (a) but without additional
constant discontinuation probability
(d) Post progression
l Same as (a) but without additional
constant discontinuation probability
Probability of receiving
vandetanib while in
post-progression state
Based on observed continuation proportion
in the vandetanib group of the restricted
EU-label population from the ZETA trial
(confidential information has been
removed)66
Based on observed switching
proportion in the placebo group of the
restricted EU-label population from the
ZETA trial (confidential information has
been removed)66
Vandetanib acquisition cost Sanofi CS66
Monitoring resource use Resource use related to ECGs and phlebotomy during the first and subsequent years of
use based on the SmPC for vandetanib22
AE incidence Grade 3/4 AEs observed within full safety population of the ZETA trial66,74
BSC resource use Assumption
AE management costs NHS Reference Costs 2015/16106
BSC costs NHS Reference Costs 2015/16106
Palliative chemotherapy costs NHS Reference Costs 2015/16106
Palliative care costs Curtis and Burns107
EQ-5D-3L, EuroQol-5-Dimensions, three-level version; N/A, not applicable; SG, standard gamble.
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population represented by the observed Kaplan–Meier data is not the same as the population reflected by
the modelled functions (the observed data reflect the safety population with the CTN/CEA biomarker but
without aggressive and progressive disease; see Critical appraisal of the economic analysis presented by
Sanofi). The corresponding AIC/BIC statistics for all five parametric models are presented in Table 40 in
Appendix 3.
With respect to the vandetanib group, the AIC and BIC were lowest for the log-normal model, whereas for
the placebo group, the AIC and BIC were lowest for the gamma model. The CS states that the Weibull
function was selected for use in the base-case analysis as, in this instance, this function ‘matches human
mortality better in the long term’ (Sanofi CS,66 p. 105). The impact of uncertainty surrounding the choice
of parametric function for PFS and OS was partially explored in the sensitivity analyses.
Progression-free survival
Progression-free survival was defined as the time from randomisation to documented progression based
on central review or death.66 The Sanofi CS66 (p. 101) notes that, although the use of central-read PFS is
subject to confounding because of treatment switching, using this end point mirrors the per-protocol end
points of the ZETA trial. The analyses of PFS used IPD for all randomised participants available at the date
of the initial data cut-off point, as reported in the original CSR of 6 July 2011.74 As with the company’s
analysis of OS, parametric survival models (Weibull, log-normal, log-logistic, exponential and gamma
functions) were fitted to the available PFS data including two covariates: (1) ‘SympProg’ (presence of
symptomatic and progressive disease) and (2) ‘BiomarkerChg’ (CEA and CTN doubling times of ≤ 24 months)
using the LIFEREG procedure in SAS. In order to reflect the restricted EU-label population, the coefficients for
both covariates were set equal to 100%. Statistical goodness-of-fit was assessed using the AIC and BIC. The
CS states that the plausibility of the long-term projections for each model was also assessed; the company’s
clarification response states that this exercise involved an expert clinician, the statistical consultants and the
modelling team (Sanofi clarification response,73 question A15).
The observed and predicted PFS curves are presented in Figure 18 in Appendix 3, based on the observed
central review PFS Kaplan–Meier curves for the restricted EU-label population presented in figure 6 of
the CS (see Sanofi CS,66 p. 56). As the CS includes only a comparison of the Weibull function against the
empirical Kaplan–Meier PFS curves, the AG digitised the Kaplan–Meier data and plotted the predictions
of the covariate-adjusted Weibull, log-normal and log-logistic PFS functions for the purposes of comparison.
The AG notes that the Kaplan–Meier curves used to compare model-predicted with observed PFS within
the Sanofi CS and those presented in the company’s model differ considerably; the reasons for these
differences are unclear. The corresponding AIC/BIC statistics for all five parametric models are presented in
Table 41 in Appendix 3.
The AIC and BIC were lowest for the log-normal model for the vandetanib group, whereas the AIC and
BIC were lowest for the exponential model for the placebo group. The CS states that ‘As there is no
clear, clinical expectation for the PFS over the long-term, Weibull was also selected in the base case for
consistency’ (Sanofi CS,66 p. 105). The impact of uncertainty surrounding the choice of parametric function
for PFS and OS was partially explored in the sensitivity analyses.
Health-related quality of life
The health utility values applied in the Sanofi model are summarised in Table 42 in Appendix 3. The ZETA
trial assessed HRQoL using the FACT-G instrument;74 the trial did not include the use of a preference-based
HRQoL instrument. Within the model, the health utility score associated with the progression-free state was
estimated by mapping FACT-G scores for participants who were progression free in the ZETA trial to the
EuroQol-5 Dimensions, three-level version (EQ-5D-3L), using a published ordinary least squares algorithm
reported by Dobrez et al.104 This mapping exercise produced a mean utility score for the progression-free
state of 0.84.
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The Sanofi CS66 notes that in the ZETA trial, post-progression FACT-G data were available for only
62 participants (27%). Rather than applying the mapping approach used for the progression-free state,
the health utility score for the post-progression state was instead estimated using a utility multiplier for the
states of post progression versus pre progression derived from a general population standard gamble study
of societal preferences for advanced melanoma states reported by Beusterien et al.105 In this study, the
ratio of progressive disease utility to stable disease utility was 0.766 (0.59/0.77); applying this multiplier to
the company’s estimated utility score for the progression-free state leads to an estimated post-progression
utility score of 0.64 (0.84 × 0.766). The disutility associated with any grade 3/4 AEs was also derived from
the Beusterien et al.105 advanced melanoma valuation study (disutility = –0.11). The same disutility was
assumed to apply to each type of AE.
Time spent receiving vandetanib
Table 43 in Appendix 3 presents the percentage of time spent receiving each dose level of vandetanib
during the progression-free period divided by the total pre-progression time on treatment, calculated
from data for the restricted EU-label population.66,78 This distribution is applied within the vandetanib
group to determine the amount of time spent receiving treatment in the progression-free state. The
Sanofi CS66 (p. 103) notes that ‘Patients whose cancer had not yet progressed were allowed, nevertheless,
to discontinue treatment. These treatment discontinuations were addressed by applying the relevant
proportion to the patients not having progressed in each cycle (21.9%)’. This value was later corrected
by the company [corrected value = (confidential information has been removed)]. Although the wording
of the CS implies that all participants start treatment on vandetanib and a proportion of participants
subsequently discontinue treatment during each cycle, this discontinuation parameter is instead applied
as a fixed proportion of participants in the progression-free state who do not receive vandetanib (and,
therefore, do not incur any costs of vandetanib treatment). The appropriateness of this parameter is unclear.
The distribution of vandetanib use, shown Table 43 in Appendix 3, is also applied in the post-progression
state for the proportions of participants who switch to or continue to receive vandetanib post progression
in each treatment group, albeit without the vandetanib discontinuation parameter. As a consequence,
participants receive more vandetanib per cycle during the post-progression phase than in the pre-progression
phase; it is unclear whether this reflects an error or an unreasonable assumption.
Probability of receiving vandetanib in the post-progression state
Based on the experience of the ZETA trial66,78 (specifically with respect to the restricted EU-label population),
the model assumes that (confidential information has been removed) of participants in the vandetanib group
continue to receive vandetanib post progression, whereas (confidential information has been removed) of
participants in the BSC group cross over to receive vandetanib post progression. Clinical advisors to the AG
noted that the use of vandetanib post progression does not reflect usual clinical practice in England.
Vandetanib acquisition cost
The acquisition costs of vandetanib are summarised in Table 44 in Appendix 3, based on the current prices
listed in the British National Formulary.108
Monitoring costs
Resource use estimates were based on the monitoring regimen detailed in the SmPC for vandetanib.22
Unit costs were derived from NHS Reference Costs 2015/16106 (see Table 45 in Appendix 3). Owing to the
inclusion of the costs associated with post-progression vandetanib use in the BSC group, these monitoring
costs are applied in both groups (to the proportion of participants who initially receive/continue vandetanib
in the intervention group and to the proportion of participants who switch from BSC to vandetanib in
the comparator group). Although the monitoring costs are presented in the CS as being dependent on
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the time since starting treatment, this time dependence is captured only in the progression-free state for
the intervention group. The lower ‘subsequent years’ cost is applied to the proportion of participants
continuing or switching to vandetanib post progression (see Sanofi CS,66 p. 111). The company states that
this approach was deemed to be conservative (see Sanofi clarification response,73 question A20), although
the AG notes that the impact on the incremental cost-effectiveness ratio (ICER) is likely to be small.
Adverse event management costs
The company’s model includes any grade 3/4 AEs that occurred in ≥ 2% of participants in either treatment
group. Table 46 in Appendix 3 presents the grade 3/4 AE incidence rate and associated management costs
included in the company’s model. The incidence of any grade 3/4 AEs was taken from the safety population
of the ZETA trial27 (derived directly from the Wells et al.27 trial publication). Unit costs associated with the
management of AEs were derived from NHS Reference Costs 2015/16.106 In response to a request for
clarification from the AG, the company clarified that the AE data for the safety population were used
because the equivalent data for the restricted EU-label population were not available at the time of the
submission (see Sanofi clarification response,73 question A11). The model applies the total AE cost once
during the first model cycle. The AG notes that all NHS reference cost codes assume that a participant is
treated in an elective inpatient setting; given that these costs are associated with the management of AEs
(i.e. non-elective), this is inappropriate but is likely to have only a negligible impact on the model results.
Palliative care costs
The company’s model includes a cost of £5775 for palliative care derived from the Personal Social Services
Research Unit (PSSRU)107 and £827 for palliative chemotherapy given at the end of life, based on NHS
Reference Costs 2015/16.106 This cost is applied for the last month before death. As these costs are common
to both groups, and because virtually all participants die within the time horizon (> 98.7% of participants),
the only differences in these costs between the two treatment groups are as a result of discounting.
Model evaluation methods
The headline results presented in the Sanofi CS66 are based on the deterministic version of the model.
Uncertainty surrounding model parameters was explored using deterministic sensitivity analysis (DSA)
and probabilistic sensitivity analysis (PSA). The company’s probabilistic results were estimated from 1000
Monte Carlo samples. Uncertainty was represented using tornado diagrams, cost-effectiveness planes and
cost-effectiveness acceptability curves (CEACs).
Sanofi model results
Sanofi central estimates of cost-effectiveness (excluding Patient Access Scheme, including
error corrections)
Table 17 presents the company’s base-case estimates of cost-effectiveness using the list price for vandetanib.
Based on the probabilistic version of the company’s model, vandetanib is expected to generate an additional
1.34 QALYs at an additional cost of £42,215 compared with BSC; the ICER for vandetanib versus BSC is
expected to be £31,546 per QALY gained. The deterministic version of the model produces a slightly higher
ICER of £31,731 per QALY gained.
Figure 9 presents the CEACs for vandetanib and BSC, generated by the AG using the corrected version of
the Sanofi model. The CEAC indicates that, assuming willingness-to-pay (WTP) thresholds of £20,000 and
£30,000 per QALY gained, the probability that vandetanib produces more net benefit than BSC is
approximately 0.33 and 0.48, respectively.
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
45
Sanofi’s deterministic sensitivity analysis results
Figure 10 presents the results of the company’s DSAs. The most influential parameters (of those assessed
by the company) relate to the probability of vandetanib continuation beyond progression, the probability
of treatment switching in the BSC group and the vandetanib discontinuation parameter applied to the
vandetanib group during the progression-free phase. The use of the log-logistic and log-normal functions
for PFS and OS (analyses not shown in Figure 10) did not have a substantial impact on the ICER for
vandetanib versus BSC (log-normal PFS and OS ICER = £37,227 per QALY gained; log-logistic PFS and OS
ICER = £28,879 per QALY gained). It should be noted that a higher proportion of vandetanib participants
are alive at 20 years (> 8%) using these functions rather than the Weibull model (< 2%).
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FIGURE 9 Cost-effectiveness acceptability curves generated using the Sanofi model: vandetanib vs. BSC (redrawn by
the AG).
TABLE 17 Sanofi’s base-case estimates of cost-effectiveness (excluding PAS)
Option
Absolute Incremental
QALYs Costs (£) QALYs Costs (£) ICER (£)
Probabilistic model
Vandetaniba 3.53 181,130 1.34 42,215 31,546
BSCa 2.19 138,915 – – –
Deterministic model
Vandetaniba 3.49 175,316 1.36 43,024 31,731
BSCa 2.13 132,292 – – –
a Includes post-progression vandetanib costs.
Note
Sanofi probabilistic sensitivity analysis results.
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Continue vandetanib (0.32–0.55)
Cross over to BSC (0.70–0.95)
Discontinue treatment pre progression (0.20–0.42)
Cost care progressed per year (£2385–£10,450)
Cost care progression-free per year (£539–£1050)
AE cost for vandetanib (total) (£192–£531)
Cost of palliative care (last month) (£4224–£8209)
Cost to monitor vandetanib year 1 (£104–£456)
Cost to monitor vandetanib year ≥ 2 (£52–£228)
AE disutility for vandetanib (0.01–0.09)
AE disutility for BSC (0.00–0.05)
AE cost for BSC (total) (£54–£171)
Utility progression free (0.80–0.88)
Utility progressed (0.60–0.68)
Low range
High range
– 13,419.80
– 11,660.75
– 8851.34
13,420.09
11,661.09
8851.64
– 2083.47
– 227.63
– 160.09
– 76.48
– 142.24
– 3.75
– 76.89
– 76.89
– 25.02
– 1097.84
– 447.45
865.52
240.19
89.89
113.60
27.09
0.89
ICER (£)
Tornado diagram (change in ICER from base case)
77.57
30.60
60.98
1179.79
460.75 ICER
FIGURE 10 The DSA results generated using the Sanofi model (reproduced from the Sanofi model). Note: tornado plot shows absolute change to base-case ICER.
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Critical appraisal of the economic analysis presented by Sanofi
Methods for reviewing the company’s economic evaluation and health economic model
The AG adopted a number of approaches to explore, interrogate and critically appraise the economic
evaluation submitted by Sanofi and the underlying health economic model on which this was based.
These approaches included the following:
l an assessment of the extent to which the model adheres to the NICE Reference Case109
l consideration of key items contained in published economic evaluation and health economic modelling
checklists110,111 to critically appraise the model and associated analysis
l scrutiny of the model and discussion of issues identified among the members of the AG
l double-programming of the deterministic version of the Sanofi model to fully assess the logic of the
company’s model structure, to draw out any unwritten assumptions and to identify any apparent errors
in the implementation of the model
l examination of the correspondence between the description of the model reported within the CS66 and
the executable model
l replication of the base-case results, PSA and scenario analysis presented within the Sanofi CS66
l when possible, checking of the Sanofi model parameter values against the original data sources
l the use of expert clinical input to judge the clinical credibility of the company’s economic evaluation
and the assumptions underpinning the model.
Adherence of the company’s economic analysis to the National Institute for Health and
Care Excellence Reference Case
Table 18 summarises the extent to which the economic analysis submitted by Sanofi adheres to the NICE
Reference Case.109
TABLE 18 Adherence of the company’s economic analysis to the NICE Reference Case
Element Reference Case AG’s comments
Defining the decision
problem
The scope developed by NICE The analysis is partially in line with the decision
problem set out in the final NICE scope. The two key
deviations are as follows:
1. The economic analysis relates specifically to the
restricted EU-label population, that is, patients
with aggressive and symptomatic unresectable
locally advanced or metastatic MTC defined as
progressive (documented progression within
12 months prior to enrolment) and symptomatic
(at least one symptom at baseline, including pain
score of > 4, ≥ 10 days of opioid use, diarrhoea,
flushing, fatigue, pain, nausea, dysphagia,
dysphonia, respiratory symptoms, weight loss) plus
CTN and CEA doubling times of ≤ 24 months.
No economic analysis is presented for the broader
licensed population
2. Cabozantinib is not included as a comparator
Comparator(s) As listed in the scope developed by
NICE
The company’s model compares vandetanib with
BSC. However, estimates of OS are not adjusted for
continued post-progression vandetanib use or
switching from placebo to vandetanib post progression,
or any pre-progression open-label vandetanib use
permitted following the January 2010 protocol
amendment to the ZETA trial. Cabozantinib is not
considered within the economic analysis. Locally
ablative therapies are not explicitly considered as
comparators
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The two main deviations from the NICE Reference Case109 concern the exclusion of cabozantinib as a
comparator and the population considered within the economic analysis (the restricted EU-label
population). The AG also notes that the clinical evidence and health utilities were not identified using
systematic review methods. These issues are discussed further in Critical appraisal of the economic analysis
presented by Sanofi.
Model verification
The AG reproduced the deterministic version of the company’s DICE model using a simple partitioned
survival approach implemented in Microsoft Excel® 2016 (Microsoft Corporation, Redmond, WA, USA).
Table 47 in Appendix 3 compares the results generated by the company’s submitted model and the AG’s
double-programmed model [including corrections detailed in critical appraisal point 6 (see Box 3)]. As
shown in the table, the results generated by the two models are very similar. The AG is confident that the
model has been implemented by the company as intended.
Summary of main issues identified within the critical appraisal
Box 3 presents a summary of the main issues surrounding the company’s health economic analysis.
These issues are discussed in further detail in the following sections.
TABLE 18 Adherence of the company’s economic analysis to the NICE Reference Case (continued )
Element Reference Case AG’s comments
Perspective on outcomes All direct health effects, whether for
patients or, when relevant, carers
The model includes direct health effects
Perspective on costs NHS and PSS The Sanofi model adopts a NHS perspective. PSS costs
are not explicitly considered
Type of economic
evaluation
Cost–utility analysis with fully
incremental analysis
The economic evaluation takes the form of a
cost–utility analysis. Results are presented in terms of
the incremental cost per QALY gained for vandetanib
vs. BSC
Time horizon Long enough to reflect all important
differences in costs or outcomes
between the technologies being
compared
A lifetime (20-year) time horizon is adopted
Synthesis of evidence on
health effects
Based on systematic review The company did not undertake a systematic review
of clinical effectiveness evidence
Measuring and valuing
health effects
Health effects should be expressed in
QALYs. The EQ-5D is the preferred
measure of HRQoL in adults
Within the progression-free state, health utility was
estimated by mapping from the FACT-G collected
in the ZETA trial to the EQ-5D. The health utility
multiplier for the post-progression state and for the
disutility associated with AEs was based on a SG study
of societal preferences for advanced melanoma states
reported by Beusterien et al.105 A disutility for any
grade 3/4 AE is included based on Beusterien et al.105
Source of data for
measurement of HRQoL
Reported directly by patients and/or
carers
Source of preference data
for valuation of changes
in HRQoL
Representative sample of the UK
population
Equity considerations An additional QALY has the same
weight regardless of the other
characteristics of the individuals
receiving the health benefit
No equity weighting is applied
Evidence on resource use
and costs
Costs should relate to NHS and PSS
resources and should be valued using
the prices relevant to the NHS and PSS
Resource use estimates were based on data from the
ZETA trial, expert opinion and assumptions. Unit costs
were taken from NHS Reference Costs 2015/16106
Discount rate The same annual rate for both costs
and health effects (currently 3.5%)
Costs and health outcomes are discounted at a rate
of 3.5% per annum
EQ-5D, EuroQol-5 Dimensions; PSS, Personal Social Services.
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Relevance of the restricted EU-label population
The company’s health economic analysis is limited to the restricted EU-label population, based on the
argument that this reflects the current use of vandetanib in clinical practice in England. In response to a
request for clarification from the AG, the company stated that:
In developing the submission, we consulted with two UK clinical experts to discuss management of
MTC in practice. Factors which determined the need for systemic treatment were speed of progression,
tumour burden/size and symptoms. CTN/CEA doubling are known markers of poor prognosis and more
aggressive disease. Sanofi Genzyme re-analysed the ZETA trial population and considered the patients
who were symptomatic, had progressed within 12 months and with CTN/CEA doubling < 24 months
most closely reflected UK clinical expert opinion. This approach is within the intent of the EU label
where benefit outweighs the risk by using local clinical approaches to identify those most in need
of treatment.
Reproduced with permission from Sanofi Genzyme, response to clarification questions,73 question A3
However, clinical advisors to the AG disagree with this assertion and instead suggest that in clinical
practice vandetanib is used in patients with symptomatic and progressive disease irrespective of CEA/CTN
biomarker levels. The clinical advisors also noted that CTN is an unstable measure and that the presence
of disease progression (which is likely to also be accompanied by symptomatic disease) is more useful for
informing treatment decisions. The advisors further noted that, although CEA and CTN are routinely
measured in patients with MTC, these biomarkers are typically used to monitor patients while they are
receiving treatment (to assess whether or not treatment is working), rather than to determine whether or
not treatment should be initiated. The clinical advisors also noted that patients with symptomatic and
progressive disease are also likely to have CEA/CTN doubling times of ≤ 24 months. As noted previously,
the CS does not contain a health economic analysis of vandetanib within the broader population indicated
by its marketing authorisation.22 The clinical advisors did, however, agree that the company’s interpretation
of what constitutes ‘progressive and symptomatic’ disease (see Chapter 3) is clinically appropriate.
Failure to adjust for continued vandetanib use and best supportive care switching to
vandetanib post progression
The Sanofi CS states that although attempts were made to account for treatment switching in the ZETA
trial using the RPSFT method, these were reported to have been unsuccessful. In response to a request for
clarification, the company stated that:
RPSFT failed to undo bias as the method looks for the effect sizes needed so that the two survival curves
match if they are given the same treatment, if the curves never separate, or don’t separate enough because
crossover happens too early or before sufficient events occur in placebo (as was the case in ZETA), the
curves will match up with effects very close to the null. This was the result obtained in the analyses.
Reproduced with permission from Sanofi Genzyme, response to clarification questions,73 question A2
BOX 3 Main issues identified by the AG
1. Relevance of the restricted EU-label population.
2. Failure to adjust for continued vandetanib use, and BSC switching to vandetanib, post progression.
3. Likely overestimation of costs of vandetanib use in post-progression state.
4. Questionable implementation of the vandetanib discontinuation parameter.
5. Robustness of covariate-adjusted survival modelling to reflect the restricted EU-label population.
6. Technical programming errors.
7. Concerns regarding health utility parameters.
8. Limited exploration of uncertainty surrounding survivor functions.
9. Concerns regarding costings.
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Based on the company’s description, it seems likely that the RPSFT model did work as it would be expected
to given its assumptions, but the company describes the approach as failing as it showed a null treatment
effect. The company’s clarification response also provides further details regarding other treatment-switching
adjustment methods considered by the company (the iterative parameter estimation, inverse probability-of-
censoring weights and two-stage methods); however, these methods were not implemented. Consequently,
the OS data for the BSC group remain subject to potential confounding because of treatment switching.
Clinical advisors to the AG noted that the continued use of vandetanib beyond disease progression does
not reflect usual clinical practice in England; hence, the survival outcomes observed in the intervention
group reflect an atypical treatment pathway. One clinical advisor suggested that if imaging showed a mixed
response with the largest or most symptomatic/problematic lesions being stable and some other lesions
progressing, vandetanib may still be continued; however, the advisor did note that this scenario is uncommon.
Consequently, the AG’s notes that the results generated by the company’s model may not be meaningful for
the purposes of decision-making.
Likely overestimation of costs of vandetanib use in post-progression state
The company’s model includes a single progression event that corresponds to the partition between
the progression-free and post-progression health states. As a result, patients who receive vandetanib post
progression in either the intervention or the comparator group are assumed to continue to do so until death.
In reality, these patients could experience a second progression event prior to death and such progression
would be likely to trigger a clinical decision to discontinue vandetanib. This is not reflected in the company’s
model. The AG accepts that, owing to the failure of the treatment-switching adjustment attempts, it is
reasonable to include the costs of the drug in both groups; however, assuming that all post-progression
treatment continues indefinitely will probably lead to the overestimation of the costs of vandetanib in both
groups. This bias strongly favours the intervention group, as a considerably higher proportion of patients
receive vandetanib post progression in the BSC group than in the intervention group [proportion of patients
on treatment post progression: BSC (confidential information has been removed) vs. vandetanib (confidential
information has been removed); post-progression drug costs: BSC £106,331 vs. vandetanib £68,490].
Removing the costs of vandetanib received post progression in both groups increases the deterministic ICER
from £31,731 per QALY gained to £59,740 per QALY gained. This same concern also applies to the pairwise
comparisons of vandetanib versus BSC undertaken using the AG model.
Questionable implementation of the vandetanib discontinuation parameter
Although the company’s model includes dose reductions (including treatment interruptions) for participants
receiving vandetanib in both groups as per the ZETA trial (see Table 43 in Appendix 3), a further discontinuation
parameter is also applied, but only to those participants in the vandetanib group during the progression-free
phase. This parameter is applied as a fixed proportion of participants who incur no vandetanib costs (confidential
information has been removed) during any model cycle, whilst participants in the intervention group are
progression free. As a consequence of this parameter, together with the long post-progression phase (see critical
appraisal point 3), the pre-progression vandetanib acquisition costs in the intervention group are lower than
the post-progression vandetanib costs in the BSC group (vandetanib pre-progression drug costs, £75,767; BSC
post-progression drug costs, £106,331). This lacks face validity and it is unclear whether or not the company’s
omission of this parameter from post-progression cost calculations was intentional. Setting this parameter equal
to zero increases the ICER from £31,731 to £57,266 per QALY gained.
Robustness of covariate-adjusted survival modelling to reflect the restricted
EU-label population
The Sanofi CS66 (p. 57) states that ‘it was not possible to fit a parametric regression model to the observed
K–M data . . . due to relatively sparse data in the restricted population producing K–M curves with long
steps would lead to inaccurate estimates of the median survival function when extrapolated for the
economic model’. Instead, the company used the ITT and safety data sets for PFS and OS, respectively, and
fitted curves including covariates for symptomatic and progressive disease and for the CEA/CTN biomarker.
The AG considers that it would have been more appropriate to fit parametric functions directly to the data
relating to the population of interest [the restricted EU-label population, vandetanib group (confidential
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
51
information has been removed), placebo group (confidential information has been removed)] as these are
the most relevant data available to estimate PFS and OS in this subgroup. Although the CS explains that
the Kaplan–Meier curves feature large steps between events because of the small sample size, it is not
clear that this would lead to more inaccurate estimates of median survival in the restricted EU-label
population than those produced by fitting a covariate-adjusted model to the broader EU-label population.
It should be noted that the model fit statistics (AIC/BIC) presented by the company reflect how well each
parametric model with covariates fits the data observed for the entire ITT/safety population, and so the
model with lowest AIC/BIC does not necessarily indicate the best fit to the population of interest.
The AG has further concerns regarding the company’s interpretation of their covariate-adjusted survival
modelling. Figure 9 of the Sanofi CS66 presents a comparison of the covariate-adjusted Weibull OS
model against the empirical Kaplan–Meier curves from the ZETA trial (see Figure 17 in Appendix 3) and
states that:
These parameterised curves appear to underestimate the benefit of vandetanib in the CTN/CEA
doubling population from the ITT dataset (figure 7), even without undoing crossover. There is
uncertainty regarding how well this function would fit the ‘true’ survival curves in the CTN/CEA
doubling population from the EU label dataset with cross over undone.
Sanofi CS,66 figure 9 (p. 59)
However, the comparison of predicted and observed OS probabilities represented in this comparison
relates to two different populations: the covariate-adjusted Weibull model relates to the restricted EU-label
population, whereas the observed Kaplan–Meier curves relate to the ZETA trial ITT population with CEA
and CTN doubling times of ≤ 24 months (excluding the progressive population characteristics). Figure 19 in
Appendix 3 shows the company’s Weibull OS model fitted against the relevant Kaplan–Meier curve for the
restricted EU-label subgroup (plotted by the AG). As shown in the figure, the company’s Weibull model
does not provide a good visual fit to either the vandetanib or the BSC group data.
Technical programming errors
According to the CS66 (p. 107), the disutility for AEs was intended to be applied during the first cycle only
(1-month duration). However, the DICE event used to calculate disutilities in each group does not include
a time adjustment; hence, this disutility is applied to the whole first year of the model. This reflects a
programming error that exaggerates the QALY loss in both groups; given that the incidence of AEs is higher
for vandetanib, the error produces a small bias in favour of the BSC comparator group. This issue was later
corrected by the company in its clarification response73 (question A18). During the appraisal process, the
company also highlighted a further error relating to the vandetanib discontinuation parameter; this was
originally reported to be (confidential information has been removed) but was later corrected to (confidential
information has been removed). Correcting these two errors reduces the company’s original deterministic
ICER from £40,363 to £31,731 per QALY gained.
The AG also notes that the model does not include any adjustment for logical inconsistency (i.e. when
the cumulative survival probability for PFS is greater than that for OS at a given time point). This does
not affect the company’s deterministic base-case Weibull functions for OS and PFS. However, this issue
is evident in scenarios in which other parametric functions are used (e.g. if the log-normal function is
used for PFS and the Weibull function is used for OS). This leads to a situation whereby the health state
population of the post-progression state becomes negative (see Table 48 in Appendix 3). This issue
could have been resolved by conditioning the PFS survivor function to be equal to or lower than the OS
survivor function.
Concerns regarding health utility parameters
The CS does not include details of a systematic review of utility estimates in MTC or other types of thyroid
cancer. The means through which the company identified the Beusterien et al.105 study, which is used to inform
the post-progression utility multiplier and the disutility for grade 3/4 AEs, are unclear from the Sanofi CS.66
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The AG also notes that the Beusterien et al.105 study relates to advanced melanoma health states, hence
its relevance to MTC is unclear. Although the Sanofi CS66 (p. 114) states that there are ‘insufficient data
available for alternative estimates’, such statements are difficult to qualify without undertaking a formal
systematic review of the available evidence. However, as shown in the company’s DSAs, these parameters
do not have a marked impact on the cost-effectiveness of vandetanib within the restricted EU-label
population (see Figure 10).
Limited exploration of uncertainty surrounding survivor functions
The CS includes only limited consideration of uncertainty surrounding the range of potentially plausible
survivor functions for PFS or OS. Although a number of parametric functions were fitted to the available
data for PFS and OS, only the impact of the log-logistic and log-normal functions for both PFS and OS
(together) were explored within the company’s DSAs (see Sanofi model results). It should also be noted
that although the company’s executable model includes the parameters for five alternative survivor
functions, only the Weibull, log-logistic and log-normal curves can be selected as options. The reasons
for this are unclear.
Concerns regarding costings
Clinical advisors to the AG noted several concerns regarding the company’s cost assumptions:
1. Monitoring costs. Although the company’s model includes the costs associated with ECGs to monitor
patients while receiving vandetanib, these costs should also include consultant-/nurse-led outpatient
appointments (typically at a frequency of around 12 consultant-led visits and four nurse-led visits per year).
2. Best supportive care costs in post-progression state. The company’s assumption of 36.5 outpatient
appointments per year (one appointment every 10 days) while patients are receiving BSC is unrealistically
high. Clinical advisors to the AG suggested that a more reasonable estimate would be around six
appointments per year.
3. Costs of managing AEs. Clinical advisors to the AG believe that the costs of managing some of the grade
3/4 events included in the company’s model are implausibly high. As noted in Evidence used to inform
the company’s model, the unit costs assumed for these events all assume that the episode is elective,
which is, by definition, incorrect. The clinical advisors suggested that the incidence of prolonged QT
interval, hypertension, decreased appetite and rash would most likely be managed by discontinuing
vandetanib. Hypertension would probably require the prescription of antihypertensive drugs.
Discussion of existing evidence relating to the cost-effectiveness of cabozantinib and
vandetanib for the treatment of locally advanced or metastatic medullary thyroid cancer
The systematic review of existing economic evaluations did not identify any relevant published studies.
The manufacturer of cabozantinib did not submit any economic evidence relating to this product. The
manufacturer of vandetanib (Sanofi) submitted a de novo model-based health economic evaluation of
vandetanib versus BSC in the restricted EU-label population (patients with symptomatic and progressive
disease with CEA/CTN doubling times of ≤ 24 months). An economic analysis for the broader licensed
population was not presented. The corrected version of the company’s submitted model suggests that the
probabilistic ICER for vandetanib versus BSC is approximately £31,546 per QALY gained. The AG notes
several concerns relating to the company’s submitted model, in particular (1) the questionable relevance
of the restricted EU-label population to current clinical practice, (2) the failure to adjust for open-label
vandetanib use in both treatment groups, (3) the likely overestimation of the costs of vandetanib use in
the post-progression state, (4) questionable assumptions regarding the amount of vandetanib received and
(5) concerns regarding the robustness of the company’s covariate-adjusted survival modelling to reflect the
restricted EU-label population. The AG considers it probable that the ICER for vandetanib is considerably
higher than the estimates presented within the Sanofi CS.
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Independent assessment group model
Model scope
The scope of the AG’s analysis is summarised in Table 19. The AG’s analyses are presented across two
populations of patients with locally advanced or metastatic MTC: (1) patients with progressive and
symptomatic disease (the EU-label population for vandetanib) and (2) the restricted EU-label population for
vandetanib. Within the broader symptomatic and progressive population, pairwise economic comparisons
are made for cabozantinib versus BSC based on the ITT population of the EXAM trial28 (AG analysis 1) and
for vandetanib versus BSC based on the post hoc EU-label (symptomatic and progressive) subgroup of the
ZETA trial66,78 (AG analysis 2). It should be noted that these analyses are limited in that they do not include all
relevant treatment options. As the AG did not have access to the underlying IPD (including data on relevant
covariates) from the ZETA trial, it was not possible to implement statistical adjustments to account for
open-label vandetanib use in either treatment group, or to adjust for other potential baseline imbalances in
the subgroup. Consequently, the comparison of vandetanib versus BSC is subject to potential confounding.
To provide more meaningful estimates of the cost-effectiveness of vandetanib and cabozantinib, two sets of
fully incremental analyses of all options are also presented. The first of these (AG analysis 3) uses the EXAM
trial data for cabozantinib and BSC and applies the PFS treatment effect for vandetanib versus placebo from
the ZETA trial EU-label subgroup to the EXAM trial placebo group baseline; OS is assumed to be the same
for both TKIs (equivalent to the cabozantinib arm in the EXAM trial). The second incremental analysis
(AG analysis 4) assumes that PFS and OS outcomes for vandetanib are equivalent to those for cabozantinib.
TABLE 19 The AG model scope
Model scope
Population
EU-label: symptomatic and progressive MTC
Restricted EU-label: symptomatic and
progressive MTC with CEA/CTN
doubling time of ≤ 24 months
Intervention(s) Vandetanib Vandetanib
Cabozantinib
Comparator BSC BSC
Outcomes Incremental cost per QALY gained Incremental cost per QALY gained
Economic
comparisons
AG analysis 1: pairwise economic evaluation of cabozantinib
vs. BSC in the EXAM trial ITT population
AG analysis 5: pairwise economic
evaluation of vandetanib vs. BSC in the
ZETA trial restricted EU-label population
AG analysis 2: pairwise economic evaluation of vandetanib
vs. BSC in the ZETA trial EU-label population
AG analysis 3: fully incremental analysis based on EXAM trial
ITT population with vandetanib PFS treatment effect applied
to EXAM trial placebo baseline; vandetanib OS assumed to
be equivalent to cabozantinib OS
AG analysis 4: fully incremental analysis based on EXAM trial
ITT population assuming PFS and OS are equivalent for
vandetanib and cabozantinib
Perspective NHS and PSSa NHS and PSSa
Time horizon 20 years 20 years
Cycle length 1 month 1 month
Discount rate 3.5% for health outcomes and costs 3.5% for health outcomes and costs
PSS, Personal Social Services.
a PSS costs not explicitly included.
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Although these incremental analyses necessarily reflect potentially strong assumptions concerning
transferable/equivalent treatment effects between vandetanib and cabozantinib, they are not subject to
potential confounding caused by post-progression vandetanib use within the clinical data. A further pairwise
comparison (AG analysis 5) that evaluates vandetanib versus BSC within the restricted EU-label population
(patients with symptomatic and progressive MTC with CEA/CTN doubling times of ≤ 24 months) is also
presented as equivalent covariate data were not available from the EXAM trial, cabozantinib could not be
included within this analysis. Across all five sets of analyses, cost-effectiveness is evaluated in terms of the
incremental cost per QALY gained from the perspective of the NHS and Personal Social Services (PSS) over a
20-year (lifetime) horizon. Costs and health outcomes were discounted at a rate of 3.5% per annum.109
Costs were valued at 2016/17 prices.
Model structure
The structure of the AG model is presented in Figure 11. As shown in the diagram, the AG model
structure is broadly similar to that adopted within the Sanofi model (see Sanofi model structure). The AG
model adopts a partitioned survival approach, based on three health states: (1) progression free, (2) post
progression and (3) dead. For any time, t, the probability that a patient is alive and progression free is
given by the cumulative survival probability for PFS, whereas the probability that a patient is alive is given
by the cumulative survival probability for OS. The probability that a patient is in the post-progression
state at any time t is given by the difference between the cumulative survival probabilities for PFS and OS.
The model includes an adjustment for logical inconsistency, whereby, if the probability of PFS is greater
than that of OS, PFS is constrained to reflect the lower OS probability. As with the Sanofi model, HRQoL is
defined according to the presence or absence of disease progression and a separate QALY loss is applied
to account for the incidence of grade 3/4 AEs during the first model cycle. The model includes costs
associated with drug acquisition, health-state costs incurred while receiving cabozantinib and vandetanib
[consultant-led outpatient visits, nurse-led outpatient visits, ECG, blood tests and computerised tomography
(CT) scans], costs associated with managing grade 3/4 AEs, BSC-related costs [consultant-led outpatient visits,
CT scans, magnetic resonance imaging (MRI) scans, specialist palliative care visits, palliative radiotherapy,
palliative surgery and bisphosphonates for bone metastases] and end-of-life care costs.
Progression free
• HRQoL
   • Utility PFS
   • AE disutility
• Resource costs
   • Drug acquisition
   • Monitoring costs
   • BSC costsa
   • AE costs
• HRQoL
   • Utility PFS
   • AE disutility
• Resource costs
   • Drug acquisitionb
   • Monitoring costsb
   • BSC costsa
   • AE costs
Post progression
• HRQoL
   • N/A
• Resource costs
   • Palliative care cost
      applied on death
Dead
FIGURE 11 The AG model structure. N/A, not applicable. a, Applies only to patients not receiving vandetanib/
cabozantinib. b, Applies only to open-label vandetanib costs within pairwise comparisons of vandetanib vs. BSC.
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The model employs the following structural assumptions:
l Health-related quality of life is assumed to be determined according to the presence/absence of disease
progression and the incidence of grade 3/4 AEs.
l The model includes an adjustment to account for logical inconsistencies [i.e. when S(t)PFS>S(t)OS].
l In the pairwise comparisons of vandetanib versus BSC (see Table 19, AG analyses 2 and 5), the modelling
of costs and health outcomes includes the level of treatment switching and continued vandetanib use
post progression observed in the ZETA trial subgroups. This was included as the company’s attempts to
adjust for treatment switching and treatment continuation post progression were reported to have been
unsuccessful (see Critical appraisal of the economic analysis presented by Sanofi).
l Grade 3/4 AEs are assumed to affect both costs and HRQoL. Health losses resulting from AEs are
assumed to be transient and resolved quickly: a QALY loss is applied during the first model cycle only
(1-month duration).
l As patients receiving BSC, by definition, have progressed disease, the costs associated with BSC are
assumed to be the same in both the progression-free and post-progression states.
l Health state resource use (including additional TKI monitoring requirements) incurred during the
progression-free period are assumed to differ between the three treatment options.
l Palliative care costs are incurred only during the final month of life.
Evidence used to inform the model’s parameters
Summary of evidence sources used to inform the assessment group model
Table 20 summarises the evidence sources used to inform the AG’s health economic model. These evidence
sources are discussed in further detail in the subsequent sections.
TABLE 20 Evidence used to inform the AG model
Parameter group Evidence source
PFS Pairwise comparisons of TKI vs. BSC (AG analyses 1, 2 and 5)
l Parametric PFS functions fitted to IPD from the EXAM and ZETA trialsa
Incremental comparison of all options including a differential PFS treatment effect
between vandetanib and cabozantinib (AG analysis 3)
l Parametric PFS functions fitted to IPD from the EXAM trial. Vandetanib PFS
effect derived using treatment effect parameter from combined model using
ZETA IPD (applied to the EXAM ITT placebo arm as the baseline)
Incremental comparison of all options assuming equivalent effectiveness for TKIs
(AG analysis 4)
l Parametric PFS functions fitted to IPD from the EXAM trial. Vandetanib
outcomes assumed to be equivalent to cabozantinib outcomes
OS Pairwise comparisons of TKI vs. BSC (AG analyses 1, 2 and 5)
l Parametric OS functions fitted to IPD from the EXAM and ZETA trials (includes
potential confounding as a result of switching/continuation post progression for
vandetanib comparisons)a
Incremental comparisons of all options (AG analyses 3 and 4)
l Parametric OS functions fitted to IPD from the EXAM trial ITT population.
Vandetanib outcomes assumed to be equivalent to cabozantinib outcomes
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Time-to-event analysis using individual patient data
Table 21 summarises the use of the time-to-event data from the ZETA and EXAM trials within the AG model.
The comparison of cabozantinib with placebo was based on IPD relating to the full population of the EXAM
trial (cabozantinib, n = 219; placebo, n = 111). These data were supplied by Ipsen for both PFS and OS.112
The comparison of vandetanib with placebo was based on post hoc subgroups of participants enrolled in
the ZETA trial: the EU-label population [vandetanib, n = (confidential information has been removed);
placebo, n = (confidential information has been removed) for PFS; placebo, n = (confidential information
has been removed) for OS] and the restricted EU-label population [vandetanib, n = (confidential
information has been removed); placebo, n = (confidential information has been removed)]. Owing to
concerns regarding the intellectual property rights of the patient-level data set, Sanofi was unable to
provide the original IPD collected during the trial. Instead, Kaplan–Meier curves for each population and
outcome were provided by Sanofi.73 The supplied Kaplan–Meier curves were digitised using Engauge
Digitizer113 and IPD were then reconstructed from the digitised curves using the algorithm reported by
Guyot et al.114 This method maps the digitised curves back to time-to-event data by finding numerical
solutions to the inverted Kaplan–Meier equations. There are four variations on the method depending on
the amount of information supplied. For both of the ZETA trial subgroups (EU label and restricted EU label)
and outcomes (PFS and OS), both the number at risk tables and the total numbers of events were supplied
TABLE 20 Evidence used to inform the AG model (continued )
Parameter group Evidence source
Health utilities Progression-free and post-progression health states
l Derived from TTO study utility valuation in radioactive iodine-refractory
differentiated thyroid cancer102
Disutility due to AEs
l Disutility for any grade 3/4 AE taken from general population SG study of
societal preferences for advanced melanoma health states105
Time spent receiving vandetanib Based on the proportion of PFS time spent on each dose level (or interrupted
treatment) for relevant subgroup in the ZETA trial.66,73,78 Vandetanib dose
distribution also applied to post-progression vandetanib use (in AG analyses 2 and 5
only). Includes vandetanib pre-progression discontinuation parameter in both
progression-free and post-progression states
Time spent receiving cabozantinib Based on the proportion of PFS time spent on each dose level (or interrupted
treatment) within the EXAM trial28
Probability of receiving vandetanib
while in post-progression state
Treatment switching/continuation proportions observed in relevant subgroups of the
ZETA trial.66,73 Vandetanib dose distribution also applied to post-progression use
Drug acquisition costs BNF108
AE incidence Derived from EXAM and ZETA trial publications27,28
Health state resource use Personal communication: Dr Jon Wadsley (Weston Park Hospital, Sheffield, 2017)
and Dr Laura Moss (Velindre Cancer Centre, Cardiff, 2017)
BSC resource use Personal communication: Dr Jon Wadsley and Dr Laura Moss
Health state unit costs NHS Reference Costs 2015/16106
AE management costs NHS Reference Costs 2015/16.106 Weighted mean of all non-elective excess bed-days
BSC costs NHS Reference Costs 2015/16106
Palliative care and palliative
chemotherapy costs
NHS Reference Costs 2015/16,106 and Curtis and Burns107
BNF, British National Formulary; SG, standard gamble; TTO, time trade-off.
a Data from the ZETA trial were reconstructed IPD rather than raw trial data.
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TABLE 21 Summary of time-to-event data used in the AG model
Outcome
Population
EU-label: symptomatic and progressive MTC
Restricted EU-label:
symptomatic and progressive
MTC with CEA/CTN doubling
times of ≤ 24 months
AG analysis 1:
cabozantinib vs. BSC
(pairwise)
AG analysis 2:
vandetanib vs. BSC
(pairwise)
AG analysis 3: all options –
vandetanib PFS treatment
effect from joint model
AG analysis 4: all options –
cabozantinib and vandetanib
equivalent
AG analysis 5: vandetanib vs.
BSC (pairwise)
PFS
Cabozantinib PFS Cabozantinib arm,
EXAM ITT
N/A Cabozantinib arm, EXAM ITT Cabozantinib arm, EXAM ITT N/A
Vandetanib PFS N/A Vandetanib arm, ZETA
EU label
Treatment effect from ZETA
EU label applied to EXAM
placebo arm
Assumed same as cabozantinib arm,
EXAM ITT
Vandetanib arm, ZETA restricted
EU label
BSC PFS Placebo arm, EXAM ITT Placebo arm, ZETA EU
label
Placebo arm, EXAM ITT Placebo arm, EXAM ITT Placebo arm, ZETA restricted EU
label
OS
Cabozantinib OS Cabozantinib arm,
EXAM ITT
N/A Cabozantinib arm, EXAM ITT Cabozantinib arm, EXAM ITT N/A
Vandetanib OS N/A Vandetanib arm, ZETA
EU label
Assumed same as
cabozantinib arm, EXAM ITT
Assumed same as cabozantinib arm,
EXAM ITT
Vandetanib arm, ZETA restricted
EU label
BSC OS Placebo arm, EXAM ITT Placebo arm, ZETA EU
label
Placebo arm, EXAM ITT Placebo arm, EXAM ITT Placebo arm, ZETA restricted EU
label
Treatment switching
Includes switching/
continued vandetanib
costs?
N/A Yes No No Yes
N/A, not applicable.
Note
Data used to inform time-to-event analysis.
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by Sanofi, thereby allowing the most accurate variation of the algorithm to be used. In addition, as the
sample sizes of the subgroups are fairly small and there are a small number of events that can be readily
identified from the Kaplan–Meier survival curves, the resulting reconstructed IPD are likely to provide a
good approximation of the original data set.
Methods for time-to-event analysis
For each data set, model selection was conducted following the process described in the NICE Decision
Support Unit Technical Support Document No. 14.115,116 Log-cumulative hazard plots were produced to
assess the type of hazards observed in the trial to help inform which types of parametric function may be
considered appropriate. For all analyses except for AG analysis 4, individual models were fitted to the data
for each treatment group, thereby avoiding unnecessarily restrictive assumptions of proportional hazards or
constant acceleration factors. The AIC and BIC were examined to assess the comparative internal validity of
competing models. The final choice of models for the economic analysis was made on the basis of fit to the
observed data as well as consideration of the clinical plausibility of competing candidate models, based on
judgements elicited from one clinical expert (JW). The final model selections used to inform the health
economic model are presented in this report (see Table 23).
To inform the fully incremental analyses of cabozantinib, vandetanib and BSC (AG analysis 3), a single
parametric model with a covariate indicating treatment arm was considered for PFS in the EU-label
population of the ZETA trial. As discussed in Chapter 3, Quantity and quality of research available and
Justification for conducting a network meta-analysis, this population is considered to be broadly comparable
to that of the EXAM trial. Fitting a combined model provides a treatment effect for vandetanib compared
with placebo (either a HR or constant acceleration factor, depending on the parametric model). This can
then be applied to the baseline model (taken to be the placebo arm in the EXAM trial) to approximate the
absolute effect for a vandetanib treatment group in the chosen baseline population. The estimated HR
from the NMA (see Chapter 3, Network meta-analysis) was not used as it is generally recommended that
estimation of the treatment effects and baseline follows a consistent modelling procedure.100 Furthermore,
the use of HRs would not be appropriate for the accelerated failure time models as these do not make the
assumption of proportional hazards.
Curve fitting was conducted in R using the flexsurv package. The muhaz package was used to estimate
the empirical hazard function. Exponential, Weibull, Gompertz, log-normal, log-logistic, gamma and
generalised gamma models were considered. The more flexible generalised F-distribution was also
considered; however, for some of the analyses, the model-fitting algorithm failed to converge. In these
cases, the AG considered that the generalised F-distribution model would not be appropriate. The
goodness-of-fit information is provided for all considered models.
Cabozantinib versus best supportive care, EXAM trial intention-to-treat population
(used in the assessment group’s analyses 1, 3 and 4)
Progression-free survival
The analysis of PFS for cabozantinib versus placebo was based on IPD from the full population of the EXAM
trial (cabozantinib, n= 219; placebo, n= 111; see Figure 20 in Appendix 4) provided by Ipsen. Empirical
diagnostic plots are provided in Figure 21 in Appendix 4. Visual inspection of the empirical hazard function plot
indicates potentially different behaviours between the two treatment arms. Visual inspection of the log–log plot
of cumulative survival versus time indicates that the exponential model may not be appropriate as the gradient
is not close to 1.0; the remaining standard parametric models were deemed suitable for consideration.
Measures of comparative internal validity are presented in Table 49 in Appendix 4. Plots of the fitted
models against the empirical Kaplan–Meier PFS curves are presented in Figures 22 (cabozantinib) and 23
(placebo) in Appendix 4. For the placebo arm, the log-logistic model provided the best fit to the observed
data according to both the AIC and BIC (AIC = 308.71; BIC = 314.13), although the log-normal model also
provided a good fit to the data (AIC = 311.48; BIC = 316.90). For the cabozantinib arm, the Weibull model
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provided the best fit according to both the AIC and BIC (AIC = 579.70; BIC = 586.48), although the BIC
was similar for several models.
Overall survival
The analysis of OS for cabozantinib versus placebo was based on IPD from the full population of the EXAM
trial (cabozantinib, n= 219; placebo, n = 111; see Figure 24 in Appendix 4) provided by Ipsen. Log-cumulative
hazard plots are provided in Figure 25, Appendix 4. Visual inspection of the empirical hazard function
indicates that the observed hazard is approximately constant for both trial arms, and visual inspection of the
log–log plot of cumulative survival versus time indicates a gradient of approximately 1.0, suggesting that the
exponential model may be appropriate in this case.
Measures of comparative internal validity are presented in Table 49 in Appendix 4. Plots of the fitted
models against the empirical Kaplan–Meier OS curves are presented in Figures 26 (cabozantinib) and
Figure 27 (placebo) in Appendix 4. Based on AIC and BIC statistics for the placebo arm, the log-logistic
and exponential models provided the best fit (log-logistic AIC = 708.31, BIC = 713.73; exponential
AIC = 709.58, BIC = 712.29). Findings were similar for the cabozantinib arm: the log-logistic model
provided the best fit to the observed data based on the AIC (1343.69) and the exponential model provided
the best fit based on the BIC (1348.42).
Vandetanib versus best supportive care, ZETA trial EU-label population (used in the
assessment group’s analysis 2)
Progression-free survival
The analysis of PFS for vandetanib versus placebo was based on Kaplan–Meier curves for the EU-label
population of the ZETA trial [vandetanib, n = (confidential information has been removed); placebo,
n = (confidential information has been removed)]. The Kaplan–Meier curves provided by Sanofi73 are
presented in Figure 28 in Appendix 4. The number of observed events was (confidential information has
been removed) in the vandetanib arm and (confidential information has been removed) in the placebo arm
(Sanofi CS appendices,78 table 5, p. 51). The replicated Kaplan–Meier curves appear consistent with the
reported data (see Figure 29 in Appendix 4): the replicated median PFS time of (confidential information
has been removed) months for placebo is close to the value reported from the observed data (median
16.4, n = 60 from Kriessl et al.57). Median PFS was not reached for the vandetanib arm.
Log cumulative hazard plots are presented in Figure 30 in Appendix 4. Visual inspection of the empirical
hazard function indicates that the observed hazard is approximately constant for both trial arms, and visual
inspection of the log–log plot of cumulative survival versus time indicates a gradient of approximately 1.0
for the placebo arm, thereby suggesting that the exponential model may be an appropriate model choice.
Measures of comparative internal validity are presented in Table 50 in Appendix 4. Plots of the fitted models
against the empirical PFS data are presented in Figures 31 (vandetanib) and 32 (placebo) in Appendix 4.
For the placebo arm, the exponential model provided the best fit to the observed data based on both the
AIC and the BIC (AIC = 296.49, BIC = 298.58). For the vandetanib arm, the gamma model provided the
best fit to the observed data based on both AIC and BIC (AIC = 467.93, BIC = 473.66); however, differences
in the goodness-of-fit statistics across models were generally small, giving little justification to discriminate
between models on this basis.
Overall survival
The analysis of OS for vandetanib was based on Kaplan–Meier curves for the EU-label population of the ZETA
trial [vandetanib, n = (confidential information has been removed); placebo, n = (confidential information has
been removed)]. The Kaplan–Meier curves provided by the company are shown in Figure 33 in Appendix 4;
the number of events observed was (confidential information has been removed) in the vandetanib arm and
(confidential information has been removed) in the placebo arm (Sanofi CS appendices,78 table 7, p. 53).
The replicated Kaplan–Meier curves appear consistent with the reported data (see Figure 34 in Appendix 4):
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the replicated median OS times of (confidential information has been removed) months for placebo and
(confidential information has been removed) months for vandetanib are close to the estimates reported
from the observed data (placebo median = (confidential information has been removed); vandetanib
median = (confidential information has been removed), from Kreissl et al.57).
Log-cumulative hazard plots are provided in Figure 35 in Appendix 4. Visual inspection of the empirical
hazard function indicates that the observed hazard is approximately constant for both trial arms, and visual
inspection of the log–log plot of cumulative survival versus time indicates a gradient of approximately 1.0
for both treatment models, thereby suggesting that the exponential model may be appropriate.
Measures of comparative internal validity are presented in Table 50 in Appendix 4. Plots of the fitted
models against the empirical Kaplan–Meier OS curves are presented in Figures 36 (vandetanib) and 37
(placebo) in Appendix 4. For the placebo arm, the exponential model provided the best fit to the observed
data (AIC = 421.65, BIC = 423.73). For the vandetanib arm, the log-normal model provided the best fit to
the observed data (AIC = 847.27, BIC = 853.01); however, differences in the AIC and BIC were generally
small, thereby giving little justification to discriminate between models on this basis.
Vandetanib versus best supportive care, restricted EU-label population, ZETA trial
(used in the assessment group’s analysis 5)
Progression-free survival
The analysis of PFS for vandetanib versus placebo was based on Kaplan–Meier curves for the restricted
EU-label population of the ZETA trial [vandetanib, n = (confidential information has been removed);
placebo, n = (confidential information has been removed)]. The Kaplan–Meier curves provided by Sanofi
are shown in Figure 38 in Appendix 4; the number of progression events observed was (confidential
information has been removed) in the vandetanib arm and (confidential information has been removed)
in the placebo arm. The replicated Kaplan–Meier curves appear to be consistent with the reported data (see
Figure 39 in Appendix 4): the replicated median PFS times of (confidential information has been removed)
months for the placebo arm and (confidential information has been removed) months for the vandetanib
arm are close to the estimates reported from the observed data [placebo median = (confidential information
has been removed) months, vandetanib median = (confidential information has been removed) months
(from the Sanofi CS,78 appendix 6)].
Log-cumulative hazard plots are presented in Figure 40 in Appendix 4. Measures of comparative internal
validity are presented in Table 51 in Appendix 4. Plots of the fitted models against the empirical Kaplan–Meier
PFS curves are presented in Figures 41 (vandetanib) and 42 (placebo) in Appendix 4. For the placebo arm,
the log-logistic model provided the best fit to the observed data based on the AIC (89.55), whereas the
exponential model provided the best fit based on the BIC (90.54). For the vandetanib arm, the log-normal
model provided the best fit based on the AIC (132.60), whereas the exponential model provided the best fit
based on the BIC (134.30); however, differences in the AIC and BIC statistics were generally small, thereby
giving little justification to discriminate between models on this basis.
Overall survival
The analysis of OS for vandetanib was based on Kaplan–Meier curves for the restricted EU-label
population within the ZETA trial [vandetanib, n = (confidential information has been removed); placebo,
n = (confidential information has been removed)]. The Kaplan–Meier curves provided by Sanofi are shown
in Figure 43 in Appendix 4; the number of progression events observed was (confidential information has
been removed) in the vandetanib arm and (confidential information has been removed) in the placebo
arm. The replicated Kaplan–Meier curves appear consistent with the reported estimates (see Figure 44
in Appendix 4): the median PFS times of (confidential information has been removed) months for placebo
and (confidential information has been removed) months for vandetanib are close to the estimates reported
from the observed data (placebo median = (confidential information has been removed) months, vandetanib
median = (confidential information has been removed) months, from the Sanofi CS,78 appendix 6).
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Log-cumulative hazard plots are provided in Figure 45 in Appendix 4. Measures of comparative internal
validity are presented in Table 51 in Appendix 4. Plots of the fitted models against the empirical Kaplan–Meier
OS curves are presented in Figures 46 (vandetanib) and 47 (placebo) in Appendix 4. For the placebo arm,
the Gompertz model provided the best fit to the observed data based on both the AIC and BIC (AIC= 150.44,
BIC = 152.11). For the vandetanib arm, the exponential model provided the best fit to the observed data
based on both the AIC and the BIC (AIC = 212.75, BIC = 214.21).
Combined model used to estimate progression-free survival treatment effect for
vandetanib and best supportive care (used in assessment group analysis 3)
The analysis of PFS for vandetanib versus placebo, used to inform AG analysis 3, utilised the Kaplan–Meier
curves for the ZETA trial EU-label population [vandetanib, n = (confidential information has been removed);
placebo, n = (confidential information has been removed)]; these curves were provided by Sanofi and
reconstructed by the AG as described in the previous sections.
Visual inspection of the log–log plot of cumulative survival versus time suggests that the proportional
hazards assumption may be considered valid for the observed period, and the use of a single model with
a covariate indicating treatment group is therefore appropriate.
Measures of comparative internal validity are presented in Table 52 in Appendix 4. The log-normal model
provided the best fit to the observed data based on both the AIC and BIC (AIC = 764.25, BIC = 773.99).
Figure 48 in Appendix 4 presents plots of the reconstructed survival data for both the placebo and
vandetanib groups.
Within the health economic model, the treatment effect covariate (shown in Table 52 in Appendix 4) is
applied to the baseline model (taken to be the placebo arm in the EXAM trial ITT population) in order to
approximate the absolute effect for a vandetanib treatment group in the chosen baseline population.
For parametric models in the proportional hazards family (exponential, Weibull, Gompertz), the estimated
treatment effect represents a HR. For parametric models in the accelerated failure time family (log-normal,
log-logistic, gamma, generalised gamma and generalised F), the estimated treatment effect represents an
acceleration factor. These parameters are applied to the survivor function of the baseline proportional
hazards/accelerated failure time model as follows.
Proportional hazards models
Given a survivor function for the placebo arm, Sp(t), and a HR, r, for treatment (vandetanib) compared with
placebo, the survivor function for the vandetanib arm, SV(t), is obtained using:
SV (t) = SP(t)
r . (1)
Further detail can be found in Collett.117
Accelerated failure time models
Given an acceleration factor of θ in the treatment arm (vandetanib) compared with placebo, the survivor
function for the vandetanib arm is given by:
SV (t) = SP(θt), (2)
where θ = exp(–βx) and β is the coefficient on the analysis scale. Applying the coefficients presented in
Appendix 4, Table 52, we have:
SV (t) = SP(exp(−βx)t). (3)
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If θ > 1, then events in the treatment arm happen more quickly than in the control arm (assuming a
negative outcome, this favours the control). If θ < 1, then events in the treatment arm happen less quickly
than in the control arm (assuming a negative outcome, this favours the treatment).
Model selection
The clinical plausibility of the competing survivor functions for each analysis was assessed using clinical
opinion. Clinical advisors were asked to select their preferred model(s) on the basis of visual fit to the data
within the observed trial period and the clinical plausibility of the extrapolated portion of each curve.
Clinicians were allowed to select more than one preferred model and were asked to provide justification
for their preferences. The responses from the first clinical advisor are presented in Table 22. The second
clinical advisor felt unable to complete the model selection exercise. The AG’s selected base-case survivor
functions for each analysis are presented in Table 23.
TABLE 22 Clinical advisor’s preferred survivor functions
Population
Advisor number 1 (JW)
Preferred curve Justificationa
EU-label population: symptomatic and progressive MTC
EXAM trial ITT, PFS,
cabozantinib
Log-logistic There is a tail to account for small proportion of patients
with extended PFS but best fit at earlier time points
EXAM trial ITT, PFS, placebo Log-logistic Appears to most closely fit observed data
EXAM trial ITT, OS,
cabozantinib
Log-logistic or
log-normal
Good fit with observed data at early time points and both
allow for a small proportion of long-term survivors
EXAM trial ITT, OS, placebo Gompertz, log-logistic
or log-normal
All have good fit at early time points and allow for
possibility of long-term survival for a small number
of patients
ZETA trial EU label, PFS,
vandetanib
Log-logistic Good fit at early time points and allows for a small
proportion of long-term PFS patients
ZETA trial EU label, PFS,
placebo
Log-logistic, log-normal,
Gompertz
Good fit at early time points and allow for small proportion
of patients without progression at later time points
ZETA trial EU label, OS,
vandetanib
Log-normal or
log-logistic
Appears to give best fit to early data
ZETA trial EU label, OS,
placebo
Log-logistic Good fit with early data and allows for a small proportion
of long-term survivors
Restricted EU-label population: symptomatic and progressive MTC with CEA/CTN doubling time of ≤ 24 months
ZETA trial EU label, PFS,
vandetanib
Log-logistic, log-normal
and Gompertz
Allow for a small but realistic proportion of long-term
survivors – too many long-term PF patients with
exponential model
ZETA trial EU label, PFS,
placebo
Log-normal, log-logistic,
Gompertz
Close fit to early data and realistic, small number of
longer-term PF survivors
ZETA trial EU label, OS,
vandetanib
Log-logistic, log-normal,
Gompertz
Good fit with early data and realistic number of
longer-term survivors
ZETA trial EU label, OS,
placebo
Gompertz Closest fit to early data and realistic upper limit of
100 months OS for this poor-prognosis group
PF, progression free.
a Dr Jon Wadsley, personal communication.
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TABLE 23 Survivor functions used in the AG’s base-case analysis
Population
Selected
curve Justification
Cabozantinib vs. BSC, EXAM trial ITT population (used in AG analyses 1, 3 and 4)
EXAM trial ITT, PFS, cabozantinib Log-logistic Selected based on clinical justification of long-term survivors.
The AIC and BIC for the log-logistic function are higher than
the best-fitting model (Weibull). It should be noted that
outcomes predicted by the log-logistic function are more
favourable than those of the Weibull model
EXAM trial ITT, PFS, placebo Log-logistic Selected based on clinical opinion and on the basis of
consistency with the model used for the intervention group.
There is a cluster of models that appear to provide a very
similar visual fit to the data during the observed period of
the trial. The log-logistic is also the best-fitting model in
terms of the AIC and BIC
EXAM trial ITT, OS, cabozantinib Log-logistic Log-logistic and log-normal provide a similar fit. The
log-logistic is the best-fitting model in terms of the AIC
(the exponential provides the best fit based on the BIC)
EXAM trial ITT, OS, placebo Log-logistic Clinician’s selected models (log-logistic, Gompertz and log-
normal) all provide a similar visual fit to the data. Log-logistic
is the best-fitting model in terms of AIC and is consistent
with the choice of model used for the intervention group
Vandetanib vs. BSC, ZETA trial, EU-label population (used in AG analysis 2)
ZETA trial EU label, PFS, vandetanib Log-logistic Reflects clinician’s choice, justified in terms of the proportion
of long-term survivors. The gamma model gives the best fit
in terms of both AIC and BIC but the log-logistic is very
similar
ZETA trial EU label, PFS, placebo Log-logistic Clinicians’ choices (log-logistic, log-normal and Gompertz) are
within a cluster of very similar models. The log-logistic model
does not provide the best AIC or BIC (the best-fitting model
is the exponential); however, the differences between the
three candidate curves are small. Log-logistic was the model
selected on basis of consistency with the intervention arm
ZETA trial EU label, OS, vandetanib Log-logistic Of the two candidate curves (log-logistic and log-normal),
the log-normal model provides best fit to observed data.
The log-logistic model was selected for consistency with the
comparator arm and is very similar in terms of AIC/BIC
ZETA trial EU label, OS, placebo Log-logistic Reflects clinician’s choice, justified in terms of the proportion
of long-term survivors
Vandetanib vs. BSC, ZETA trial, restricted EU-label population (used in AG analysis 5)
ZETA trial restricted EU label, PFS,
vandetanib
Log-normal Predicted outcomes are very similar for all three candidate
models (log logistic, log normal and Gompertz). The
log-normal model was selected because it had the lowest
AIC among the competing candidate models
ZETA trial restricted EU label, PFS,
placebo
Log-normal Log-normal selected for consistency with the intervention
arm, and very similar to log-logistic model in terms of AIC
ZETA trial restricted EU label, OS,
vandetanib
Gompertz Selected on basis of consistency with comparator arm
ZETA trial restricted EU label, OS, placebo Gompertz Models selected on basis of clinical justification (proportion
of long-term survivors). Gompertz model has best AIC/BIC
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Health-related quality of life
The AG’s systematic searches for HRQoL evidence identified only one published study102 that reports health
utilities for states of progression free and post progression in patients with thyroid cancer. In this study, the
authors developed vignettes for seven health states based on the results of a previous qualitative study118
in differentiated thyroid cancer. These states included (1) stable/no response, (2) response (partial and
complete), (3) progressive disease, (4) stable/no response with grade 3 diarrhoea, (5) stable/no response
with grade 3 fatigue, (6) stable/no response with grade 3 HFS and (7) stable/no response with grades 1
and 2 alopecia. A total of 100 members of the UK general public participated in time trade-off (TTO)
interviews to value the defined health states. Utility scores were estimated directly from the raw interview
response data and using regression analyses. The results of the TTO valuations are presented in Table 24.
Owing to the lack of published evidence relating to the HRQoL associated with thyroid cancer states, the
AG also explored the health utility values considered within previous thyroid cancer drug submissions to
the SMC and the AWMSG. Table 25 summarises the health utilities assumed within these submissions.
The health utilities assumed in the AG’s base-case analysis are summarised in Table 53 in Appendix 4.
Health utilities associated with the absence/presence of disease progression were based on the study
reported by Fordham et al.,102 as this study specifically relates to thyroid cancer states, and health utilities
were valued using a preference-based measure (TTO).102 The disutility associated with grade 3/4 AEs was
based on the lower value reported by Beusterien et al.105 (disutility = –0.11). Uncertainty surrounding these
parameters was modelled using beta distributions. Alternative utility values based on the cabozantinib122
and the sorafenib120 SMC submissions are explored within the sensitivity analyses.
Adverse event rates
The probability of experiencing grade 3/4 AEs was taken directly from the EXAM and ZETA trial publications
(each based on the ITT study populations, see Table 54 in Appendix 4).27,28 Within the incremental
comparisons (AG analyses 3 and 4), the AE rates for the BSC group were assumed to reflect those observed
in the placebo group of the EXAM trial. AEs were assumed to have a duration of 1 month.
Treatment switching/continuation parameters (assessment group analyses 2 and 5 only)
As noted in Scope of the Sanofi economic evaluation, Sanofi applied the RPSFT approach in an attempt
to adjust for the high level of treatment switching that occurred within the ZETA trial.66 However, the
company’s attempts were reported to have been unsuccessful; hence, the available OS data for vandetanib
that are used in the pairwise comparisons of vandetanib versus BSC in the symptomatic and progressive
MTC population and the restricted EU-label MTC population remain subject to potential confounding
(AG analyses 2 and 5). In order to allow for a fairer comparison, the AG included the costs associated with
treatment switching and vandetanib continuation post progression in the pairwise analyses of vandetanib
versus BSC. The number of participants who received vandetanib post progression in each arm of each
subgroup of the ZETA trial was provided by Sanofi (see Table 55 in Appendix 4).
TABLE 24 Utility values reported by Fordham et al.102
Health state Mean utility (observed, no adjustment) 95% CI
Best state: stable/no response 0.80 0.77 to 0.84
Response to therapy 0.86 0.83 to 0.89
Progressive disease 0.50 0.45 to 0.56
Diarrhoea 0.42 0.36 to 0.48
Fatigue 0.72 0.67 to 0.77
HFS 0.52 0.46 to 0.58
Alopecia 0.75 0.71 to 0.79
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Resource use and costs
Drug acquisition
Table 56 in Appendix 4 presents the drug acquisition costs for cabozantinib and vandetanib based on
their current list prices.108 As shown in the table, the cost of cabozantinib is the same for all dose packs.
Both vandetanib and cabozantinib have separate agreed PAS schemes. The results of the AG’s economic
analysis including the PAS discounts for vandetanib and cabozantinib are presented in a separate
confidential appendix to this report.
Time spent receiving cabozantinib and vandetanib
Table 57 in Appendix 4 presents the proportion of PFS time spent receiving each dose of cabozantinib
within the EXAM trial.112 Table 58 in Appendix 4 presents the proportion of PFS time spent receiving
each dose of vandetanib within the ZETA trial subgroups.66,73 As these data are multinomial in nature,
uncertainty was modelled using a Dirichlet distribution with minimally informative priors.
TABLE 25 Health utility values applied in other UK thyroid cancer submissions
Body Drug Indication Health utility values
SMC Lenvatinib119 Adult patients with progressive, locally
advanced or metastatic, differentiated
(papillary/follicular/Hürthle cell) thyroid
carcinoma, refractory to radioactive
iodine
Derived from Fordham et al.102
Stable disease: 0.80
Response: 0.86
Progressive disease: 0.50
Utility decrements of –0.042 for lenvatinib and
–0.117 for sorafenib applied for AEs (diarrhoea,
fatigue, HFS, alopecia)
SMC Sorafenib120 Patients with progressive, locally
advanced or metastatic, differentiated
thyroid carcinoma, refractory to
radioactive iodine
Utilities derived from EQ-5D data from the
DECISION study121
Sorafenib, progression free: 0.72
BSC, progression free: 0.80
Post progression (both groups): 0.64
SMC Cabozantinib122 Adult patients with progressive,
unresectable locally advanced or
metastatic MTC
Published trial data in thyroid cancer (not
specified) in which SF-36 outcomes had been
converted to utilities by mapping to EQ-5D and
converting to SF-6D values for the non-progressed
and progressed states
Progression free: 0.796
Post progression: 0.624
AWMSG Vandetanib123 Patients with aggressive and
symptomatic unresectable locally
advanced or metastatic MTC
FACT-G scores collected in the ZETA trial mapped
to TTO values. Pre- and post-progression utility
values not reported
Disutilities for AEs based on Beusterien et al.105
(values of −0.11 and −0.13 assumed)
AWMSG Cabozantinib124 Adult patients with progressive,
unresectable, locally advanced or
metastatic MTC
For the base-case analysis, utility values were taken
from two published studies in thyroid cancer,
albeit in patients with less severe disease than the
progressive MTC population (sources and values
not specified)
Utility decrements for AEs were derived from the
published literature (also not specified)
EQ-5D, EuroQol-5 Dimensions; SF-6D, Short Form questionnaire-6 Dimensions.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
66
The model also includes a further parameter to reflect those participants who discontinued vandetanib
prior to disease progression [(confidential information has been removed) in the restricted EU-label
population and 22.31% in the broader EU-label population]. Although these participants could have
discontinued treatment at any time, assuming that they incur no drug costs (i.e. discontinued at day 0) is
likely to bias the model in favour of vandetanib (see Critical appraisal of the economic analysis presented
by Sanofi, critical appraisal point 4). In contrast to the assumption taken within the Sanofi model, the AG
assumed that these participants incur half of the total cost of vandetanib during the progression-free
phase (hence the discontinuation parameter was divided by 2). Uncertainty surrounding this parameter
was modelled using a beta distribution.
Cost of managing grade 3/4 adverse events
The cost associated with managing grade 3/4 AEs was assumed to require a single non-elective bed-day.
The unit cost per AE was assumed to reflect the weighted mean cost of a non-elective excess bed-day,
based on the NHS Reference Costs 2015/16106 (mean cost £298.41). Uncertainty surrounding this
parameter was modelled using a normal distribution, assuming that the standard error (SE) was equal
to 15% of the mean (SE £44.76).
Best supportive care costs
Resource use for patients receiving cabozantinib, vandetanib and BSC was estimated using expert opinion
(Dr Jon Wadsley and Dr Laura Moss, personal communication) (see Tables 59 and 60 in Appendix 4).
Clinical advice received by the AG suggested that the resource use associated with BSC is likely to be
the same for both the pre-progression and post-progression states as these patients have, by definition,
progressed disease. Conversely, total health-state resource use associated with cabozantinib and vandetanib
was assumed to be time dependent in order to account for the monitoring requirements associated with
the TKIs. With respect to the pairwise comparisons of vandetanib versus BSC (AG analyses 2 and 5), patients
who switch from BSC to vandetanib post progression are assumed to incur the ‘subsequent years’ costs for
vandetanib; this assumption was also made in the Sanofi model.
One clinical expert (JW) provided resource use estimates (central estimates, minimum and maximum),
which were then verified and augmented with additional components by a second clinical expert (LM).
As the elicited information relates to ranges and some of the distributions are highly skewed, uncertainty
surrounding these parameters was represented using triangular distributions. The experts’ central estimates
were taken to be the mode of the distribution; means were calculated as:
Lower limit +mode + upper limit
3
. (4)
The numbers of ECGs, CT scans, and blood tests were not associated with uncertain ranges and were thus
held as fixed values within the probabilistic analysis.
Cost of palliative care
The costs associated with palliative care and palliative chemotherapy are applied at the point of death to
all patients. These costs were based on the same data used in the Sanofi model,66 which were, in turn,
derived from the NHS Reference Costs 2015/16106 and the PSSRU.107 A total cost of £6602.52 is applied
per patient.
Unit costs
Table 61 in Appendix 4 summarises the unit costs included in the AG model.
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Model evaluation methods
Uncertainty was evaluated using PSA and DSA. PSA was undertaken using simple Monte Carlo sampling
methods (2000 samples). The choice of distribution assumed for each parameter group is summarised in
Table 62 in Appendix 4. The results of the PSA are presented as CEACs. DSAs were undertaken to explore
the impact of alternative assumptions regarding discount rates, choices of parametric survivor functions,
disutilities associated with AEs, and resource use and cost assumptions.
Model validation
The AG adopted a number of approaches to ensure the credibility of the model. These included scrutiny of
the implemented model coding and formulae by two modellers, black-box testing, double-programming
of the deterministic base case for all pairwise comparisons, checking the accuracy of all model inputs
against the original sources, consultation with clinical experts, peer review of the model assumptions by
clinical experts and peer review of the report by two third-party modellers (see Acknowledgements).
Assessment group model results
This section presents the results based on the AG model for each of the five sets of analyses.
Analysis 1: EU-label population (symptomatic and progressive medullary thyroid cancer),
cabozantinib versus best supportive care (pairwise)
Table 26 presents the results of the pairwise comparison of cabozantinib versus BSC within the EU-label
(symptomatic and progressive) MTC population. Disaggregated life-years gained (LYGs), QALYs and costs
are presented in Table 63 in Appendix 5. Based on the probabilistic version of the AG model (assuming the
log-logistic function for both PFS and OS), cabozantinib is expected to generate 0.48 additional QALYs at
an additional cost of £72,734 compared with BSC; the ICER for cabozantinib versus BSC is expected to be
£150,874 per QALY gained. The deterministic version of the model (based on point estimates of parameters)
produces similar results (deterministic ICER = £148,169 per QALY gained). The disaggregated results show
that a considerable amount of the OS gain in both groups is accrued in the post-progression state.
Figure 12 presents CEACs for the pairwise comparison of cabozantinib versus BSC within the EU-label
(symptomatic and progressive) MTC population. Assuming a WTP threshold (λ) of £30,000 per QALY
gained, the probability that cabozantinib produces more net benefit than BSC is zero.
TABLE 26 Analysis 1: EU-label population (symptomatic and progressive MTC), cabozantinib vs. BSC (pairwise),
central estimates of cost-effectiveness (PFS = log-logistic, OS = log-logistic for both options)
Option
Absolute Incremental
ICER (£)QALYs Costs (£) QALYs Costs (£)
Probabilistic model
Cabozantinib 2.28 88,527 0.48 72,734 150,874
BSC 1.79 15,793 – – –
Deterministic model
Cabozantinib 2.27 87,960 0.49 72,287 148,169
BSC 1.79 15,672 – – –
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Table 27 presents the results of the DSAs for the pairwise comparison of cabozantinib versus BSC within
the EU-label (symptomatic and progressive) MTC population. As shown in the table, the ICER remains
in excess of £135,000 per QALY gained across all scenarios. The alternative scenarios regarding health
utilities, AE impacts and health state resource use do not have a marked impact on the cost-effectiveness
of cabozantinib. The exclusion of dose reductions for cabozantinib increases the ICER to £174,297 per
QALY gained. The choice of survivor functions for PFS and OS produces ICERs for cabozantinib versus
BSC in the range £138,259 to £239,141 per QALY gained; the curves used in the AG’s base-case analysis
(PFS = log-logistic, OS = log-logistic) are close to the most favourable scenario.
Analysis 2: EU-label population (symptomatic and progressive MTC), vandetanib versus
best supportive care (pairwise)
Table 28 presents the results of the pairwise comparison of vandetanib versus BSC within the EU-label
(symptomatic and progressive) MTC population. It should be noted that this analysis is subject to potential
confounding as a result of the open-label use of vandetanib in the ZETA trial; hence, post-progression
vandetanib costs are included for both treatment groups. Disaggregated LYGs, QALYs and costs are
presented in Table 64 in Appendix 5. Based on the probabilistic version of the AG model (assuming the
log-logistic function for both PFS and OS), vandetanib is expected to generate 0.23 additional QALYs at
an additional cost of £79,745 compared with BSC; the ICER for vandetanib versus BSC is expected to be
£352,508 per QALY gained. The deterministic version of the model yields a lower ICER of £336,896 per
QALY gained. The disaggregated results indicate that, based on the log-logistic model, OS is expected to
be higher in the BSC group than in the vandetanib group: this is likely to be a consequence of confounding
as a result of open-label vandetanib use in the placebo group. It is also noteworthy that, based on the
selected OS functions, a similar proportion of patients in each group (11–12%) are predicted to still be
alive at 20 years as a consequence of the flattening of the tails of the modelled curves; additional analyses
undertaken by the AG indicate that the ICER for vandetanib versus BSC remains stable over longer time
horizons (the ICER using a 30-year time horizon, excluding any general population mortality constraints,
is £345,284 per QALY gained).
Figure 13 presents CEACs for the pairwise comparison of vandetanib versus BSC within the EU-label
(symptomatic and progressive) MTC population. Assuming a WTP threshold (λ) of £30,000 per QALY
gained, the probability that vandetanib produces more net benefit than BSC is approximately 0.01.
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FIGURE 12 Analysis 1: EU-label population (symptomatic and progressive MTC), cabozantinib vs. BSC (pairwise),
CEACs (PFS= log-logistic, OS = log-logistic for both options).
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TABLE 27 Analysis 1: EU-label population (symptomatic and progressive MTC), cabozantinib vs. BSC (pairwise),
DSA results
Scenario
Incremental
ICER (£)QALYs Costs (£)
Base case 0.49 72,287 148,169
Undiscounted health outcomes and costs 0.57 77,243 135,531
Sanofi CS utilities 0.47 72,287 154,582
DECISION study utilities 0.43 72,287 166,890
Cabozantinib SMC utilities 0.44 72,287 165,816
AE disutility doubled 0.48 72,287 150,159
AE disutility halved 0.49 72,287 147,194
AE management costs doubled 0.49 72,498 148,601
AE management costs halved 0.49 72,182 147,954
Health state resource use doubled 0.49 72,959 149,546
Health state resource use halved 0.49 71,951 147,481
No cabozantinib dose reductions 0.49 85,034 174,297
Curve choice
PFS – exponential; OS – exponential 0.45 71,195 158,030
PFS – exponential; OS – Weibull 0.42 71,012 170,550
PFS – exponential; OS – Gompertz 0.31 70,525 227,293
PFS – exponential; OS – log-normal 0.47 71,298 150,146
PFS – exponential; OS – log-logistic 0.46 71,251 153,284
PFS – exponential; OS – gamma 0.43 71,061 166,964
PFS – Weibull; OS – exponential 0.38 55,213 147,111
PFS – Weibull; OS – Weibull 0.34 55,035 161,300
PFS – Weibull; OS – Gompertz 0.24 54,530 232,034
PFS – Weibull; OS – log-normal 0.40 55,345 138,424
PFS – Weibull; OS – log-logistic 0.39 55,297 141,864
PFS – Weibull; OS – gamma 0.35 55,093 157,191
PFS – Gompertz; OS – exponential 0.36 52,776 147,369
PFS – Gompertz; OS – Weibull 0.32 52,593 162,336
PFS – Gompertz; OS – Gompertz 0.22 52,105 239,141
PFS – Gompertz; OS – log-normal 0.38 52,879 138,259
PFS – Gompertz; OS – log-logistic 0.37 52,831 141,855
PFS – Gompertz; OS – gamma 0.33 52,642 157,984
PFS – log-normal; OS – exponential 0.46 70,719 152,833
PFS – log-normal; OS – Weibull 0.43 70,551 164,542
PFS – log-normal; OS – Gompertz 0.32 70,024 217,141
PFS – log-normal; OS – log-normal 0.49 70,909 145,511
PFS – log-normal; OS – log-logistic 0.48 70,834 148,443
PFS – log-normal; OS – gamma 0.44 70,617 161,210
PFS – log-logistic; OS – exponential 0.47 72,176 152,470
PFS – log-logistic; OS – Weibull 0.44 72,008 163,867
PFS – log-logistic; OS – Gompertz 0.33 71,481 214,567
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TABLE 27 Analysis 1: EU-label population (symptomatic and progressive MTC), cabozantinib vs. BSC (pairwise),
DSA results (continued )
Scenario
Incremental
ICER (£)QALYs Costs (£)
PFS – log-logistic; OS – log-normal 0.50 72,342 145,282
PFS – log-logistic; OS – log-logistica 0.49 72,287 148,169
PFS – log-logistic; OS – gamma 0.45 72,070 160,627
PFS – gamma; OS – exponential 0.39 57,437 147,094
PFS – gamma; OS – Weibull 0.36 57,260 160,678
PFS – gamma; OS – Gompertz 0.25 56,743 226,874
PFS – gamma; OS – log-normal 0.42 57,582 138,733
PFS – gamma; OS – log-logistic 0.41 57,535 142,051
PFS – gamma; OS – gamma 0.37 57,318 156,755
a The AG’s base-case curve choice.
TABLE 28 Analysis 2: EU-label population (symptomatic and progressive MTC), vandetanib vs. BSC (pairwise),
central estimates of cost-effectiveness (PFS = log-logistic, OS = log-logistic for both options)
Option
Absolute Incremental
ICER (£)QALYs Costs (£) QALYs Costs (£)
Probabilistic model
Vandetanib 4.02 255,677 0.23 79,745 352,508
BSC 3.79 175,932 – – –
Deterministic model
Vandetanib 4.02 255,114 0.23 79,044 336,896
BSC 3.78 176,070 – – –
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FIGURE 13 Analysis 2: EU-label population (symptomatic and progressive MTC), vandetanib vs. BSC (pairwise),
CEACs (PFS= log-logistic, OS = log-logistic for both options).
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Table 29 presents the results of the DSAs for the pairwise comparison of vandetanib versus BSC within the
EU-label (symptomatic and progressive) MTC population. Across the range of DSAs considered, the ICERs
for vandetanib versus BSC remain above £123,000 per QALY gained. In several scenarios in which the
Gompertz function is used to model PFS, vandetanib is expected to be dominated by BSC. The DSAs indicate
that the choice of utility values used in the base-case analysis produces a considerably more favourable ICER
for vandetanib versus BSC than the alternative sources identified. The scenarios surrounding health state
resource use assumptions do not substantially alter the ICER; however, the exclusion of post-progression
vandetanib costs in both groups produces a marked increase in the ICER for vandetanib (ICER = £752,136
per QALY gained). In addition, setting the vandetanib discontinuation parameter equal to zero leads to
an increase in the ICER for vandetanib (ICER = £378,272 per QALY gained). The choice of survival curves
produces ICERs for vandetanib versus BSC ranging from £123,723 per QALY gained to dominated; the
parametric survivor functions selected for use in the AG’s base case do not represent the most optimistic
case for vandetanib, nor do they represent they least favourable.
TABLE 29 Analysis 2: EU-label population (symptomatic and progressive MTC), vandetanib vs. BSC (pairwise),
DSA results
Scenario
Incremental
ICER (£)QALYs Costs (£)
Base case 0.23 79,044 336,896
Undiscounted health outcomes and costs 0.25 81,248 320,133
Sanofi CS utilities 0.10 79,044 822,117
DECISION study utilities 0.05 79,044 1,532,109
Cabozantinib SMC utilities 0.07 79,044 1,161,487
AE disutility doubled 0.23 79,044 340,951
AE disutility halved 0.24 79,044 334,904
AE management costs doubled 0.23 79,134 337,283
AE management costs halved 0.23 78,998 336,702
Post-progression vandetanib costs excluded 0.23 176,468 752,136
Vandetanib discontinuation parameter equal to zero 0.23 88,751 378,272
Health state resource use doubled 0.23 80,593 343,500
Health state resource use halved 0.23 78,269 333,593
No vandetanib dose reductions 0.23 85,802 365,703
Curve choice
PFS – exponential; OS – exponential 0.46 59,484 130,328
PFS – exponential; OS – Weibull 0.46 62,545 137,196
PFS – exponential; OS – Gompertz 0.59 72,938 123,723
PFS – exponential; OS – log-normal 0.39 49,372 128,083
PFS – exponential; OS – log-logistic 0.37 49,310 134,230
PFS – exponential; OS – gamma 0.43 60,268 139,406
PFS – Weibull; OS – exponential 0.22 37,245 165,924
PFS – Weibull; OS – Weibull 0.22 40,327 179,916
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TABLE 29 Analysis 2: EU-label population (symptomatic and progressive MTC), vandetanib vs. BSC (pairwise),
DSA results (continued )
Scenario
Incremental
ICER (£)QALYs Costs (£)
PFS – Weibull; OS – Gompertz 0.36 50,707 141,776
PFS – Weibull; OS – log-normal 0.15 27,155 176,631
PFS – Weibull; OS – log-logistic 0.14 27,093 199,768
PFS – Weibull; OS – gamma 0.20 38,051 189,697
PFS – Gompertz; OS – exponential –0.08 53,486 Dominated
PFS – Gompertz; OS – Weibull –0.08 56,486 Dominated
PFS – Gompertz; OS – Gompertz 0.07 64,762 969,254
PFS – Gompertz; OS – log-normal –0.15 43,375 Dominated
PFS – Gompertz; OS – log-logistic –0.17 43,313 Dominated
PFS – Gompertz; OS – gamma –0.11 54,271 Dominated
PFS – log-normal; OS – exponential 0.39 97,481 249,691
PFS – log-normal; OS – Weibull 0.39 100,596 257,665
PFS – log-normal; OS – Gompertz 0.53 110,381 209,110
PFS – log-normal; OS – log-normal 0.32 87,433 273,140
PFS – log-normal; OS – log-logistic 0.30 87,371 289,324
PFS – log-normal; OS – gamma 0.37 98,325 267,980
PFS – log-logistic; OS – exponential 0.32 89,180 275,834
PFS – log-logistic; OS – Weibull 0.32 92,278 285,560
PFS – log-logistic; OS – Gompertz 0.46 101,633 218,981
PFS – log-logistic; OS – log-normal 0.25 79,106 312,992
PFS – log-logistic; OS – log-logistica 0.23 79,044 336,896
PFS – log-logistic; OS – gamma 0.30 90,002 300,416
PFS – gamma; OS – exponential 0.28 41,060 147,850
PFS – gamma; OS – Weibull 0.28 44,151 159,114
PFS – gamma; OS – Gompertz 0.41 54,525 132,686
PFS – gamma; OS – log-normal 0.21 30,979 149,603
PFS – gamma; OS – log-logistic 0.19 30,917 163,617
PFS – gamma; OS – gamma 0.25 41,875 164,911
a The AG’s base-case curve choice.
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
73
Analysis 3: EU-label population (symptomatic and progressive MTC), fully incremental
analysis of all options using vandetanib progression-free survival treatment effect from
combined model, central estimates of cost-effectiveness
Table 30 presents the results of the fully incremental analysis of all options within the EU-label (symptomatic
and progressive) MTC population based on the EXAM trial baseline, together with the PFS treatment effect
derived from the EU-label population of the ZETA trial. It should be noted that this analysis assumes that OS
for vandetanib is equal to that of cabozantinib, which, given the increased hazard rate/acceleration factor
for PFS, may be seen to be optimistic for vandetanib. Disaggregated LYGs, QALYs and costs are presented in
Table 65 in Appendix 5. Based on the probabilistic version of the model (assuming the log-logistic function
for both PFS and OS), the ICER for vandetanib versus BSC is expected to be £138,405 per QALY gained,
whilst the ICER for cabozantinib versus vandetanib is expected to be £195,593 per QALY gained. The
deterministic version of the model produces similar results (vandetanib vs. BSC ICER = £134,817 per QALY
gained; cabozantinib vs. vandetanib ICER = £195,053 per QALY gained). The disaggregated results indicate
that a considerable amount of the OS gain for all options is accrued in the post-progression state.
Figure 14 presents CEACs for the pairwise comparison of cabozantinib, vandetanib and BSC within the
EU-label (symptomatic and progressive) MTC population, including the PFS treatment effect for vandetanib
from the ZETA trial. Assuming a WTP threshold (λ) of £30,000 per QALY gained, the probability that either
cabozantinib or vandetanib produces more net benefit than BSC is zero.
Table 31 presents the results of the DSAs for the fully incremental analyses of cabozantinib, vandetanib and
BSC within the EU-label (symptomatic and progressive) MTC population, including the PFS treatment effect
for vandetanib from the ZETA trial. Across the range of DSAs considered, the ICERs for vandetanib remain
above £85,000 per QALY gained, whilst the ICERs for cabozantinib remain above £148,000 per QALY
gained. In several scenarios in which the Gompertz function is used to model OS, vandetanib is ruled out
of the analysis because of extended dominance. The DSAs indicate that the choice of utility values used
in the base-case analysis produces a considerably more favourable ICER for cabozantinib than for the
alternative sources identified. The scenarios surrounding alternative health state resource use assumptions
do not substantially alter the ICER. Setting the vandetanib discontinuation parameter equal to zero leads
to a situation in which vandetanib is ruled out because of extended dominance; the ICER for cabozantinib
versus BSC is estimated to be £148,169 per QALY gained. The choice of survival curves produces ICERs for
vandetanib in the range £85,217 per QALY gained to extendedly dominated and ICERs for cabozantinib in
the range £180,985 to £239,141 per QALY gained. The parametric survivor functions selected for use in the
AG’s base case do not represent the most optimistic case for either drug, nor are they the least favourable.
TABLE 30 Analysis 3: EU-label population (symptomatic and progressive MTC), fully incremental analysis of all
options using vandetanib PFS treatment effect from combined model, central estimates of cost-effectiveness
(PFS = log-logistic, OS = log-logistic for all options)
Option
Absolute Incremental
ICER (£)QALYs Costs (£) QALYs Costs (£)
Probabilistic model
Cabozantinib 2.28 88,527 0.11 20,559 195,593
Vandetanib 2.17 67,968 0.38 52,175 138,405
BSC 1.79 15,793 – – –
Deterministic model
Cabozantinib 2.27 87,960 0.11 21,094 195,053
Vandetanib 2.16 66,866 0.38 51,193 134,817
BSC 1.79 15,672 – – –
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TABLE 31 Analysis 3: EU-label population (symptomatic and progressive MTC), fully incremental analysis of all
options using vandetanib PFS treatment effect from combined model, DSA results
Scenario
ICER (£) (vs. next-best comparator)
Cabozantinib Vandetanib
Base case 195,053 (vs. vandetanib) 134,817 (vs. BSC)
Undiscounted health outcomes and costs 192,555 (vs. vandetanib) 119,397 (vs. BSC)
Sanofi CS utilities 298,889 (vs. vandetanib) 128,932 (vs. BSC)
DECISION study utilities 379,753 (vs. vandetanib) 135,577 (vs. BSC)
Cabozantinib SMC utilities 351,244 (vs. vandetanib) 136,191 (vs. BSC)
AE disutility doubled 203,651 (vs. vandetanib) 135,495 (vs. BSC)
AE disutility halved 191,021 (vs. vandetanib) 134,480 (vs. BSC)
AE management costs doubled 196,428 (vs. vandetanib) 134,980 (vs. BSC)
AE management costs halved 194,366 (vs. vandetanib) 134,735 (vs. BSC)
Vandetanib discontinuation parameter equal to zero 148,169 (vs. BSC) Extended dominance
Health state resource use doubled 173,521 (vs. vandetanib) 142,718 (vs. BSC)
Health state resource use halved 205,819 (vs. vandetanib) 130,866 (vs. BSC)
No vandetanib or cabozantinib dose reductions 273,909 (vs. vandetanib) 145,927 (vs. BSC)
Curve choice
PFS – exponential; OS – exponential 204,220 (vs. vandetanib) 147,531 (vs. BSC)
PFS – exponential; OS – Weibull 204,220 (vs. vandetanib) 162,113 (vs. BSC)
PFS – exponential; OS – Gompertz 227,293 (vs. BSC) Extended dominance
PFS – exponential; OS – log-normal 204,220 (vs. vandetanib) 138,620 (vs. BSC)
PFS – exponential; OS – log-logistic 204,220 (vs. vandetanib) 142,141 (vs. BSC)
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FIGURE 14 Analysis 3: EU-label population (symptomatic and progressive MTC), fully incremental analysis of all
options using vandetanib PFS treatment effect from combined model, CEACs (PFS = log-logistic, OS = log-logistic for
all options).
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TABLE 31 Analysis 3: EU-label population (symptomatic and progressive MTC), fully incremental analysis of all
options using vandetanib PFS treatment effect from combined model, DSA results (continued )
Scenario
ICER (£) (vs. next-best comparator)
Cabozantinib Vandetanib
PFS – exponential; OS – gamma 204,220 (vs. vandetanib) 157,880 (vs. BSC)
PFS – Weibull; OS – exponential 197,918 (vs. vandetanib) 133,290 (vs. BSC)
PFS – Weibull; OS – Weibull 197,908 (vs. vandetanib) 150,033 (vs. BSC)
PFS – Weibull; OS – Gompertz 232,034 (vs. BSC) Extended dominance
PFS – Weibull; OS – log-normal 197,873 (vs. vandetanib) 123,454 (vs. BSC)
PFS – Weibull; OS – log-logistic 197,873 (vs. vandetanib) 127,303 (vs. BSC)
PFS – Weibull; OS – gamma 197,895 (vs. vandetanib) 145,084 (vs. BSC)
PFS – Gompertz; OS – exponential 207,886 (vs. vandetanib) 135,751 (vs. BSC)
PFS – Gompertz; OS – Weibull 207,886 (vs. vandetanib) 152,470 (vs. BSC)
PFS – Gompertz; OS – Gompertz 239,141 (vs. BSC) Extended dominance
PFS – Gompertz; OS – log-normal 207,886 (vs. vandetanib) 125,894 (vs. BSC)
PFS – Gompertz; OS – log-logistic 207,886 (vs. vandetanib) 129,755 (vs. BSC)
PFS – Gompertz; OS – gamma 207,886 (vs. vandetanib) 147,537 (vs. BSC)
PFS – log-normal; OS – exponential 204,639 (vs. vandetanib) 142,355 (vs. BSC)
PFS – log-normal; OS – Weibull 204,672 (vs. vandetanib) 155,650 (vs. BSC)
PFS – log-normal; OS – Gompertz 217,141 (vs. BSC) Extended dominance
PFS – log-normal; OS – log-normal 204,981 (vs. vandetanib) 134,340 (vs. BSC)
PFS – log-normal; OS – log-logistic 204,897 (vs. vandetanib) 137,538 (vs. BSC)
PFS – log-normal; OS – gamma 204,722 (vs. vandetanib) 151,833 (vs. BSC)
PFS – log-logistic; OS – exponential 194,919 (vs. vandetanib) 139,808 (vs. BSC)
PFS – log-logistic; OS – Weibull 194,936 (vs. vandetanib) 153,657 (vs. BSC)
PFS – log-logistic; OS – Gompertz 214,567 (vs. BSC) Extended dominance
PFS – log-logistic; OS – log-normal 195,113 (vs. vandetanib) 131,503 (vs. BSC)
PFS – log-logistic; OS – log-logistica 195,053 (vs. vandetanib) 134,817 (vs. BSC)
PFS – log-logistic; OS – gamma 194,966 (vs. vandetanib) 149,667 (vs. BSC)
PFS – gamma; OS – exponential 180,990 (vs. vandetanib) 97,633 (vs. BSC)
PFS – gamma; OS – Weibull 180,990 (vs. vandetanib) 122,911 (vs. BSC)
PFS – gamma; OS – Gompertz 226,874 (vs. BSC) Extended dominance
PFS – gamma; OS – log-normal 180,985 (vs. vandetanib) 85,217 (vs. BSC)
PFS – gamma; OS – log-logistic 180,985 (vs. vandetanib) 89,881 (vs. BSC)
PFS – gamma; OS – gamma 180,989 (vs. vandetanib) 114,798 (vs. BSC)
a The AG’s base-case curve choice.
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Analysis 4: EU-label population (symptomatic and progressive medullary thyroid cancer),
cabozantinib and vandetanib assumed equivalent
Table 32 presents the results of the fully incremental analysis of all options within the EU-label (symptomatic and
progressive) MTC population, assuming equivalent PFS and OS outcomes for cabozantinib and vandetanib, using
time-to-event data from the EXAM trial. Disaggregated LYGs, QALYs and costs are presented in Table 66 in
Appendix 5. Based on the probabilistic version of the model (assuming the log-logistic function for both PFS and
OS), cabozantinib is expected to be dominated; this is a consequence of the more favourable grade 3 or higher
AE profile and the slightly lower total relative dose intensity-adjusted drug costs for vandetanib. The probabilistic
ICER for vandetanib versus BSC is estimated to be £144,841 per QALY gained. The deterministic version of the
model produces a similar result (deterministic ICER= £142,279 per QALY gained). The disaggregated results
indicate that a considerable proportion of the total OS gain for all options is accrued in the post-progression state.
Figure 15 presents CEACs for the pairwise comparison of vandetanib versus BSC within the EU-label
(symptomatic and progressive) MTC population for the analysis in which PFS and OS outcomes are
assumed to be equivalent for both drugs. Assuming a WTP threshold (λ) of £30,000 per QALY gained,
the probability that either cabozantinib or vandetanib produces more net benefit than BSC is zero.
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FIGURE 15 Analysis 4: EU-label population (symptomatic and progressive MTC), cabozantinib and vandetanib
assumed equivalent, CEACs (PFS = log-logistic, OS = log-logistic for all options).
TABLE 32 Analysis 4: EU-label population (symptomatic and progressive MTC), cabozantinib and vandetanib
assumed equivalent, central estimates of cost-effectiveness (PFS= log-logistic, OS = log-logistic for all options)
Option
Absolute Incremental
ICER (£)QALYs Costs (£) QALYs Costs (£)
Probabilistic model
Vandetanib 2.28 86,276 0.49 70,482 144,841
Cabozantinib 2.28 88,527 – – Dominated
BSC 1.79 15,793 – – –
Deterministic model
Vandetanib 2.28 85,736 0.49 70,063 142,279
Cabozantinib 2.27 87,960 – – Dominated
BSC 1.79 15,672 – – –
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Table 33 presents the results of the DSAs for the fully incremental analysis of all options based on the
assumption of equivalent PFS and OS outcomes for cabozantinib and vandetanib, using time-to-event
outcome data from the EXAM trial. Cabozantinib remains dominated across all scenarios, except for the
scenario in which the vandetanib discontinuation parameter is set equal to zero. In this scenario, the
ICER for cabozantinib versus BSC is estimated to be £148,169 per QALY gained, whilst the ICER for
vandetanib versus cabozantinib is estimated to be in excess of £1.35M per QALY gained. Across the
remaining scenarios, the ICER for vandetanib versus BSC remains > £130,000 per QALY gained. The DSAs
indicate that the choice of utility values and assumptions regarding AE impacts and health state resource
use do not have a marked impact on the conclusions of the analysis. The choice of survival curves
produces ICERs for vandetanib versus BSC in the range of £132,998 to £227,918 per QALY gained; the
parametric survivor functions selected for use in the AG’s base case are close to the most favourable
scenario for vandetanib.
TABLE 33 Analysis 4: EU-label population (symptomatic and progressive MTC), cabozantinib and vandetanib
assumed equivalent, DSA results
Scenario
ICER (£) (vs. next-best comparator)
Cabozantinib Vandetanib
Base case Dominated 142,279 (vs. BSC)
Undiscounted health outcomes and costs Dominated 130,280 (vs. BSC)
Sanofi CS utilities Dominated 148,377 (vs. BSC)
DECISION study utilities Dominated 160,069 (vs. BSC)
Cabozantinib SMC utilities Dominated 159,049 (vs. BSC)
AE disutility doubled Dominated 142,831 (vs. BSC)
AE disutility halved Dominated 142,005 (vs. BSC)
AE management costs doubled Dominated 142,405 (vs. BSC)
AE management costs halved Dominated 142,217 (vs. BSC)
Vandetanib discontinuation parameter equal to zero 148,169 (vs. BSC) 1,354,088 (vs. cabozantinib)
Health state resource use doubled Extended dominance 148,745 (vs. BSC)
Health state resource use halved Dominated 139,047 (vs. BSC)
No vandetanib or cabozantinib dose reductions Dominated 154,164 (vs. BSC)
Curve choice
PFS – exponential; OS – exponential Dominated 151,561 (vs. BSC)
PFS – exponential; OS – Weibull Dominated 163,420 (vs. BSC)
PFS – exponential; OS – Gompertz Dominated 216,938 (vs. BSC)
PFS – exponential; OS – log-normal Dominated 144,080 (vs. BSC)
PFS – exponential; OS – log-logistic Dominated 147,058 (vs. BSC)
PFS – exponential; OS – gamma Dominated 160,026 (vs. BSC)
PFS – Weibull; OS – exponential Dominated 141,362 (vs. BSC)
PFS – Weibull; OS – Weibull Dominated 154,796 (vs. BSC)
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TABLE 33 Analysis 4: EU-label population (symptomatic and progressive MTC), cabozantinib and vandetanib
assumed equivalent, DSA results (continued )
Scenario
ICER (£) (vs. next-best comparator)
Cabozantinib Vandetanib
PFS – Weibull; OS – Gompertz Dominated 221,301 (vs. BSC)
PFS – Weibull; OS – log-normal Dominated 133,120 (vs. BSC)
PFS – Weibull; OS – log-logistic Dominated 136,386 (vs. BSC)
PFS – Weibull; OS – gamma Dominated 150,910 (vs. BSC)
PFS – Gompertz; OS – exponential Dominated 141,640 (vs. BSC)
PFS – Gompertz; OS – Weibull Dominated 155,804 (vs. BSC)
PFS – Gompertz; OS – Gompertz Dominated 227,918 (vs. BSC)
PFS – Gompertz; OS – log-normal Dominated 132,998 (vs. BSC)
PFS – Gompertz; OS – log-logistic Dominated 136,411 (vs. BSC)
PFS – Gompertz; OS – gamma Dominated 151,689 (vs. BSC)
PFS – log-normal; OS – exponential Dominated 146,684 (vs. BSC)
PFS – log-normal; OS – Weibull Dominated 157,787 (vs. BSC)
PFS – log-normal; OS – Gompertz Dominated 207,458 (vs. BSC)
PFS – log-normal; OS – log-normal Dominated 139,734 (vs. BSC)
PFS – log-normal; OS – log-logistic Dominated 142,517 (vs. BSC)
PFS – log-normal; OS – gamma Dominated 154,630 (vs. BSC)
PFS – log-logistic; OS – exponential Dominated 146,363 (vs. BSC)
PFS – log-logistic; OS – Weibull Dominated 157,175 (vs. BSC)
PFS – log-logistic; OS – Gompertz Dominated 205,085 (vs. BSC)
PFS – log-logistic; OS – log-normal Dominated 139,536 (vs. BSC)
PFS – log-logistic; OS – log-logistica Dominated 142,279 (vs. BSC)
PFS – log-logistic; OS – gamma Dominated 154,103 (vs. BSC)
PFS – gamma; OS – exponential Dominated 141,316 (vs. BSC)
PFS – gamma; OS – Weibull Dominated 154,181 (vs. BSC)
PFS – gamma; OS – Gompertz Dominated 216,482 (vs. BSC)
PFS – gamma; OS – log-normal Dominated 133,382 (vs. BSC)
PFS – gamma; OS – log-logistic Dominated 136,532 (vs. BSC)
PFS – gamma; OS – gamma Dominated 150,469 (vs. BSC)
a The AG’s base-case curve choice.
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Analysis 5: restricted EU-label population (symptomatic and progressive medullary
thyroid cancer with carcinoembryonic antigen/calcitonin doubling times of ≤ 24 months),
vandetanib versus best supportive care (pairwise)
Table 34 presents the results of the pairwise comparison of vandetanib versus BSC for the restricted
EU-label population (symptomatic and progressive MTC plus CEA/CTN doubling times of ≤ 24 months).
Disaggregated LYGs, QALYs and costs are presented in Table 67 in Appendix 5. This analysis closely
reflects the economic analysis presented within the Sanofi CS,66 but includes survival models fitted directly
to the observed data for the ZETA trial restricted EU-label subgroup, alternative assumptions regarding the
vandetanib discontinuation parameter, different health state costs and different utility values. It should
also be noted that this analysis is subject to potential confounding as a result of the open-label use of
vandetanib; hence, post-progression vandetanib costs are included in both treatment groups. Based on
the probabilistic version of the AG model (assuming the log-normal function for PFS and the Gompertz
function for OS), vandetanib is expected to generate 1.61 additional QALYs at an additional cost of
£107,780 compared with BSC; the ICER for vandetanib versus BSC is expected to be £66,779 per QALY
gained. The deterministic version of the model yields a slightly lower ICER of £65,184 per QALY gained.
The disaggregated results indicate that the majority of the incremental OS gain for vandetanib is accrued in
the progression-free state. It is also noteworthy that, based on the selected Gompertz OS function, ≈12%
of the vandetanib cohort are still alive at 20 years (indicated by the tail of the modelled curve). Additional
analyses undertaken by the AG indicate that the ICER for vandetanib versus BSC is similar over longer time
horizons (the ICER using a 30-year time horizon, excluding any general population mortality constraints,
is £63,357 per QALY gained). However, the AG considers that the level of survival at 20 years may be
an overestimate, and that the true ICER for vandetanib may therefore be > £67,000 per QALY gained.
The impact of assuming alternative OS functions is explored within the sensitivity analyses (see Table 35).
Figure 16 presents CEACs for the pairwise comparison of vandetanib versus BSC within the restricted
EU-label MTC population. Assuming a WTP threshold (λ) of £30,000 per QALY gained, the probability
that vandetanib produces more net benefit than BSC is approximately 0.02.
Table 35 presents the results of the DSAs for the pairwise comparison of vandetanib versus BSC within the
restricted EU-label population. As shown in the table, the ICER remains > £51,000 per QALY gained across
all scenarios. The DSAs indicate that the choice of utility values used in the base-case analysis produces a
slightly less favourable ICER for vandetanib versus BSC within this population compared with the alternative
sources identified. The alternative assumptions regarding health state resource use and AEs do not have a
marked impact on the cost-effectiveness of vandetanib. In this population, excluding the post-progression
vandetanib costs increases the ICER to £84,438 per QALY gained. Setting the vandetanib discontinuation
parameter equal to zero increases the ICER to £76,352 per QALY gained. The choice of survival curves
produces ICERs for vandetanib versus BSC in the range of £51,194 to £71,128 per QALY gained; the curves
used in the AG’s base-case analysis (PFS = log-normal, OS =Gompertz) represent neither the most
favourable nor the least favourable scenario for vandetanib within the restricted EU-label population.
TABLE 34 Analysis 5: restricted EU-label population (symptomatic and progressive MTC with CEA/CTN doubling
times of ≤ 24 months), vandetanib vs. BSC (pairwise), central estimates of cost-effectiveness (PFS = log-normal,
OS =Gompertz for both options)
Option
Absolute Incremental
ICER (£)QALYs Costs (£) QALYs Costs (£)
Probabilistic model
Vandetanib 3.45 204,539 1.61 107,780 66,779
BSC 1.83 96,759 – – –
Deterministic model
Vandetanib 3.46 205,457 1.64 106,762 65,184
BSC 1.82 98,695 – – –
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FIGURE 16 Analysis 5: restricted EU-label population (symptomatic and progressive MTC with CEA/CTN doubling
times of ≤ 24 months), vandetanib vs. BSC (pairwise), CEACs (PFS = log-normal, OS =Gompertz for both options).
TABLE 35 Analysis 5: restricted EU-label population (symptomatic and progressive MTC with CEA/CTN doubling
times of ≤ 24 months), vandetanib vs. BSC (pairwise), DSA results
Scenario
Incremental
ICER (£)QALYs Costs (£)
Base case 1.64 106,762 65,184
Undiscounted health outcomes and costs 2.23 137,406 61,584
Sanofi CS utilities 1.76 106,762 60,576
DECISION study utilities 1.69 106,762 63,186
Cabozantinib SMC utilities 1.68 106,762 63,683
AE disutility doubled 1.64 106,762 65,295
AE disutility halved 1.64 106,762 65,128
AE management costs doubled 1.64 106,853 65,239
AE management costs halved 1.64 106,717 65,156
Post-progression vandetanib costs excluded 1.64 138,298 84,438
Vandetanib discontinuation parameter equal to zero 1.64 125,054 76,352
Health state resource use doubled 1.64 115,552 70,551
Health state resource use halved 1.64 102,367 62,500
No vandetanib dose reductions 1.64 116,928 71,390
Curve choice
PFS – exponential; OS – exponential 1.30 81,931 63,007
PFS – exponential; OS – Weibull 1.30 82,041 63,165
PFS – exponential; OS – Gompertz 1.50 90,264 60,296
PFS – exponential; OS – log-normal 1.28 73,914 57,821
continued
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TABLE 35 Analysis 5: restricted EU-label population (symptomatic and progressive MTC with CEA/CTN doubling
times of ≤ 24 months), vandetanib vs. BSC (pairwise), DSA results (continued )
Scenario
Incremental
ICER (£)QALYs Costs (£)
PFS – exponential; OS – log-logistic 1.06 56,920 53,857
PFS – exponential; OS – gamma 1.27 80,262 63,172
PFS – Weibull; OS – exponential 1.25 77,205 61,602
PFS – Weibull; OS – Weibull 1.25 77,316 61,765
PFS – Weibull; OS – Gompertz 1.45 85,538 58,993
PFS – Weibull; OS – log-normal 1.23 69,188 56,193
PFS – Weibull; OS – log-logistic 1.01 52,195 51,687
PFS – Weibull; OS – gamma 1.22 75,537 61,739
PFS – Gompertz; OS – exponential 1.40 99,812 71,119
PFS – Gompertz; OS – Weibull 1.41 99,165 70,439
PFS – Gompertz; OS – Gompertz 1.61 106,531 66,060
PFS – Gompertz; OS – log-normal 1.38 91,856 66,516
PFS – Gompertz; OS – log-logistic 1.16 74,863 64,564
PFS – Gompertz; OS – gamma 1.38 97,861 71,128
PFS – log-normal; OS – exponential 1.44 98,830 68,718
PFS – log-normal; OS – Weibull 1.44 98,899 68,821
PFS – log-normal; OS – Gompertza 1.64 106,762 65,184
PFS – log-normal; OS – log-normal 1.42 90,824 64,128
PFS – log-normal; OS – log-logistic 1.19 73,831 61,791
PFS – log-normal; OS – gamma 1.41 97,169 68,989
PFS – log-logistic; OS – exponential 1.44 100,247 69,779
PFS – log-logistic; OS – Weibull 1.44 99,816 69,348
PFS – log-logistic; OS – Gompertz 1.64 107,120 65,132
PFS – log-logistic; OS – log-normal 1.41 92,230 65,198
PFS – log-logistic; OS – log-logistic 1.19 75,237 63,056
PFS – log-logistic; OS – gamma 1.41 98,433 69,923
PFS – gamma; OS – exponential 1.25 76,695 61,206
PFS – gamma; OS – Weibull 1.25 76,806 61,368
PFS – gamma; OS – Gompertz 1.45 85,028 58,651
PFS – gamma; OS – log-normal 1.23 68,678 55,789
PFS – gamma; OS – log-logistic 1.01 51,685 51,194
PFS – gamma; OS – gamma 1.22 75,027 61,334
a The AG’s base-case curve choice.
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Budget impact analysis
Table 36 presents a budget impact analysis for cabozantinib and vandetanib based on year-on-year drug
acquisition costs predicted using the AG model. The budget impact analysis makes the following assumptions:
l The analysis considers only the acquisition costs of the drugs; other resource use components are excluded.
l The analysis includes prevalent (surviving) and incident (new) patients.
l Cumulative costs for surviving patients remaining progression free and on treatment (based on the
log-logistic PFS models) are considered over a period of 10 years. The costs of post-progression
vandetanib use are excluded from the analysis.
l The analysis assumes a constant eligible incident population of (confidential information has been
removed) MTC patients per year, based on the current use of the drugs on the CDF.
l The maximum annual budget impact is calculated using the total incident and prevalent cohort at 10 years.
The maximum annual budget impact for cabozantinib within the symptomatic and progressive population
is expected to be ≈£2.35M. The maximum budget impact for vandetanib within the symptomatic and
progressive population is expected to be ≈£5.53M; the costs of vandetanib in the restricted EU-label
population are expected to be lower.
Discussion
The AG’s systematic review of existing economic evaluations did not identify any relevant published studies.
The manufacturer of cabozantinib did not submit any economic evidence relating to this product.
The manufacturer of vandetanib submitted a de novo model-based health economic evaluation of vandetanib
versus BSC in the restricted EU-label population (symptomatic and progressive MTC plus CTN/CEA doubling
times of ≤ 24 months). An economic analysis for the broader licensed population was not presented. The
corrected version of Sanofi’s partitioned survival model suggests that the probabilistic ICER for vandetanib
versus BSC is approximately £31,546 per QALY gained. The AG notes several concerns relating to the
company’s submitted model, in particular (1) the questionable relevance of the restricted EU-label population
to current clinical practice, (2) the failure to adjust for open-label vandetanib use in both treatment groups,
(3) the likely overestimation of the costs of vandetanib use in the post-progression state, (4) questionable
assumptions regarding the amount of vandetanib received and (5) concerns regarding the robustness of
the company’s covariate-adjusted survival modelling to reflect the restricted EU-label population. The AG
considers that the ICER for vandetanib is likely to be considerably higher than the estimates presented within
the Sanofi CS.66
In the light of concerns regarding the economic analysis submitted by Sanofi and the absence of any
economic evidence for cabozantinib, the AG developed a de novo health economic model. The AG model
was evaluated across five sets of analyses from the perspective of the NHS and PSS over a lifetime horizon.
Four sets of analyses of cabozantinib and/or vandetanib versus BSC were undertaken in the EU-label
(symptomatic and progressive) MTC population and one set of analyses of vandetanib versus BSC was
undertaken in the restricted EU-label population (symptomatic and progressive MTC with CTN/CEA
doubling times of ≤ 24 months). Costs and health outcomes were discounted at a rate of 3.5% per
annum. Costs were valued at 2016/17 prices. The AG model used a partitioned survival approach based
on three health states: (1) progression free, (2) post progression and (3) dead. Costs and health utilities
were assumed to differ according to the presence/absence of disease progression. The model parameters
were informed by analyses of IPD from the EXAM trial, replicated IPD from the ZETA trial, the submissions
from Sanofi and Ipsen and data contained within subsequent clarification responses, as well as published
literature, standard reference cost sources and expert judgement. The results of the AG’s economic
analysis are summarised in Table 37.
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TABLE 36 Budget impact analysis (£): cabozantinib and vandetanib, EU-label (symptomatic and progressive) MTC population
Cohort year
Cohort year
1 2 3 4 5 6 7 8 9 10
Budget impact – cabozantinib, symptomatic and progressive MTC population (based on EXAM trial ITT PFS population, log-logistic model)
Entry year 1 1,293,225 488,370 214,984 118,396 74,784 51,564 37,756 28,878 22,828 18,518
2 – 1,293,225 488,370 214,984 118,396 74,784 51,564 37,756 28,878 22,828
3 – – 1,293,225 488,370 214,984 118,396 74,784 51,564 37,756 28,878
4 – – – 1,293,225 488,370 214,984 118,396 74,784 51,564 37,756
5 – – – – 1,293,225 488,370 214,984 118,396 74,784 51,564
6 – – – – – 1,293,225 488,370 214,984 118,396 74,784
7 – – – – – – 1,293,225 488,370 214,984 118,396
8 – – – – – – – 1,293,225 488,370 214,984
9 – – – – – – – – 1,293,225 488,370
10 – – – – – – – – – 1,293,225
Total annual cost 1,293,225 1,781,595 1,996,579 2,114,975 2,189,759 2,241,323 2,279,080 2,307,958 2,330,786 2,349,304
Budget impact: vandetanib, symptomatic and progressive MTC population (based on ZETA trial EU-label subgroup PFS, log-logistic model)
Entry year 1 1,465,575 1,087,458 775,968 568,666 432,204 339,574 274,328 226,761 191,027 163,483
2 – 1,465,575 1,087,458 775,968 568,666 432,204 339,574 274,328 226,761 191,027
3 – – 1,465,575 1,087,458 775,968 568,666 432,204 339,574 274,328 226,761
4 – – – 1,465,575 1,087,458 775,968 568,666 432,204 339,574 274,328
5 – – – – 1,465,575 1,087,458 775,968 568,666 432,204 339,574
6 – – – – – 1,465,575 1,087,458 775,968 568,666 432,204
7 – – – – – – 1,465,575 1,087,458 775,968 568,666
8 – – – – – – – 1,465,575 1,087,458 775,968
9 – – – – – – – – 1,465,575 1,087,458
10 – – – – – – – – – 1,465,575
Total annual cost 1,465,575 2,553,033 3,329,001 3,897,667 4,329,872 4,669,446 4,943,774 5,170,534 5,361,561 5,525,045
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Assessment group analysis 1: EU-label population (symptomatic and progressive medullary
thyroid cancer), pairwise economic evaluation of cabozantinib versus best supportive care
Based on the AG’s probabilistic model (assuming the log-logistic function for both PFS and OS), the ICER
for cabozantinib versus BSC is expected to be £150,874 per QALY gained. The DSAs indicate that the AG’s
base case is close to the most favourable scenario.
Assessment group analysis 2: EU-label population (symptomatic and progressive medullary
thyroid cancer), pairwise economic evaluation of vandetanib versus best supportive care
Based on the probabilistic version of the AG model (assuming the log-logistic function for both PFS and
OS), the ICER for vandetanib versus BSC is expected to be £352,508 per QALY gained. The DSAs indicate
that the AG’s base case does not represent the most optimistic case for vandetanib, nor does it reflect the
most pessimistic scenario.
Assessment group analysis 3: EU-label population (symptomatic and progressive
medullary thyroid cancer), fully incremental analysis, vandetanib progression-free
survival treatment effect applied to EXAM trial placebo baseline, vandetanib overall
survival assumed equivalent to cabozantinib overall survival
Within this analysis, the ICER for vandetanib versus BSC is expected to be £138,405 per QALY gained,
whilst the ICER for cabozantinib versus vandetanib is expected to £195,593 per QALY gained. The DSAs
indicate that the AG’s base case represents neither the most favourable nor the least favourable scenario
for either drug.
TABLE 37 Summary of the AG’s cost-effectiveness results
Analysis
number Description
Probabilistic ICER
(£ per QALY gained)
Probability of
being cost-
effective at
λ= £30,000 per
QALY gained
ICER range (£ per
QALY gained) from
alternative parametric
survivor functions
1 Pairwise economic evaluation
of cabozantinib vs. BSC in
the EXAM trial ITT
population
150,874 Cabozantinib: 0.00 138,259–239,141
2 Pairwise economic evaluation
of vandetanib vs. BSC in the
ZETA trial EU-label
population
352,508 Vandetanib: 0.01 123,723 to dominated
3 Fully incremental analysis
based on EXAM trial ITT
population with vandetanib
PFS treatment effect applied
to EXAM trial placebo
baseline; vandetanib OS
assumed to be equivalent to
cabozantinib OS
Vandetanib vs. BSC:
138,405
Vandetanib: 0.00 Vandetanib vs.
next-best comparator:
85,217 to extendedly
dominated
Cabozantinib vs.
vandetanib: 195,593
Cabozantinib: 0.00 Cabozantinib vs.
next-best comparator:
180,985–239,141
4 Fully incremental analysis
based on EXAM trial ITT
population assuming PFS
and OS are equivalent
for vandetanib and
cabozantinib
Cabozantinib = dominated Cabozantinib: 0.00 Cabozantinib:
dominated to
dominated
Vandetanib vs. BSC:
144,841
Vandetanib: 0.00 Vandetanib:
132,998–227,918
5 Pairwise economic evaluation
of vandetanib vs. BSC using
ZETA trial restricted EU-label
population
66,779 Vandetanib: 0.02 51,194–71,128
λ, WTP threshold.
AG analysis 1: EU-label population (symptomatic and progressive MTC), pairwise economic evaluation of cabozantinib vs. BSC.
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Assessment group analysis 4: EU-label population (symptomatic and progressive
medullary thyroid cancer), fully incremental analysis, progression-free and overall
survival outcomes assumed equivalent for vandetanib and cabozantinib
Based on the probabilistic version of the model (assuming the log-logistic function for both PFS and OS),
cabozantinib is expected to be dominated; this is a consequence of the more favourable grade 3 or higher
AE profile and the slightly lower total relative dose intensity-adjusted drug costs for vandetanib. The
probabilistic ICER for vandetanib versus BSC is expected to be £144,841 per QALY gained. The DSAs
indicate that the AG’s base case represents one of the more favourable scenarios for vandetanib.
Assessment group analysis 5: restricted EU-label population (symptomatic and
progressive medullary thyroid cancer plus carcinoembryonic antigen/calcitonin doubling
times of ≤ 24 months), pairwise economic evaluation of vandetanib versus best
supportive care
Based on the probabilistic version of the AG model (assuming the log-normal function for PFS and the
Gompertz function for OS), the ICER for vandetanib versus BSC is expected to be £66,779 per QALY
gained. The DSAs indicate that the AG’s base case represents neither a highly favourable nor a highly
unfavourable scenario for vandetanib.
Table 38 highlights the key differences between the AG model and the Sanofi model. Although the
two models are very similar in terms of their structure and definition of parameters, the key differences
between the analyses relate to (1) the scope of the economic comparisons, (2) the time-to-event data
used to inform the analyses (covariate-adjusted ITT/safety data set vs. actual subgroup data), (3) the source
of health utility values, (4) assumptions regarding the costs associated with BSC and (5) assumptions
regarding the costs of vandetanib in patients who discontinue therapy prior to disease progression.
TABLE 38 Key differences between the Sanofi model and the AG model
Element of
economic analysis
Model
Sanofi AG
Comparisons Vandetanib vs. BSC Cabozantinib vs. BSC
Vandetanib vs. BSC
Full incremental analysis of all options
Trial evidence used to
inform time-to-event
outcomes
ZETA trial ITT/safety population EXAM trial ITT, ZETA trial EU label, ZETA trial
restricted EU label
Structure Partitioned survival model. No adjustment
for logical inconsistency
Partitioned survival model. Includes adjustment for
logical inconsistency
Survival modelling
approach
Covariate-adjusted survivor functions fitted
to ITT/safety data set
Survivor functions fitted directly to data for
relevant populations
Health state utilities Mapped utilities for progression-free state,
decrement for post progression based on
Beusterien et al.105
Health state utilities derived from Fordham et al.102
Costing approach Different costs for BSC in progression-free
and post-progression states
Same costs for BSC in progression-free and
post-progression states. Additional resource use
components included for patients receiving TKIs
and for those receiving BSC
Vandetanib
discontinuation
parameter
Applied in full only to the
pre-progression vandetanib group
Half of total value applied to all patients
receiving vandetanib in progression-free and
post-progression states (when applicable)
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Chapter 5 Assessment of factors relevant to the
NHS and other parties
Additional monitoring requirements
Vandetanib and cabozantinib are associated with additional monitoring requirements, particularly during
the first 3 months after initiating treatment (see Chapter 1, Significance for the NHS) These additional
monitoring requirements impose additional costs on the NHS over and above the costs of drug acquisition.
However, given the small population of MTC patients eligible to receive vandetanib and cabozantinib,
these additional resource requirements are expected to be negligible.
Current availability of cabozantinib and vandetanib for medullary
thyroid cancer
Both vandetanib and cabozantinib are currently available for the treatment of symptomatic and progressive
MTC through the CDF. The current CDF recommendations for each TKI allow for the use of the other TKIs
for patients in whom toxicity occurs, provided that (1) switching to the other TKI takes place within 3 months
of starting the initial TKI, (2) the toxicity cannot be managed by dose delay or dose modification and (3) the
patient has not experienced disease progression on the initial TKI. In addition, given the different AE profiles
of cabozantinib and vandetanib and special warnings listed within their SmPCs,22,23 some patients will not be
able to receive both therapies. The clinical advisors to the AG consider that there is value in having access to
both TKIs for this reason.
End-of-life considerations
The end-of-life supplementary advice from NICE109 should be applied in the following circumstances and
when the criteria referred to below are satisfied:
l the treatment is indicated for patients with a short life expectancy, usually < 24 months and
l there is sufficient evidence to indicate that the treatment offers an extension to life at least 3 additional
months, compared with current NHS treatments.
Table 39 presents the undiscounted LYGs predicted by the AG’s base-case model (see Chapter 4, Time to
event analysis using individual patient data). As shown in the table, the expected mean survival in the
placebo group of the EXAM trial and the subgroups of the ZETA trial is > 24 months. This conclusion
remains consistent irrespective of the choice of parametric model used to represent OS. However, it should
be noted that the analyses of the OS data for the ZETA trial subgroups remain confounded by open-label
vandetanib use; hence, the true survival duration in this population is unknown. The analyses suggest
that the criterion relating to > 3 months life extension is likely to be met for cabozantinib in the EU-label
(symptomatic and progressive) MTC population and for vandetanib within the restricted EU-label
population (symptomatic and progressive MTC with CEA/CTN doubling times of ≤ 24 months).
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TABLE 39 Undiscounted survival estimates used in the AG model
Outcome
Trial population/subgroup
EXAM safety
population
ZETA symptomatic
and progressive
ZETA symptomatic
and progressive with
CEA/CTN biomarker
Cabozantinib BSC Vandetanib BSC Vandetanib BSC
AG base-case OS (undiscounted LYGs) 4.49 3.91 7.32 7.58 6.50 3.34
Incremental OS gain (undiscounted LYGs) 0.59 –0.27 3.16
ASSESSMENT OF FACTORS RELEVANT TO THE NHS AND OTHER PARTIES
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Chapter 6 Discussion
Statement of principal findings
The systematic review of the clinical effectiveness evidence identified two relevant placebo-controlled
RCTs: (1) the EXAM trial, which evaluated cabozantinib (n = 330), and (2) the ZETA trial, which evaluated
vandetanib. The EXAM trial was deemed to be at low risk of bias across most domains, whereas the
ZETA trial was deemed to be at moderate to high risk of bias across a number of domains. The two trials
assessed different populations (the ZETA trial inclusion criteria did not specify ‘progressive’ disease), but the
ZETA trial did include a subgroup with ‘progressive and symptomatic disease’ (n = 186), which formed the
‘EU-label’ population. This group was considered to be comparable to the EXAM ITT population. In terms
of efficacy, both cabozantinib and vandetanib significantly improved PFS compared with placebo. In the
absence of direct evidence comparing the two interventions, a NMA was performed, which suggested that
the results of the two treatments were broadly similar in terms of PFS, although these findings must be
treated with caution because of the sparsity of the network.
Both cabozantinib and vandetanib also demonstrated significant benefits compared with placebo in terms of
ORR, as determined by RECIST criteria. However, there was no significant OS benefit for either cabozantinib
or vandetanib compared with placebo, although the data from the vandetanib trial were subject to potential
confounding due to open-label vandetanib use in both groups. The two trials also conducted exploratory
assessments of patients’ quality of life using instruments that evaluated various criteria, but no difference
was found between the treatment or placebo arms at follow-up in either trial. Clinical advice received by the
AG suggested that these tools did not necessarily capture symptomatic benefits produced by improved PFS
or response to treatment. Both cabozantinib and vandetanib produced frequent AEs, with similar types and
rates of grade 3 or higher AEs, except for higher rates of HFS (13%) for cabozantinib, and prolonged ECG
QT (8%) for vandetanib. Similar proportions of patients across the two trials discontinued treatment because
of AEs, but a higher percentage of patients experienced AEs leading to dose interruption or reduction on
cabozantinib than on vandetanib.
Based on the AG’s probabilistic analysis of cabozantinib versus placebo in the EU-label (symptomatic and
progressive) MTC population, the ICER for cabozantinib versus BSC is expected to be £150,874 per QALY
gained. Within the EU-label (symptomatic and progressive) MTC population of the ZETA trial, the AG’s
probabilistic analysis suggests that the ICER for vandetanib versus BSC is expected to be £352,508 per
QALY gained. The fully incremental analysis of cabozantinib, vandetanib and BSC based on the EXAM
ITT population and the vandetanib PFS treatment effect from the ZETA trial suggests that the ICER for
vandetanib versus BSC is expected to be £138,405 per QALY gained, whilst the ICER for cabozantinib
versus vandetanib is expected to be £195,593 per QALY gained. Within the fully incremental analysis in
which the PFS and OS outcomes for vandetanib were assumed to be equivalent to the cabozantinib group
outcomes in the EXAM trial, cabozantinib is expected to be dominated, whilst the ICER for vandetanib
versus BSC is expected to be £144,841 per QALY gained. Within the restricted EU-label population
(symptomatic and progressive MTC plus CEA/CTN doubling times of ≤ 24 months), the ICER for
vandetanib versus BSC is expected to be £66,779 per QALY gained.
The AG’s economic analysis suggests that NICE’s criteria109 for life-extending therapies given at the end of
life are not met for cabozantinib in the EU-label population (symptomatic and progressive MTC) or for
vandetanib in either the EU-label population or the restricted EU-label population (symptomatic and
progressive MTC with CEA/CTN doubling times of ≤ 24 months).
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Strengths and limitations of the assessment
The key strengths of this assessment are as follows:
l The AG’s economic evaluation includes fully incremental analyses of cabozantinib, vandetanib and BSC
within the symptomatic and progressive MTC population.
l The health economic model developed by the AG uses a simple partitioned survival approach that
directly uses the available data on PFS and OS from the EXAM and ZETA trials. This model structure is
very similar to that used within the Sanofi model.
l The AG’s economic analysis includes a thorough assessment of uncertainty surrounding the impact of
using alternative parametric functions for PFS and OS based on models fitted directly to data for the
relevant population/subgroup under consideration. This is particularly important given that the choice
of parametric functions has been informed by only one clinical expert; it is possible that other clinical
experts may have selected different preferred curves.
The main weaknesses of the assessment are largely a consequence of weaknesses and gaps in the clinical
evidence base:
l The AG did not have access to IPD from the ZETA trial; instead, PFS and OS outcomes were replicated
using a published algorithm. Although the accuracy of this replication is likely to be good, this process
may have introduced a small loss of accuracy relative to using the IPD directly.
l The ITT populations for the EXAM and ZETA trials are notably different. The analyses of the ZETA trial
subgroups have been defined post hoc and may be subject to confounding because of differences in
baseline characteristics.
l The OS data for the ZETA trial are subject to potential confounding due to open-label vandetanib use.
Sanofi’s attempts to adjust OS estimates using the RPSFT approach were reported to be unsuccessful.
As a consequence, the pairwise economic comparisons of vandetanib versus BSC (presented by both
Sanofi and the AG) may be of limited relevance for decision-making. Conversely, the AG’s incremental
analyses make potentially strong assumptions concerning transferable/equivalent treatment effects
between vandetanib and cabozantinib.
l The systematic review of HRQoL evidence did not identify any relevant published health valuation
studies relating specifically to the MTC population.
Uncertainties
The key uncertainties associated with this evaluation are as follows:
l Quality-of-life gains as a result of PFS and related symptom management. These have not been
adequately explored in the literature.
l The comparative clinical effectiveness and cost-effectiveness of cabozantinib and vandetanib compared
with each other and compared with BSC.
l The incremental OS benefits associated with vandetanib in patients with symptomatic and progressive
MTC and in patients with the additional CEA/CTN biomarker. Other outcomes, for example safety,
are also subject to potential confounding.
l Treatment duration in patients who discontinue TKI therapy prior to disease progression.
l The impact of locally advanced or metastatic MTC on HRQoL, as measured using a preference-based
utility instrument.
l The relative AE profiles of vandetanib and cabozantinib within the symptomatic and progressive
MTC population.
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Other relevant factors
The number of patients who would be eligible for these treatments is very small. In 2016, (confidential
information has been removed) patients initiated treatment using cabozantinib [n = (confidential
information has been removed)] or vandetanib [n = (confidential information has been removed)].
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Chapter 7 Conclusions
The systematic review of the clinical effectiveness evidence identified two relevant placebo-controlledRCTs: (1) the EXAM trial, which evaluated cabozantinib (n = 330); and (2) the ZETA trial, which
evaluated vandetanib (n = 331). The two trials assessed different MTC populations (the ZETA trial inclusion
criteria did not specify ‘progressive’ disease), but the ZETA trial did include a subgroup with ‘progressive
and symptomatic disease’ (n = 186), which formed the ‘EU-label’ population. This group was considered to
be comparable to the EXAM ITT population. Both cabozantinib and vandetanib demonstrated significant
benefits compared with placebo in terms of PFS and appear to be broadly similar in terms of efficacy,
although neither drug has demonstrated significant OS benefit compared with placebo. Both cabozantinib
and vandetanib produced frequent AEs, with substantial proportions of patients experiencing AEs that led
to dose interruption or reduction.
Based on the AG’s probabilistic analysis of cabozantinib versus placebo in the EU-label (symptomatic and
progressive) MTC population, the ICER for cabozantinib versus BSC is expected to be £150,874 per QALY
gained. Within the EU-label (symptomatic and progressive) MTC population of the ZETA trial, the AG’s
probabilistic analysis suggests that the ICER for vandetanib versus BSC is expected to be £352,508 per
QALY gained. The fully incremental analysis of cabozantinib, vandetanib and BSC based on the EXAM
ITT population and the vandetanib PFS treatment effect from the ZETA trial suggests that the ICER for
vandetanib versus BSC is expected to be £138,405 per QALY gained, whilst the ICER for cabozantinib
versus vandetanib is expected to be £195,593 per QALY gained. Within the fully incremental analysis in
which the PFS and OS outcomes for vandetanib were assumed to be equivalent to the cabozantinib group
outcomes in the EXAM trial, cabozantinib is expected to be dominated, whilst the ICER for vandetanib
versus BSC is expected to be £144,841 per QALY gained. Within the restricted EU-label population
(symptomatic and progressive MTC plus CEA/CTN doubling times of ≤ 24 months), the ICER for
vandetanib versus BSC is expected to be £66,779 per QALY gained.
The AG’s economic analysis suggests that NICE’s criteria109 for life-extending therapies given at the end
of life are not met for cabozantinib in the EU-label population (symptomatic and progressive MTC) or for
vandetanib in either the EU-label population or the restricted EU-label population (symptomatic and
progressive MTC with CEA/CTN doubling times of ≤ 24 months).
The AG’s economic analysis suggests that the maximum annual budget impact for cabozantinib within the
symptomatic and progressive population is expected to be ≈£2.35M. The maximum budget impact for
vandetanib within the symptomatic and progressive population is expected to be ≈£5.53M; the costs of
vandetanib in the restricted EU-label population are expected to be lower.
Implications for service provision
The implications for service provision are minimal owing to the rarity of the disease and the current
availability of both therapies through the CDF.
Suggested research priorities
l Primary research comparing the long-term clinical benefits of cabozantinib and vandetanib within
relevant subgroups.
l Analyses of existing evidence from the ZETA trial to investigate the impact of adjusting for open-label
vandetanib use using appropriate statistical methods.
l Studies assessing the impact of MTC on HRQoL using a preference-based measure, such as the
EuroQol-5 Dimensions (EQ-5D).
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Literature search strategies
Clinical effectiveness studies
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)
Daily and Ovid MEDLINE(R)
Date range searched: 1946 to present.
Date searched: 2 November 2016.
# Searches
1 exp Thyroid Neoplasms/
2 exp Goiter, Nodular/
3 (thyr?oid* adj5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or adenocarcinoma*)).mp.
4 Thyroid Gland/
5 exp Neoplasms/
6 4 and 5
7 or/1-3,6
8 exp Carcinoma, medullary/
9 (medullary or MTC).mp.
10 8 or 9
11 7 and 10
12 Randomized controlled trials as Topic/
13 Randomized controlled trial/
14 Random allocation/
15 randomized controlled trial.pt.
16 Double blind method/
17 Single blind method/
18 Clinical trial/
19 exp Clinical Trials as Topic/
20 controlled clinical trial.pt.
21 clinical trial$.pt.
22 multicenter study.pt.
23 or/12-22
24 (clinic$ adj25 trial$).ti,ab.
25 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$ or mask$)).tw.
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# Searches
26 Placebos/
27 Placebo$.tw.
28 (allocated adj2 random).tw.
29 or/24-28
30 23 or 29
31 Case report.tw.
32 Letter/
33 Historical article/
34 31 or 32 or 33
35 exp Animals/
36 Humans/
37 35 not (35 and 36)
38 34 or 37
39 30 not 38
40 meta-analysis/
41 meta-analysis as topic/
42 (meta analy* or metanaly* or metaanaly*).ti,ab.
43 ((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
44 (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
45 (search strategy or search criteria or systematic search or study selection or data extraction).ab.
46 (search* adj4 literature).ab.
47 (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or scie nce citation
index or bids or cancerlit).ab.
48 cochrane.jw.
49 ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
50 or/40-49
51 39 or 50
52 11 and 51
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Cost-effectiveness studies
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)
Daily and Ovid MEDLINE(R)
Date range searched: 1946 to present.
Date searched: 3 November 2016.
# Searches
1 exp Thyroid Neoplasms/
2 exp Goiter, Nodular/
3 (thyr?oid* adj5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or adenocarcinoma*)).mp.
4 Thyroid Gland/
5 exp Neoplasms/
6 4 and 5
7 or/1-3,6
8 exp “Costs and Cost Analysis”/
9 Economics/
10 exp Economics, Hospital/
11 exp Economics, Medical/
12 Economics, Nursing/
13 exp models, economic/
14 Economics, Pharmaceutical/
15 exp “Fees and Charges"/
16 exp Budgets/
17 budget$.tw.
18 ec.fs.
19 cost$.ti.
20 (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab.
21 (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti.
22 (price$ or pricing$).tw.
23 (financial or finance or finances or financed).tw.
24 (fee or fees).tw.
25 (value adj2 (money or monetary)).tw.
26 quality-adjusted life years/
27 (qaly or qalys).af.
28 (quality adjusted life year or quality adjusted life years).af.
29 or/8-28
30 7 and 29
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EMBASE
Date range searched: 1974 to 1 November 2016.
Date searched: 3 November 2016.
# Searches
1 exp thyroid tumor/
2 exp nodular goiter/
3 (thyr?oid* adj5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or adenocarcinoma*)).mp.
4 thyroid gland/
5 exp neoplasm/
6 4 and 5
7 or/1-3,6
8 Socioeconomics/
9 Cost benefit analysis/
10 Cost effectiveness analysis/
11 Cost of illness/
12 Cost control/
13 Economic aspect/
14 Financial management/
15 Health care cost/
16 Health care financing/
17 Health economics/
18 Hospital cost/
19 (fiscal or financial or finance or funding).tw.
20 Cost minimization analysis/
21 (cost adj estimate$).mp.
22 (cost adj variable$).mp.
23 (unit adj cost$).mp.
24 or/8-23
25 7 and 24
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
Web of Science Core Collection
Science Citation Index Expanded (1900–).
Conference Proceedings Citation Index – Science (1990–).
Date searched: 3 November 2016.
# Searches
#1 TOPIC: ((thyr*oid* NEAR/5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or
adenocarcinoma*)))
#2 TS=(cost* and (effective* or utilit* or benefit* or minimi*)) OR TS=(cost*) OR TI=(economic* or
pharmacoeconomic* or pharmaco-economic*) OR TS=(price* or pricing*) OR TS=(financial or finance or finances or
financed) OR TS=(fee or fees) OR TS=(value and (money or monetary)) OR TS=(economic*) OR TS=(economic* and
(hospital or medical or nursing or pharmaceutical)) OR TS=(“quality adjusted life year” or “quality adjusted life
years”) OR TS=(qaly or qalys) OR TS=(budget*)
#3 #2 AND #1
Cochrane Database of Systematic Reviews: Wiley Online Library
Health Technology Assessment database: Wiley Online Library.
NHS Economic Evaluation Database: Wiley Online Library.
Date range searched: 1995–2015.
Date searched: 3 November 2016.
# Searches
#1 MeSH descriptor: [Thyroid Neoplasms] explode all trees
#2 MeSH descriptor: [Goiter, Nodular] explode all trees
#3 (thyr*oid* near/5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or adenocarcinoma*)):ti,
ab,kw
#4 MeSH descriptor: [Thyroid Gland] this term only
#5 MeSH descriptor: [Neoplasms] explode all trees
#6 #4 and #5
#7 30-#3,#6
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Cumulative Index to Nursing and Allied Health Literature
Date range searched: 1982 to present.
Date searched: 3 November 2016.
# Searches
S1 (MH “Thyroid Neoplasms+”)
S2 (thyr?oid* N5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or adenocarcinoma*))
S3 (MH “Thyroid Gland”)
S4 (MH “Neoplasms+”)
S5 S3 AND S4
S6 S1 OR S2 OR S5
S7 (MH “Costs and Cost Analysis+”)
S8 (MH “Economics”)
S9 (MH “Economics, Pharmaceutical”)
S10 (MH “Fees and Charges+”)
S11 (MH “Budgets”)
S12 budget*
S13 cost*
S14 AB cost* and (effective* or utilit* or benefit* or minimi*)
S15 TI economic* or pharmacoeconomic* or pharmaco-economic*
S16 price* or pricing*
S17 financial or finance or finances or financed
S18 fee or fees
S19 value and (money or monetary)
S20 qaly or qalys
S21 quality adjusted life year or quality adjusted life years
S22 S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21
S23 S6 AND S22
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Quality-of-life studies
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)
Daily and Ovid MEDLINE(R)
Date range searched: 1946 to present.
Date searched: 3 November 2016.
# Searches
1 exp Thyroid Neoplasms/
2 exp Goiter, Nodular/
3 (thyr?oid* adj5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or adenocarcinoma*)).mp.
4 Thyroid Gland/
5 exp Neoplasms/
6 4 and 5
7 or/1-3,6
8 “Quality of Life”/
9 (qol or (quality adj2 life)).ab,ti.
10 (value adj2 (money or monetary)).tw.
11 value of life/
12 quality adjusted life year/
13 quality adjusted life.tw.
14 (qaly$ or qald$ or qale$ or qtime$).tw.
15 disability adjusted life.tw.
16 daly$.tw.
17 health status indicators/
18 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shorform thirtysix or shortform thirty six
or short form thirtysix or short form thirty six).tw.
19 (sf 6 or sf6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
20 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
21 (sf6D or sf 6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or short form six D).tw.
22 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty).tw.
23 (euroqol or euro qol or eq5d or eq 5d).tw.
24 (hql or hqol or h qol or hrqol or hr qol).tw.
25 (hye or hyes).tw.
26 health$ year$ equivalent$.tw.
27 health utilit$.tw.
28 (hui or hui1 or hui2 or hui3).tw.
29 disutilit$.tw.
30 rosser.tw.
31 (quality adj2 wellbeing).tw.
32 qwb.tw.
33 (willingness adj2 pay).tw.
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
113
# Searches
34 standard gamble$.tw.
35 time trade off.tw.
36 time tradeoff.tw.
37 tto.tw.
38 letter.pt.
39 editorial.pt.
40 comment.pt.
41 38 or 39 or 40
42 or/8-37
43 42 not 41
44 7 and 43
EMBASE
Date range searched: 1974 to 1 November 2016.
Date searched: 3 November 2016.
# Searches
1 exp thyroid tumor/
2 exp nodular goiter/
3 (thyr?oid* adj5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or adenocarcinoma*)).mp.
4 thyroid gland/
5 exp neoplasm/
6 4 and 5
7 or/1-3,6
8 socioeconomics/
9 quality adjusted life year/
10 quality adjusted life.tw.
11 (qaly$ or qald$ or qale$ or qtime$).tw.
12 disability adjusted life.tw.
13 daly$.tw.
14 health survey/
15 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty
six or short form thirtysix or short form thirty six).tw.
16 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
17 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
18 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).tw.
19 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty).tw.
20 (euroqol or euro qol or eq5d or eq 5d).tw.
21 (hql or hqol or h qol or hrqol or hr qol).tw.
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# Searches
22 (hye or hyes).tw.
23 health$ year$ equivalent$.tw.
24 health utilit$.tw.
25 (hui or hui1 or hui2 or hui3).tw.
26 disutili$.tw.
27 rosser.tw.
28 quality of wellbeing.tw.
29 qwb.tw.
30 willingness to pay.tw.
31 standard gamble$.tw.
32 time trade off.tw.
33 time tradeoff.tw.
34 tto.tw.
35 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or
28 or 29 or 30 or 31 or 32 or 33 or 34
36 7 and 35
Web of Science Core Collection
Science Citation Index Expanded (1900–).
Conference Proceedings Citation Index – Science (1990–).
Date searched: 3 November 2016.
# Searches
#1 TOPIC: ((thyr*oid* NEAR/5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or adenocarcinoma*)))
#2 TS=(qol or “quality of life” or “quality adjusted life” or qaly* or qald* or qale* or qtime* or “disability adjusted life"
or daly*)
#3 TS=(sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shorform thirtysix or shortform
thirty six or short form thirtysix or short form thirty six) OR TS=(sf 6 or sf6 or short form 6 or shortform 6 or sf six or
sfsix or shortform six or short form six) OR TS=(sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve
or shortform twelve or short form twelve) OR TS=(sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or
sfsixteen or shortfrom sixteen or short form sixteen) OR TS=(sf20 or sf 20 or short form 20 or shortform 20 or sf
twenty or sftwenty or shortform twenty or short form twenty)
#4 TS=(euroqol or euro qol or eq5d or eq 5d or hql or hqol or h qol or hrqol or hr qol or disutilit* or rosser “quality of
wellbeing” or qwb or “willingness to pay” or “standard gamble*” or “time trade off” or “time tradeoff” or tto)
#5 #4 OR #3 OR #2
#6 #5 AND #1
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Cochrane Database of Systematic Reviews: Wiley Online Library
Health Technology Assessment database: Wiley Online Library.
NHS Economic Evaluation Database: Wiley Online Library.
Date range searched: 1995–2015.
Date searched: 3 November 2016.
# Searches
#1 MeSH descriptor: [Thyroid Neoplasms] explode all trees
#2 MeSH descriptor: [Goiter, Nodular] explode all trees
#3 (thyr*oid* near/5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or adenocarcinoma*)):ti,
ab,kw
#4 MeSH descriptor: [Thyroid Gland] this term only
#5 MeSH descriptor: [Neoplasms] explode all trees
#6 #4 and #5
#7 {or #1-#3, #6}
Cumulative Index to Nursing and Allied Health Literature
Date range searched: 1982 to present.
Date searched: 3 November 2016.
# Searches
S1 (MH “Thyroid Neoplasms+”)
S2 (thyr?oid* N5 (cancer* or neoplas* or carcinoma* or malignan* or tumor* or tumour* or adenocarcinoma*))
S3 (MH “Thyroid Gland”)
S4 (MH “Neoplasms+”)
S5 S3 AND S4
S6 S1 OR S2 OR S5
S7 (MH “Quality of Life”)
S8 TI ( qol or (quality N2 life) ) or AB ( qol or (quality N2 life) )
S9 TI value and TI ( money or monetary ) or AB value and AB ( money or monetary )
S10 (MH “Economic Value of Life”)
S11 (MH “Quality-Adjusted Life Years”)
S12 TI ( qaly* or qald* or qale* or qtime* ) or AB ( qaly* or qald* or qale* or qtime* )
S13 TI disability adjusted life or AB disability adjusted life
S14 TI daly* or AB daly*
S15 (MH “Health Status Indicators”)
S16 TI ( sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shorform thirtysix or shortform
thirty six or short form thirtysix or short form thirty six ) or AB ( sf36 or sf 36 or short form 36 or shortform 36 or sf
thirtysix or sf thirty six or shorform thirtysix or shortform thirty six or short form thirtysix or short form thirty six )
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# Searches
S17 TI ( sf 6 or sf6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six ) or AB ( sf 6 or sf6
or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six )
S18 TI quality adjusted life or AB quality adjusted life
S19 TI ( sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve ) or
AB ( sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve )
S20 TI ( sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortfrom sixteen or short form
sixteen ) or AB ( sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortfrom sixteen or
short form sixteen )
S21 TI ( sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form
twenty ) or AB ( sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or
short form twenty )
S22 TI ( euroqol or euro qol or eq5d or eq 5d ) or AB ( euroqol or euro qol or eq5d or eq 5d )
S23 TI ( hql or hqol or h qol or hrqol or hr qol ) or AB ( hql or hqol or h qol or hrqol or hr qol )
S24 TI ( hye or hyes ) or AB ( hye or hyes )
S25 TI health* year* equivalent* or AB health* year* equivalent*
S26 TI health utilit* or AB health utilit*
S27 TI ( hui or hui1 or hui2 or hui3 ) or AB ( hui or hui1 or hui2 or hui3 )
S28 TI disutilit* or AB disutilit*
S29 TI rosser or AB rosser
S30 TI quality N2 wellbeing or AB quality N2 wellbeing
S31 TI qwb or AB qwb
S32 TI willingness N2 pay or AB willingness N2 pay
S33 TI standard gamble* or AB standard gamble*
S34 TI time trade off or AB time trade off
S35 TI time tradeoff or AB time tradeoff
S36 TI tto or AB tto
S37 PT letter
S38 PT editorial
S39 PT comment
S40 S37 or S38 or S39
S41 S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23
or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36
S42 S41 NOT S40
S43 S6 AND S42
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Appendix 2 Excluded studies with reasons
Single-arm studies
Anagnostou E, Saltiki K, Vasiliou V, Tsigkos C, Papanastasiou L, Alevizaki M, et al. Experience from the
administration of tyrosine kinase inhibitors (TKI) in patients with metastatic progressive medullary thyroid
carcinoma (MTC) in a referral centre in Greece. Eur Thyroid J 2016;5:75. https://doi.org/10.1159/000447416
Chougnet C, Schlumberger M, Isabelle B. Efficacy and toxicity of vandetanib for advanced medullary thyroid
cancer treatment, the French experience. Eur Thyroid 2014;3:77–8. https://doi.org/10.1159/000365244
Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, et al. Vandetanib for
the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Thyroid 2015;25:386–91. https://doi.org/10.1089/thy.2014.0361
Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, et al. Tumor marker and measurement
fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term
RET inhibitor therapy. Ann Oncol 2013;24:2256–61. https://doi.org/10.1093/annonc/mdt177
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184
(Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol
2011;29:2660–6. https://doi.org/10.1200/JCO.2010.32.4145
Marquez Fernandez E, Marmesat Rodas B, Quesada Sanz MP, Guerra Estévez D, Villanueva Jiménez P.
Use of vandetanib in medullary thyroid cancer. Int J Clin Pharm 2016;38:587. https://doi.org/10.1007/
s11096-015-0240-y
ClinicalTrials.gov. NCT00098345. Efficacy and Tolerability of ZD6474 in Patients with Thyroid Cancer.
2004. URL: https://clinicaltrials.gov/ct2/show/NCT00098345 (accessed 25 October 2018).
ClinicalTrials.gov. NCT00358956. A Study to Assess ZD6474 (ZACTIMA™) Monotherapy in Locally
Advanced or Metastatic Hereditary Medullary Thyroid Cancer. 2006. URL: https://clinicaltrials.gov/ct2/show/
NCT00358956 (accessed 25 October 2018).
ClinicalTrials.gov. NCT01661179. Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients
with Medullary Thyroid Carcinoma. 2012. URL: https://clinicaltrials.gov/ct2/show/NCT01661179
(accessed 25 October 2018).
ClinicalTrials.gov. NCT01683110. Expanded Access of Cabozantinib in Medullary Thyroid Cancer. 2012.
URL: https://clinicaltrials.gov/ct2/show/NCT01683110 (accessed 25 October 2018).
ClinicalTrials.gov. NCT01945762. Observational Study to Evaluate Vandetanib in RET –/+ Patients with
Metastatic Medullary Thyroid Cancer. 2013. URL: https://clinicaltrials.gov/ct2/show/NCT01945762
(accessed 25 October 2018).
Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally
advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664–71.
https://doi.org/10.1210/jc.2009-2461
Takahashi S, Tomomatsu J, Okamoto T, Horiuchi K, Tsuji A, Ito Y, et al. Safety and tolerability of
vandetanib in Japanese patients (PTS) with medullary thyroid cancer (MTC): a phase I/II open-label study.
Thyroid 2015;25:A273. https://doi.org/10.1089/thy.2015.29004
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Tiedje V, Locati LD, Kroiss M, Frank-Raue K, Garcia A, Kreissl M, et al. Cabozantinib therapy in medullary
thyroid carcinoma patients outside a clinical trial. Thyroid 2015;25:A266. https://doi.org/10.1089/
thy.2015.29004
Tiedje V, Ting S, Walter RF, Herold T, Worm K, Badziong J, et al. Prognostic markers and response to
vandetanib therapy in sporadic medullary thyroid cancer patients. Eur J Endocrinol 2016;175:173–80.
https://doi.org/10.1530/EJE-16-0252
Wells SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients
with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767–72.
https://doi.org/10.1200/JCO.2009.23.6604
Zhang L, Li S, Zhang Y, Zhan J, Zou BY, Smith R, et al. Pharmacokinetics and tolerability of vandetanib in
Chinese patients with solid, malignant tumors: an open-label, Phase I, rising multiple-dose study. Clin Ther
2011;33:315–27. https://doi.org/10.1016/j.clinthera.2011.04.005
Reviews
Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Incidence and risk of hand–foot skin reaction with
cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol 2016;41:8–15.
https://doi.org/10.1111/ced.12694
Huo Z, Yu S, Hong S, Cao X, Xiu L, Liao Z, et al. A systematic review and meta-analysis of the risk of
diarrhea associated with vandetanib treatment in carcinoma patients. Onco Targets Ther 2016;9:3621–31.
https://doi.org/10.2147/OTT.S96830
Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al. Incidence and risk of hypertension with vandetanib
in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol
2013;75:919–30. https://doi.org/10.1111/j.1365-2125.2012.04417.x
Rinciog C, Myrén KJ, Aldén M, Diamantopoulos A, LeReun C. An indirect treatment comparison
of cabozantinib verse vandetanib in progressive medullary thyroid cancer (MTC). Value Health
2014;17:A616–7. https://doi.org/10.1016/j.jval.2014.08.2173
Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME. Risk of rash in cancer patients treated with
vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 2012;97:1125–33.
https://doi.org/10.1210/jc.2011-2677
Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, et al. Vandetanib for the treatment
of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or
metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res
2012;18:3722–30. https://doi.org/10.1158/1078-0432.CCR-12-0411
Letters/commentaries
Anonymous. Vandetanib (Caprelsa) for medullary thyroid cancer. Med Lett Drugs Ther 2012;54:3–4.
Anonymous. Vandetanib: too dangerous in medullary thyroid cancer. Pres Int 2012;21:233.
Baudry C, Paepegaey AC, Groussin L. Reversal of Cushing’s syndrome by vandetanib in medullary thyroid
carcinoma. N Engl J Med 2013;369:584–6. https://doi.org/10.1056/NEJMc1301428
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Chatal JF, Kraeber-Bodéré F, Goldenberg DM, Barbet J. Treatment of metastatic medullary thyroid cancer
with vandetanib: need to stratify patients on basis of calcitonin doubling time. J Clin Oncol 2012;30:2165.
https://doi.org/10.1200/JCO.2012.42.3160
Fuerst M. Medullary thyroid cancer: cabozantinib extends PFS in patients with RET or RAS mutations.
Oncology Times 2013;35:11–12.
Susman E. Cabozantinib linked to worrisome weight loss. Oncology Times 2015;37:55–6.
Population
Fox E, Widemann BC, Chuk MK, Marcus L, Aikin A, Whitcomb PO, et al. Vandetanib in children and
adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Clin Cancer Res 2013;19:4239–48. https://doi.org/10.1158/1078-0432.CCR-13-0071
ClinicalTrials.gov. NCT00514046. Vandetanib to Treat Children and Adolescents with Medullary Thyroid
Cancer. 2007. URL: https://clinicaltrials.gov/ct2/show/NCT00514046 (accessed 25 October 2018).
ClinicalTrials.gov. NCT01709435. Cabozantinib S-Malate in Treating Younger Patients with Recurrent
or Refractory Solid Tumors. 2012. URL: https://clinicaltrials.gov/ct2/show/NCT01709435 (accessed
25 October 2018).
ClinicalTrials.gov. NCT02867592. Cabozantinib-s-malate in Treating Younger Patients with Recurrent,
Refractory, or Newly Diagnosed Sarcomas, Wilms tumor, or Other Rare Tumors. 2016. URL: https://clinicaltrials.
gov/ct2/show/NCT02867592 (accessed 25 October 2018).
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Appendix 3 Additional tables and figures relating
to the Sanofi model
FIGURE 17 (Confidential information has been removed.)
TABLE 40 The AIC and BIC statistics from Sanofi’s covariate-adjusted analysis of the ZETA trial observed OS
Model
Statistic
AIC BIC
Vandetanib
Weibull (Confidential information has been removed) (Confidential information has been removed)
Log-normal (Confidential information has been removed) (Confidential information has been removed)
Log-logistic (Confidential information has been removed) (Confidential information has been removed)
Exponentiala (Confidential information has been removed) (Confidential information has been removed)
Gammaa (Confidential information has been removed) (Confidential information has been removed)
Placebo
Weibull (Confidential information has been removed) (Confidential information has been removed)
Log-normal (Confidential information has been removed) (Confidential information has been removed)
Log-logistic (Confidential information has been removed) (Confidential information has been removed)
Exponentiala (Confidential information has been removed) (Confidential information has been removed)
Gammaa (Confidential information has been removed) (Confidential information has been removed)
a Not reported in CS; obtained from company’s model.
FIGURE 18 (Confidential information has been removed.)
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TABLE 41 The AIC and BIC statistics from Sanofi’s covariate-adjusted analysis of ZETA trial observed PFS
Model
Statistic
AIC BIC
Vandetanib
Weibull (Confidential information has been removed) (Confidential information has been removed)
Log-normal (Confidential information has been removed) (Confidential information has been removed)
Log-logistic (Confidential information has been removed) (Confidential information has been removed)
Exponentiala (Confidential information has been removed) (Confidential information has been removed)
Gammaa (Confidential information has been removed) (Confidential information has been removed)
Placebo
Weibull (Confidential information has been removed) (Confidential information has been removed)
Log-normal (Confidential information has been removed) (Confidential information has been removed)
Log-logistic (Confidential information has been removed) (Confidential information has been removed)
Exponentiala (Confidential information has been removed) (Confidential information has been removed)
Gammaa (Confidential information has been removed) (Confidential information has been removed)
a Not reported in CS; obtained from company’s model.
TABLE 42 The HRQoL parameters used in the Sanofi model
Health state Value Source
Progression free 0.84 FACT-G mapped to EQ-5D using Dobrez et al.104
Post progression 0.64 Derived by applying progressive disease to stable disease multiplier from
Beusterien et al.105 to pre-progression utility from ZETA trial FACT-G
mapping exercise
Disutility any grade 3/4 AE –0.11 Beusterien et al.105
TABLE 43 Use of vandetanib during progression-free period
Dose % of PFS time receiving vandetaniba
300mg (full dose) 66.3
200-mg dose 16.5
100-mg dose 15.5
Interrupted 1.7
a Also applied to post-progression states in both treatment groups.
TABLE 44 Vandetanib acquisition costs according to pack size
Intervention: vandetanib tablets
Cost (£)
Per pack (30 tablets) Annual (assuming full dose)
300 mg 5000.00 60,875.00
100 mg 2500.00 30,437.50
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TABLE 45 Vandetanib monitoring costs assumed in the Sanofi model
Resource item Unit cost (£)
Frequency/year Total cost (£)
Year 1
Subsequent
years Year 1
Subsequent
years
EY51Z ECG monitoring or stress testing
(directly accessed diagnostic services)
40.00 8 4 320.00 160.00
DAPS04 Clinical biochemistry; DAPS08
Phlebotomy; DAPS05 Haematology
7.00 8 4 56.00 28.00
DAPS09 Other (thyroid-stimulating hormone) 3.00 8 4 24.00 12.00
TABLE 46 Incidence and costs associated with grade 3/4 AEs
AE type Unit cost (£) Vandetanib BSC NHS Reference Cost 2015/16106 HRG code
Diarrhoea 1102.00 11% 2% FZ91M: non-malignant gastrointestinal tract
disorders without interventions, with a CC score
of 0–2
Hypertension 982.00 9% 0% EB04Z: hypertension
ECG QT prolonged 1014.00 8% 1% EB07E: arrhythmia or conduction disorders,
with a CC score of 0–3
Fatigue 0.00 6% 1% N/A
Decreased appetite 1512.00 4% 0% FZ49H: nutritional disorders without
interventions, with a CC score of 0 or 1
Rash 1078.00 4% 1% JD07 K: skin disorders without interventions,
with a CC score of 0 or 1
Asthenia 0.00 3% 1% N/A
Dyspnoea 896.00 1% 3% DZ19 N: other respiratory disorders without
interventions, with a CC score of 0–4
Back pain 1510.00 0% 3% HC32 K: low back pain without interventions,
with a CC score of 0–2
Syncope 1067.00 0% 2% EB08E: syncope or collapse, with a CC score
of 0–3
Weighted AE cost (£) – 413.42 136.48 –
CC, complexity and comorbidity; HRG, Healthcare Resource Group; N/A, not applicable.
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TABLE 47 Comparison of DICE model results and double-programmed AG partitioned survival model
Outcome
Model
Company AG’s double programmed
Vandetanib Placebo Incremental Vandetanib Placebo Incremental
LYGs 4.84 3.10 1.74 4.84 3.10 1.74
PFLYGsa 2.07 0.77 1.30 2.07 0.77 1.30
QALYs 3.49 2.13 1.36 3.49 2.13 1.36
Treatment costs,
pre progression (£)
75,766.71 0.00 75,766.71 75,817.76 0.00 75,817.76
Treatment costs,
post progression (£)
68,490.03 106,330.94 –37,840.91 68,490.35 106,317.39 –37,827.04
Monitoring costs (£) 653.86 385.80 268.06 646.21 385.75 260.46
AE costs (£) 409.32 136.48 272.84 409.32 136.48 272.84
Cost of BSC (£) 24,506.37 19,521.81 4984.56 24,506.45 19,519.65 4986.80
Palliative care costs (£) 5489.93 5916.92 –426.99 5574.17 6004.49 –430.31
Total costs (£) 175,316.22 132,291.95 43,024.27 175,444.26 132,363.76 43,080.50
ICER (£) – – 31,730.99 – – 31,636.28
PFLYG, progression-free life-year gained.
a Undiscounted.
FIGURE 19 (Confidential information has been removed.)
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TABLE 48 Health state populations by year, PFS (log-normal) and OS (Weibull)
Year
Group
BSC Vandetanib
OS PFS
PPS state population
(OS minus PFS) OS PFS
PPS state population
(OS minus PFS)
0 1.000 1.000 0.000 1.000 1.000 0.000
1 0.768 0.322 0.446 0.886 0.737 0.149
2 0.575 0.171 0.404 0.760 0.516 0.244
3 0.424 0.107 0.317 0.640 0.378 0.262
4 0.310 0.074 0.236 0.533 0.287 0.246
5 0.224 0.054 0.170 0.439 0.225 0.214
6 0.162 0.041 0.121 0.359 0.180 0.179
7 0.116 0.032 0.084 0.291 0.147 0.144
8 0.082 0.026 0.056 0.235 0.121 0.114
9 0.058 0.021 0.037 0.188 0.102 0.086
10 0.041 0.017 0.024 0.150 0.086 0.064
11 0.029 0.015 0.014 0.119 0.074 0.045
12 0.020 0.012 0.008 0.094 0.064 0.030
13 0.014 0.011 0.003 0.074 0.055 0.019
14 0.010 0.009 0.001 0.058 0.049 0.009
15 0.007 0.008 –0.001 0.045 0.043 0.002
16 0.005 0.007 –0.002 0.035 0.038 –0.003
17 0.003 0.006 –0.003 0.027 0.034 –0.007
18 0.002 0.006 –0.004 0.021 0.030 –0.009
19 0.002 0.005 –0.003 0.016 0.027 –0.011
20 0.001 0.004 –0.003 0.012 0.024 –0.012
PPS, post-progression survival.
Note
Bold text indicates logically inconsistent results.
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Appendix 4 The Assessment group’s model:
time-to-event analysis and other model inputs
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FIGURE 20 EXAM trial ITT population PFS.
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FIGURE 21 ITT EXAM trial standard diagnostic plots for PFS. (a) Empirical hazard function plot; (b) plot for Weibull
and exponential; (c) plot for log-logistic; and (d) plot for log-normal. (continued )
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FIGURE 21 ITT EXAM trial standard diagnostic plots for PFS. (a) Empirical hazard function plot; (b) plot for Weibull
and exponential; (c) plot for log-logistic; and (d) plot for log-normal.
TABLE 49 Model fit statistics: the EXAM trial’s ITT population, individual models for each treatment arm, PFS and OS
Model fit statistic
Treatment arm
Placebo Cabozantinib
AIC BIC AIC BIC
PFS
Exponential 338.71 341.42 599.32 602.71
Weibull 320.19 325.61 579.70 586.48
Gompertz 333.52 338.94 582.76 589.54
Log-normal 311.48 316.90 584.68 591.46
Log-logistic 308.71 314.13 583.59 590.37
Gamma 314.44 319.86 580.06 586.84
Generalised gamma 313.16 321.28 581.68 591.85
Generalised F Failed to converge Failed to converge 583.69 597.24
OS
Exponential 709.58 712.29 1345.03 1348.42
Weibull 711.35 716.77 1346.97 1353.75
Gompertz 709.88 715.29 1346.48 1353.26
Log normal 708.80 714.22 1344.34 1351.12
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TABLE 49 Model fit statistics: the EXAM trial’s ITT population, individual models for each treatment arm, PFS and OS
(continued )
Model fit statistic
Treatment arm
Placebo Cabozantinib
AIC BIC AIC BIC
Log-logistic 708.31 713.73 1343.69 1350.47
Gamma 711.54 716.95 1346.76 1353.54
Generalised gamma 710.22 718.34 1345.03 1355.19
Generalised F 712.18 723.01 1347.03 1360.59
Note
Bold indicates the best-fitting model (lowest AIC/BIC).
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FIGURE 22 EXAM trial ITT population, PFS, cabozantinib group (extrapolation up to 10 years).
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FIGURE 23 EXAM trial ITT population, PFS, placebo group (extrapolation up to 10 years).
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FIGURE 25 EXAM trial ITT population, standard diagnostic plots for OS. (a) Empirical hazard function plot;
(b) plot for Weibull and exponential; (c) plot for log-logistic; and (d) plot for log-normal. (continued )
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FIGURE 25 EXAM trial ITT population, standard diagnostic plots for OS. (a) Empirical hazard function plot;
(b) plot for Weibull and exponential; (c) plot for log-logistic; and (d) plot for log-normal.
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FIGURE 26 EXAM trial ITT population, OS, cabozantinib group (extrapolation up to 20 years).
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FIGURE 27 EXAM trial ITT population, OS, placebo group (extrapolation up to 20 years).
DOI: 10.3310/hta23080 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Tappenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
133
FIGURE 28 (Confidential information has been removed.)
FIGURE 29 (Confidential information has been removed.)
FIGURE 30 (Confidential information has been removed.)
TABLE 50 Model fit statistics: the ZETA trial’s EU-label population, individual models for each treatment, PFS and OS
Model fit statistic
Treatment arm
Placebo Vandetanib
AIC BIC AIC BIC
PFS
Exponential 296.49 298.58 471.89 474.76
Weibull 298.48 302.67 467.96 473.69
Gompertz 298.05 302.24 468.95 474.69
Log-normal 296.85 301.04 468.52 474.26
Log-logistic 296.80 300.99 468.57 474.31
Gamma 298.43 302.62 467.93 473.66
Generalised gamma 298.76 305.05 469.92 478.53
Generalised F 300.24 308.62 Failed to converge Failed to converge
OS
Exponential 421.65 423.73 851.75 854.62
Weibull 422.13 426.29 851.32 857.05
Gompertz 422.37 426.52 853.57 859.31
Log-normal 425.21 429.36 847.27 853.01
Log-logistic 423.24 427.39 847.62 853.36
Gamma 422.21 426.37 850.40 856.14
Generalised gamma 424.11 430.34 849.20 857.80
Generalised F 425.97 434.28 850.91 862.38
Note
Bold text indicates the best-fitting model (lowest AIC/BIC).
FIGURE 31 (Confidential information has been removed.)
FIGURE 32 (Confidential information has been removed.)
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FIGURE 33 (Confidential information has been removed.)
FIGURE 34 (Confidential information has been removed.)
FIGURE 35 (Confidential information has been removed.)
FIGURE 36 (Confidential information has been removed.)
FIGURE 37 (Confidential information has been removed.)
FIGURE 38 (Confidential information has been removed.)
FIGURE 39 (Confidential information has been removed.)
FIGURE 40 (Confidential information has been removed.)
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TABLE 51 Model fit statistics: the ZETA trial’s restricted EU-label population, individual models for each treatment,
PFS and OS
Model fit statistic
Treatment arm
Placebo Vandetanib
AIC BIC AIC BIC
PFS
Exponential 89.71 90.54 132.83 134.30
Weibull 91.64 93.31 134.63 137.56
Gompertz 91.48 93.14 134.79 137.72
Log-normal 89.62 91.29 132.60 135.53
Log-logistic 89.55 91.22 133.60 136.53
Gamma 91.43 93.10 134.44 137.38
Generalised gamma 91.57 94.07 133.70 138.10
Generalised F 92.83 96.16 135.70 141.56
OS
Exponential 152.90 153.74 212.75 214.21
Weibull 153.02 154.69 214.74 217.67
Gompertz 150.44 152.11 214.23 217.16
Log-normal 158.84 160.51 212.96 215.89
Log-logistic 158.34 160.00 213.19 216.12
Gamma 153.95 155.62 214.68 217.61
Generalised gamma 152.19 154.69 214.92 219.32
Generalised F 154.19 157.52 216.92 222.79
Note
Bold text indicates the best-fitting model (lowest AIC/BIC).
FIGURE 41 (Confidential information has been removed.)
FIGURE 42 (Confidential information has been removed.)
FIGURE 43 (Confidential information has been removed.)
FIGURE 44 (Confidential information has been removed.)
FIGURE 45 (Confidential information has been removed.)
FIGURE 46 (Confidential information has been removed.)
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TABLE 52 ZETA trial EU-label model fit statistics and treatment-effect estimates (HR or AFT factor) for single
parametric models, PFS
Model fit
statistic PH/AFT
Model fit Treatment effect
AIC BIC β SE (β) HR/AFT
Exponential PH 768.38 774.87 (Confidential
information has been
removed)
(Confidential
information has been
removed)
(Confidential
information has been
removed)
Weibull PH 767.30 777.04 (Confidential
information has been
removed)
(Confidential
information has been
removed)
(Confidential
information has been
removed)
Gompertz PH 768.80 778.54 (Confidential
information has been
removed)
(Confidential
information has been
removed)
(Confidential
information has been
removed)
Log-normal AFT 764.25 773.99 (Confidential
information has been
removed)
(Confidential
information has been
removed)
(Confidential
information has been
removed)
Log-logistic AFT 764.57 774.31 (Confidential
information has been
removed)
(Confidential
information has been
removed)
(Confidential
information has been
removed)
Gamma AFT 766.55 776.29 (Confidential
information has been
removed)
(Confidential
information has been
removed)
(Confidential
information has been
removed)
Generalised
gamma
AFT 766.09 779.08 (Confidential
information has been
removed)
(Confidential
information has been
removed)
(Confidential
information has been
removed)
AFT, accelerated failure time; PH, proportional hazards.
β, coefficient on analysis scale.
Note
Bold text indicates the best-fitting model (lowest AIC/BIC).
FIGURE 47 (Confidential information has been removed.)
FIGURE 48 (Confidential information has been removed.)
TABLE 53 Health utilities used in the AG model
Health state Mean (95% CI)
Beta distribution parameters
Sourceα β
Progression free 0.80 (0.77 to 0.84) 400.61 100.15 Fordham et al.102
Post progression 0.50 (0.45 to 0.56) 158.24 158.24
Disutility AEs –0.11 (SE 0.02) 26.81 216.94 Beusterien et al.105
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TABLE 54 Grade 3/4 AE rates assumed in the AG model
Treatment arm
Pairwise comparison
Incremental comparisons:
all options (AG analyses 3
and 4)
Cabozantinib vs. BSC
(AG analysis 1)
Vandetanib vs. BSC
(AG analyses 2 and 5)
Cabozantinib 0.94 N/A 0.94
Vandetanib N/A 0.45 0.45
Placebo 0.24 0.14 0.24
N/A, not applicable.
TABLE 55 Proportion of patients who switched to vandetanib or continued vandetanib post progression
Parameter
Population
EU-label: symptomatic and progressive MTC
Restricted EU-label: symptomatic and
progressive MTC with CEA/CTN doubling
time of ≤ 24 months
Proportion
Continued
PP
Not
continued PP Proportion
Continued
PP
Not
continued PP
Proportion of
vandetanib group
continuing
vandetanib PP
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
Proportion of BSC
group switching
to vandetanib PP
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
PP, post progression.
TABLE 56 Drug acquisition costs: vandetanib and cabozantinib
Item
Cost (£)
Per pack
Annual at full
dose
Cabozantinib, 84 × 20-mg capsules (two-level dose reduction) 4800.00 62,614.29
Cabozantinib, 28 × 20-mg and 28 × 80-mg capsule combination (one-level dose reduction) 4800.00 62,614.29
Cabozantinib, 84 × 20-mg and 28 × 80-mg capsule combination (full dose) 4800.00 62,614.29
Vandetanib, 30 × 300-mg tablets 5000.00 60,875.00
Vandetanib, 30 × 100-mg tablets 2500.00 30,437.50
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TABLE 58 Vandetanib: proportion of PFS time spent at dose level
Dose
Mean proportion of PFS time
spent on specified dose
Dirichlet parameters
Days on dose Total PFS days
EU-label population: symptomatic and progressive MTC
Vandetanib, 300 mg 0.73 76,994.70 106,105.13
Vandetanib, 200 mg 0.13 13,806.45 106,105.13
Vandetanib, 100 mg 0.13 13,550.78 106,105.13
Vandetanib, interrupted dose 0.02 1753.20 106,105.13
Restricted EU-label population: symptomatic and progressive MTC with CEA/CTN doubling times of ≤ 24 months
Vandetanib, 300 mg 0.66 13,769.93 20,746
Vandetanib, 200 mg 0.17 3433.35 20,746
Vandetanib, 100 mg 0.15 3214.20 20,746
Vandetanib, interrupted dose 0.02 328.73 20,746
TABLE 59 Annual BSC resource use included in the AG model
Resource item
Visits/items per year
Progression-free and post-progression states
Consultant outpatient visits 6 (range 2–12)
CT scans 2 (range 0–4)
MRI scan 1 (range 0–2)
Community palliative care support 12 (range 0–20)
Palliative radiotherapy 2 (fixed)
Bisphosphonates for bone metastases 0.6 (fixed)a
Palliative surgery 0.03 (fixed)
a Assumed to reflect monthly intravenous regimen for 5% of patients, also costed to include outpatient visit.
TABLE 57 Cabozantinib: proportion of PFS time spent at dose level
Dose Mean proportion
Dirichlet parameters
Days on dose Total PFS days
Cabozantinib, 140mg Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
Cabozantinib, 100mg Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
Cabozantinib, 60 mg Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
Cabozantinib,
interrupted dose
Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
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TABLE 61 Unit costs applied in the AG model
Unit Cost (£) SE (£) Source
Consultant-led outpatient visit
(medical oncology)
162.84 6.48 NHS Reference Costs 2015/16,106
consultant-led, non-admitted face-to-face
attendance, follow-up, WF01A
Nurse-led outpatient
(medical oncology)
99.97 8.46 NHS Reference Costs 2015/16,106
non-consultant-led, non-admitted
face-to-face attendance, follow-up, WF01A
CT scan 136.50 7.13 NHS Reference Costs 2015/16,106
outpatient, complex CT scan, RD28Z
MRI scan 161.93 3.68 NHS Reference Costs 2015/16,106
outpatient, MRI scan of two or three
areas, without contrast, RD04Z
ECG 207.98 29.16 NHS Reference Costs 2015/16,106
outpatient (medical oncology), ECG
monitoring or stress testing, EY51Z
Blood test 3.37 0.26 NHS Reference Costs 2015/16,106 directly
accessed pathology, phlebotomy, DAPS08
Palliative care nurse visit 91.83 4.81 NHS Reference Costs 2015/16,106 specialist
nursing, palliative/respite care, adult, face
to face, N21AF
Palliative radiotherapy
(per fraction)
104.77 7.47 NHS Reference Costs 2015/16,106
outpatient, deliver a fraction of treatment
on a megavoltage machine, SC22Z
Palliative surgery 3363.82 70.08 NHS Reference Costs 2015/16,106 elective
inpatient, thyroid procedures with a CC
score of 0 or 1, KA09E
Bisphosphonates for bone
metastases (4 mg per 100-ml
infusion bags)a
150.00 N/A BNF,108 Zerlinda 4 mg per 100-ml infusion
bags [Actavis UK Ltd (now Accord
Healthcare Ltd, Barnstaple, UK)]
Palliative care (last month of
life)
5775.52 866.33b PSSRU,107 palliative care costs (assumes
equal weighting between child and adult
inpatient and outpatient)
TABLE 60 Total annual health state resource use for cabozantinib and vandetanib included in the AG model
Resource item
Treatment
Cabozantinib Vandetanib
Year 1 Subsequent yearsa Year 1 Subsequent yearsa
Consultant-led outpatient visits 12 (range 4–16) 6 (range 4–12) 12 (range 4–16) 6 (range 4–12)
Nurse-led outpatient visits 4 (range 0–6) 6 (range 0–6) 4 (range 0–6) 6 (range 0–6)
ECG 0 0 12 6
Blood tests 12 6 12 6
CT scan 4 4 4 4
a Assessment group analyses 2 and 5 – subsequent years’ costs applied to patients receiving vandetanib in the
post-progression state, irrespective of time since model entry.
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TABLE 62 Distributions used in PSA
Parameter group Distribution Comments
Time-to-event outcomes (PFS and OS) Normal/multivariate normal Sampled via Cholesky decomposition using
variance–covariance matrices for each
parametric model
Vandetanib PFS treatment effect
(AG analysis 3 only)
Normal (log-scale) Treatment effect parameters (HRs and
acceleration factors) derived from joint models
fitted to ZETA trial subgroup data
Grade 3/4 AE rates Beta Distribution parameters based on total number
of AEs reported in ITT population
Vandetanib switching/continuation
parameters
Beta Distribution parameters based on numbers
continuing/not continuing in ZETA trial
subgroups
Health state utilities Beta Derived using method of moments
Disutility for grade 3/4 AEs Beta Derived using method of moments
Drug dose distributions for cabozantinib
and vandetanib
Dirichlet Includes minimally informative priors, specified
in days
Proportion of patients discontinuing
vandetanib prior to progression
Beta Distribution parameters based on observed
data for ZETA subgroups
BSC resource use (outpatient visits,
CT scans, MRI scans and community
palliative care support)a
Triangular Distribution selected to reflect expert’s beliefs
Vandetanib and cabozantinib health state
resource useb
Triangular Distribution selected to reflect expert’s beliefs
Drug acquisition costs Fixed –
Unit costs Normal SE derived from interquartile ranges
Palliative care costs Normal SE assumed to be 15% of mean
AE costs Normal SE assumed to be 15% of mean
a Intravenous bisphosphonates, palliative radiotherapy and palliative surgery held fixed.
b Resources related to monitoring held fixed (ECGs, CT scans and blood tests).
TABLE 61 Unit costs applied in the AG model (continued )
Unit Cost (£) SE (£) Source
Palliative chemotherapy
(last month of life)
827.00 124.05b Sanofi CS66 (based on NHS Reference
Costs 2015/16,106) other, procure
chemotherapy drugs for regimens in band
1–10, SB01Z–10Z
Cost of managing AEs 298.41 44.76b NHS Reference Costs 2015/16,106
weighted mean of all non-elective excess
bed-days, AA22C–YR55Z
CC, complexity and comorbidity; N/A, not applicable.
a Assumed to be given during additional outpatient appointment.
b SE assumed to be 15% of mean.
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Appendix 5 The Assessment group’s model:
disaggregated results
TABLE 63 Analysis 1: EU-label population (symptomatic and progressive MTC), cabozantinib vs. BSC (pairwise),
disaggregated LYGs, QALYs and costs
Outcomes (undiscounted)
Treatment
Cabozantinib BSC
LYGs 4.49 3.91
LYGs in progression-free state 1.39 0.45
LYGs in post-progression state 3.10 3.46
Total QALYs 2.66 2.09
Total QALYs in progression-free state 1.10 0.36
Total QALYs in post-progression state 1.55 1.73
Total cost (£) 95,307.00 18,063.00
Total cost in progression-free state (£) 79,788.00 1417.00
Total cost in post-progression state (£) 15,519.00 16,647.00
Modelled probability of being alive at 20 years 0.06 0.05
TABLE 64 Analysis 2: EU-label population (symptomatic and progressive MTC), vandetanib vs. BSC (pairwise),
disaggregated LYGs, QALYs and costs
Outcomes (undiscounted)
Treatment
Vandetanib BSC
LYGs 7.32 7.58
LYGs in progression-free state 4.00 2.70
LYGs in post-progression state 3.32 4.89
Total QALYs 4.85 4.60
Total QALYs in progression-free state 3.20 2.16
Total QALYs in post-progression state 1.66 2.44
Total cost (£) 305,003.00 223,755.00
Total cost in progression-free state (£) 216,263.00 8131.00
Total cost in post-progression state (£) 88,740.00 215,624.00
Modelled probability of being alive at 20 years 0.11 0.12
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TABLE 65 Analysis 3: EU-label population (symptomatic and progressive MTC), fully incremental analysis of all
options using vandetanib PFS treatment effect from combined model, disaggregated LYGs, QALYs and costs
Outcomes (undiscounted)
Treatment
Cabozantinib Vandetanib BSC
LYGs 4.49 4.49 3.91
LYGs in progression-free state 1.39 0.96 0.45
LYGs in post-progression state 3.10 3.54 3.46
Total QALYs 2.66 2.53 2.09
Total QALYs in progression-free state 1.10 0.76 0.36
Total QALYs in post-progression state 1.55 1.77 1.73
Total cost (£) 95,307.00 71,105.00 18,063.00
Total cost in progression-free state (£) 79,788.00 54,284.00 1417.00
Total cost in post-progression state (£) 15,519.00 16,820.00 16,647.00
Modelled probability of being alive at 20 years 0.06 0.06 0.05
TABLE 66 Analysis 4: EU-label population (symptomatic and progressive MTC), cabozantinib and vandetanib
assumed equivalent, disaggregated LYGs, QALYs and costs
Outcomes (undiscounted)
Treatment
Cabozantinib Vandetanib BSC
LYGs 4.49 4.49 3.91
LYGs in progression-free state 1.39 1.39 0.45
LYGs in post-progression state 3.10 3.10 3.46
Total QALYs 2.66 2.66 2.09
Total QALYs in progression-free state 1.10 1.11 0.36
Total QALYs in post-progression state 1.55 1.55 1.73
Total cost (£) 95,307.00 92,909.00 18,063.00
Total cost in progression-free state (£) 79,788.00 77,390.00 1417.00
Total cost in post-progression state (£) 15,519.00 15,519.00 16,647.00
Modelled probability of being alive at 20 years 0.06 0.06 0.05
TABLE 67 Analysis 5: restricted EU-label population (symptomatic and progressive MTC with CEA/CTN doubling
times of ≤ 24 months), vandetanib vs. BSC (pairwise), disaggregated LYGs, QALYs and costs
Outcomes (undiscounted)
Treatment
Vandetanib BSC
LYGs 6.50 3.34
LYGs in progression-free state 3.15 0.97
LYGs in post-progression state 3.35 2.37
Total QALYs 4.19 1.96
Total QALYs in progression-free state 2.52 0.78
Total QALYs in post-progression state 1.67 1.18
Total cost (£) 245,641.00 108,236.00
Total cost in progression-free state (£) 161,051.00 2956.00
Total cost in post-progression state (£) 84,591.00 105,279.00
Modelled probability of being alive at 20 years 0.12 0.00
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